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Summary
Peptidases are indispensable for physiological activation and turnover of pro-
teins but in the extracellular space they may escape control and be harmful
to the organism. This thesis focuses on the mechanism of interaction between
peptidases and modifiers taking into account the peculiar microenvironment
concerned with cells, enzymes, inhibitors and activators.
The insoluble nature of extracellular matrix components, which build up
connective tissues, is a central point in the pharmacological management
of pathological peptidases, for which adequate investigation tools are nec-
essary. The kinetic mechanism of inhibition of enzyme modifiers designed
for pharmacological applications has been considered so far only marginally
but is nevertheless of paramount importance. Indeed, ascribing modifiers to
their correct inhibition/activation category by kinetic studies carefully per-
formed in vitro, provide support to the interpretation of pharmacokinetic
and pharmacodynamic issues.
We performed a systematic re-evaluation of enzyme inactivators using acetyl-
cholinesterase as a model enzyme. Considering a comprehensive collection of
common and rare mechanisms of action, we set up diagnostic tools for model
discrimination, which were tested and validated with practical examples.
Conventional, competitive inhibitors carrying warheads directed to the active
center of extracellular matrix degrading peptidases may experience serious
difficulties in reaching and effectively controlling their targets. This occurs
because the enzymes are tightly bound to their insoluble substrates and vir-
tually do not detach during their permanence in the tissues. We identified
a compound that binds outside the catalytic center of cathepsin B and con-
trols the flexibility of a key structural element, which is responsible for the
exo- and endopeptidase activity of the enzyme. This and similar inhibitors
possessing engineered structures that bind to accessible sites of the target
enzymes, even when these are tightly bound to their substrates, represent
valuable candidates for the pharmacological control of pathological pepti-
dases.
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Artificially designed modifiers target outside the active site of enzymes may
be engaged in multiple interactions with naturally occurring inhibitors as
well as with unspecific ligands such as components of the extracellular ma-
trix. We elaborated a kinetic model for describing double interaction between
modifiers and enzymes, which assists in making predictions of synergy, zero-
interaction and antagonism between inhibitors and/or activators and can be
used for non-linear regression analysis of experimental data as well.
Ordinary, uncommon and even bizarre effects brought about by the combi-
nation of two modifiers, such as reactivation at high effector concentration
following inhibition at low concentration, can be quantitatively interpreted
with the aid of easy-to-use kinetic equations. The theoretical treatment
could be used for interpreting puzzling results obtained with elastase-2 in
interaction with sulfated glycosaminoglycans.
Zusammenfassung
Peptidasen sind für die physiologische Aktivierung und den Umsatz von
Proteinen unabdingbar. Jedoch können sie in der extrazellulären Matrix
der natürlichen Kontrolle entkommen und in der Folge für den Organismus
schädlich wirken. Die vorliegende Arbeit fokussiert sich auf die Interaktions-
mechanismen zwischen Peptidasen und ihren Modifiern unter Miteinbezug
der auffälligen Mikroumgebung bestehend aus Zellen, Enzymen, Inhibitoren
und Aktivatoren.
Die Unlöslichkeit der das Bindegewebe aufbauen extrazellulären Bestandteile,
ist ein zentraler Punkt innerhalb der pharmakologischen Handhabung von
pathologischen Peptidasen. Deshalb werden bei Untersuchungen von Pep-
tidasen geeignete Werkzeuge benötigt. Bisher wurde der kinetische Mech-
anismus einer Enzyminhibition trotz seiner Wichtigkeit in pharmakologis-
chen Anwendungen nur geringfügig in die Analysen miteinbezogen. Je-
doch kann die Zuordnung eines Modifiers zu seinem Inhibitions-/Aktivations-
mechanismus durch sorgfältige in vitro Messungen unterstützend bei der
Interpretation von pharmakokinetischen und pharmakodynamischen Proble-
men wirken.
Wir führten eine systematische Neubeurteilung von Inaktivatoren durch unter
Benutzung von Acetylcholinesterase als Modellenzym. In Anbetracht einer
umfangreichen Kollektion von häufigen und seltenen Mechanismen stellten
wir diagnostische Werkzeuge für die Modelldiskriminierung auf, die anhand
praktischer Beispiele getested und validiert wurden.
Herkömmliche kompetitive Inhibitoren, die sogenannte ’warheads’ gerichtet
gegen das aktive Zentrum einer extrazellulären Matrix abbauenden Peptidase
tragen, können ernsthafte Schwierigkeiten in der Erreichung und effektiven
Kontrolle ihrer Targets erfahren. Der Grund liegt in der sehr starken An-
bindung der Enzyme an ihre unlöslichen Substrate von denen sie während
ihrer Zeit im Gewebe praktisch nicht weg dissoziieren. Wir identifizierten
ein Molekül das ausserhalb der aktiven Stelle von Cathepsin B bindet und
die Flexibilität eines strukturellen Schlüsselelementes, verantwortlich für die
Exo- und Endopeptidaseaktivität des Enzyms, kontrolliert. Solche und ähn-
liche Inhibitoren welche konstruierte Strukturen besitzen die ausserhalb der
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aktiven Stelle eines Enzyms binden auch wenn dieses fest an ein Substrat
gebunden ist, repräsentieren wertvolle Kantidaten für die pharmakologische
Kontrolle von pathologischen Peptidasen.
Künstlich hergestellte Modifier welche ausserhalb des aktiven Zentrums eines
Enzyms binden, können mit den natürlich vorkommenden Inhibitoren wie
auch unspezifischen Liganden, z.B. Komponeten der extrazellulären Matrix,
in Wechselwirkung treten. Wir arbeiteten ein kinetischen Modell aus um
die doppelte Interaktion zwischen Modifiern und Enzymen zu beschreiben,
was in der Vorhersage von ’Synergy’, ’Zero-Interaction’ und ’Antagonism’
zwischen Inhibitoren und/oder Aktivatoren benutzt werden kann, wie auch
für die nicht-lineare Regressionsanalyse von experimentellen Daten.
Gewöhliche, ungewöhnliche aber auch sonderbare Effekte hervorgerufen durch
die Kombination von zwei Modifiern, wie beispielsweise die Reaktivierung
bei hoher Modifierkonzentration nach einer unsprünglichen Inhibition bei
tiefen Modifierkonzentration, können quantitativ durch die Zuhilfenahme
von einfach zu benützenden kinetischen Gleichungen interpretiert werden.
Die theoretische Behandlung konnte für die Interpretation der rätselhaften
Resultate eingesetzt werden, welche sich bei der Interaktion von Elastase-2
mit Glykosaminoglykanen zeigten.
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Introduction

The Area Under
Investigation
Hydrolytic enzymes, chiefly peptidases, are involved in tumor malignancy
and invasion as well as in destruction of connective tissue in inflammatory
and non-inflammatory rheumatic diseases. Cellular invasion characterizes
many physiological (e.g. wound healing, uterine involution, tooth eruption)
and pathological processes (e.g. tumor invasion, angiogenesis, inflamma-
tion), and the enzymatic mechanisms of all these situations are similar. Inva-
sive cells produce enzymes which are able to degrade the barriers (basement
membranes and extracellular matrices) they must cross.
The pharmacological inhibition of extracellular matrix degrading peptidases
by exogenous modifiers is a delicate task, for which a solution has not yet
been found. The obstacles to this goal must be sought in the peculiar na-
ture of the substrates of these enzymes, which are insoluble macromolecular
assemblies, and in the demanding properties exogenous inhibitors should
possess for accomplishing their difficult mission.
Before describing the aims of this thesis, an overview of the extracellular
matrix, of the cellular events responsible for matrix homeostasis and enzyme
production, as well as a short portrait of the enzymes involved are presented
below.
1.1 The Extracellular Matrix
Connective tissue consists of an extracellular matrix (ECM) and a cellular
component. Here, the building blocks, the properties and the interactions
between these structures, with focus on ECM remodeling and degradation,
are discussed. Because of the possible harmful effects, caused by excessive
or insufficient degradation of tissue matrix, the remodeling processes need
to be tightly controlled. Thus, in the last part of this section a few patholo-
gies relevant to the topic of this thesis are described and control failure is
discussed.
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1.1.1 Cells Involved in ECMRemodeling and Degradation
The cells responsible for the synthesis and maintenance of the ECM are
of mesenchymal origin, fibroblasts, osteoblasts, chondrocytes, myocytes and
adipocytes, which undergo developmental transformation until reaching a
characteristic tissue-specific phenotype, which governs the correct expression
of matrix components, such as the collagen types II, IX and XI in articular
cartilage, the collagen types I and III in skin, as well as elastin and the pro-
teoglycans.
Besides being involved in physiological remodeling, the cells mentioned above
may also participate in pathological connective tissue degradation following
failure of the natural control mechanisms.
Blood-borne cells sustain the role of resident cells in the ECM by partici-
pating in physiological remodeling, e.g. in bone fracture and wound healing,
as well as in pathological situations, such as tumor invasion and cartilage
degradation. Among the cells involved in the process of ECM remodeling
are leukocytes and fibroblasts.
Leukocytes are part of the immune system and are further classified into
lymphocytes, polymorphonuclear leukocytes (among which the neutrophilic
granulocytes, ’neutrophils’, play a leading role being the first cells recruited
at inflammatory sites), platelets, monocytes and macrophages.
Fibroblasts, chondrocytes and osteocytes are the major cells in the synthe-
sis and maintenance of ECM and produce the non-collagenous components,
collectively called the ground substance that mainly comprise the proteo-
glycans, as well as elastic and collagen fibers, called the fibrous substance.
Under homeostatic conditions they are found in their differentiated state,
but upon stimulation these cells may undergo phenotypic transition, often
towards a primitive fibroblast-like state. Following this transformation, the
metabolic habits of the cells and their characteristic protein expression pat-
terns change, including excessive synthesis of peptidases, which results in net
degradation of the ECM.
Especially macrophages and neutrophils are involved in the degradation of
matrix components. Tissue material that needs to be degraded is either
phagocytosed and hydrolyzed intracellularly by these cells, or the degrada-
tion occurs in the extracellular space through the action of secreted/exo-
cytosed peptidases.
Tissue remodeling by extracellular proteolysis is a vital process in the human
organism. Alveolar macrophages for example, contain lysosomes with vari-
ous hydrolytic enzymes, which digest most ECM components. Additionally,
these cells use an oxygen-dependent mechanism to rapidly produce the su-
peroxide radical and hydrogen peroxide (respiratory burst, p. 10) to destroy
microorganisms which entered the upper respiratory airways. Also the neu-
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trophils, besides exploiting oxygen-dependent mechanisms to kill microor-
ganisms, possess a complete battery of hydrolases and bactericidal proteins
stored in large amounts in specific and azurophil granules, which are used
for both intracellular and extracellular tasks.
Not all cells that take part in the maintenance of the equilibrium between
degradation and production of the tissue matrix are permanently in the ma-
trix. Preservation of the equilibrium between degradation by proteolysis
and synthesis of new extracellular structures by different cells is indispens-
able to life. Fixed structures in the matrix and second messengers, such as
chemokines and cytokines, provide guidance in communication and migra-
tion of the cells involved in tissue remodeling.
1.1.2 Structural Components of the ECM
As mentioned before, the ECM is divided into fibrous substance and ground
substance. Collagen and elastin contribute the fibrous substance of the ex-
tracellular matrix, proteoglycans and the ground substance. Depending on
the tissue type, the proportion of the two substances fits to the properties
required.
Fibrous Substance
Elastic fibers are composed of elastin, microfibrils as well as proteoglycans.
Owing to their great elasticity, they are mainly found in organs subjected to
stress, like lungs and aorta. Stability, organization and strength is supplied
by collagen fibers, made up by over 20 different, genetically distinct collagen
types. Collagen and elastin fibers are often interweaved to prevent rupture
of the tissue. Imbalance in the proportion of either one of these fibers at the
wrong place in the organism can cause severe pathologies [39, 97].
Ground Substance
Proteoglycan monomers, consisting of a core protein with covalently linked
glycosaminoglycans (Figure 1.1a), which, in association with hyaluronan and
linked proteins build large aggregates (Figure 1.1b), the main components
of the ground substance.
We distinguish between extracellular proteoglycans (e.g. fibromodulin, lu-
mican, decorin) and proteoglycans on the cell membrane (e.g. syndecan,
CD44, perlecan). Decorin is the smallest proteoglycan with only one gly-
cosaminoglycan side chain and aggrecan found in cartilages is the largest
(up to 100MDa). The turnover of proteoglycans is relatively fast. Having
a short half-life (e.g. around 20 days for aggrecan), they are continuously
renewed and interactions between these structures and fibers of the ECM
affect their dimension.
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(a)
(b)
Figure 1.1: Structure of a proteoglycan. a) Proteoglycan monomer. G1, G2
and G3: Globular domains with disulfide bridges, KS: Keratan sulfate rich
region, CS1 and CS2: Chondroitin sulfate rich region. N and C denote the
amino and carboxy termini, respectively. b) Aggregate of a proteoglycan.
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Since the composition of proteoglycans is very variable, their function is
manifold: they act as lubricants, space fillers, impact absorbers and regu-
lators of diffusion [52]. Because of their anionic character due to carboxyl
residues (COO−) and sulfate ester groups (OSO−3 ), cations such as potassium
(K+), sodium (Na+) and calcium (Ca+2 ) are bound to these glycosaminogly-
cans. These osmotically active cations bind water to form hydrated gels. A
proteoglycan can in fact bind up to 50 times its weight of water and thus
participates in the transport of nutrients through the ECM.
GAG
GAG
H2O
(a) unloaded cartilage
GAG
GAG
(b) cartilage under pressure
GAG
GAG
(c) removal of cartilage pressure
The proteoglycans support and anchor
cells within the ECM and interact with
enzymes and chemokines in order to fo-
cus and increase their effects. Moreover,
proteoglycans control the osmotic pres-
sure within the connective tissues.
In articular cartilage for instance, the re-
sulting ’Donnan effect’ produces a pres-
sure comparable to that present in the
tires of an automobile conferring this tis-
sue the necessary resilience and impact
absorber properties.
The functional aspects of proteoglycans
are depicted in the cartoon on the right,
showing the reversible compressibility of
articular cartilage with a) the unloaded
cartilage, where water is structurally or-
ganized between negative charges of gly-
cosaminoglycans. b) The cartilage ex-
periences compressive load, which dis-
places water and the negative charges
come closer. c) With the removal of carti-
lage compression water is restored within
ordered domains between the negative
charges.
The glycosaminoglycans (chondroitin-, dermatan-, heparan-, keratan sulfate
and hyaluronan) are highly negatively charged heteropolysaccharides of re-
peating disaccharide units with uronic acid and hexosamine (see below).
They fill out most of the space in the ECM, even though they represent only
10% of the extracellular weight.
In virtue of its strong hydrophilic character and its stiffness, hyaluronan (or
hyaluronic acid) is often used to create cell free environments. Abundant
above all in brain, cartilage as well as bone is the glycosaminoglycan chon-
droitin sulfate. In most tissues an inhomogeneous sulfatation distribution
of the disaccharide units, either at the C-4 or the C-6 position of the hex-
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osamine ring, is found along the chondroitin sulfate chain. Even if labeled
either chondroitin-4-sulfate or chondroitin-6-sulfate, commercially available
chondroitin sulfates are always copolymers of the two isomers with interca-
lating sulfate-free sequences. The most common glycosaminoglycan in skin is
dermatan sulfate, which is involved in processes of wound healing [107]. The
chemical and physical properties of dermatan sulfate are due to the presence
of iduronic acid in place of glucuronic acid found in chondroitin sulfates.
This uronic acid confers dermatan sulfate additional molecular flexibility to
adapt and favor binding to several proteins.
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Heparan sulfate plays a key function in the kidney, where it takes part in
glomerular filtration. Additionally, it binds several proteins, such as the fi-
broblast growth factor (FGF), a mediator in the stimulation of fibroblast
proliferation. Chemokines are also immobilized by heparan sulfates, result-
ing in chemotactic activity for leukocytes. Because of its large hydration
keratan sulfate is suitable for the absorption of mechanical shock. It is pre-
dominantly found in the cornea and cartilage [47].
Heparin has a structure similar to that of heparan sulfate and acts indirectly
as anticoagulant by preventing the formation of blood clots interacting with
antithrombin III. Following proteolytic activation of the precursor prothrom-
bin, fibrinogen is degraded by thrombin and as a result, fibrin polymers are
formed. After binding to heparin, antithrombin III (the true anticoagu-
lant) undergoes a conformational change, which increases its binding affinity
to thrombin and thus inhibits the coagulation cascade. The following ir-
reversible formation of the antithrombin-thrombin complex, through cleav-
age of the antithrombin molecules, decreases the affinity of heparin again
[87, 88].
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1.1.3 Interactions Between Cells and the ECM
Communication between the ECM-resident cells and between cells and the
matrix assures regular tissue remodeling. This exchange of information is
carried out by cell-cell interactions (such as cadherins, or members of the
immunoglobulin (Ig) family), cell-matrix interactions (via integrins, keratin
filaments, selectins, glycoproteins), and through the mediation of second
messengers (e.g. cytokines, interferons).
Remodeling of the tissue matrix beyond the normal processes resulting in
local tissue destruction may be caused by infection or mechanical injury. In
such situations, the immune system and especially inflammatory processes
play an important role in establishing the success or failure of ECM remod-
eling.
The Immune System
A distinction is made between the innate and the adaptive immune system.
The innate immune system, comprising the complement system, is antigen
independent, whereas the adaptive immune system is characterized by its
high specificity and antigen dependency.
Decisive for a fast initial reaction of the organism facing an invading pathogen,
is the innate system as a ’first line of defense’ with its defensive anatomic,
physiologic, phagocytic and inflammatory barriers. The adaptive system,
which is able to recognize and selectively eliminate specific antigens and mi-
croorganisms, needs more time to act effectively.
The internalization and degradation of pathogens is primarily performed by
antigen presenting cells such as macrophages, B-cells and dentritic cells. The
peptide fragments resulting from intracellular degradation of the pathogen
are complexed with the major histocompatibility complex (MHC) II and
presented on the surface of the cells. Intracellular antigens, such as viruses
or tumor proteins, are also degraded by these cells but are presented with
the MHC I complex.
The cell-mediated response includes the recognition of these antigens by T-
cell (thymus), more specifically TH-cells (helper) and TC-cells (cytotoxic).
Antigens bound to MHC II complexes are recognized by TH-cells, MHC I
complexed peptides by TC-cells.
Once the interaction between a TH-cell and a MHC II complex has occurred,
the T-cell starts to produce cytokines and interleukins such as IL-2 that
stimulates B-cells as well as TC-cells. Upon cytokine stimulation, TC-cells
transform into cytotoxic TC-cells enabling them to recognize and eliminate
antigen-bearing cells more efficiently. TH-cells also stimulate their clonal se-
lection by the secretion of IL-1.
When B-cells interact with an antigen over cell membrane-bound antibod-
ies, a humoral response takes place. The interaction causes the B-cell to
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differentiate into an antibody-secreting plasma cell. The secreted antibodies
facilitate the recognition and elimination of the corresponding antigen by
phagocytosis.
In contrast to the cell-mediated response, most suitable for endogenous anti-
gens, the humoral response is more suitable for exogenous antigens. Never-
theless, for an effective defense both systems are necessary.
Inflammation
Inflammation is a complex response of the organism triggered by local injury
or infection and includes five development stages: 1) Tissue injury, followed
by the release of inflammation mediators, such as histamine and cytokines.
2) Circulation disturbance resulting from a defective microcirculation (rubor,
calor, dolor). 3) Exudation (tumor), as a result of the increased migration
of inflammation mediators into the injured tissue. 4) Proliferation of cells
and matrix components. 5) Healing and scarring.
In the first phase of inflammation, secreted mediators such as thrombin,
histamine, IL-1 and the tumor necrosis factor-α (TNF-α) increase the pro-
duction of cell adhesion molecules (CAMs), such as selectins, in local blood
vessels. Following cell binding and with the aid of other cytokines (e.g. IL-
8), the cell adhesion molecules control transendothelial migration.
In the tissue itself, neutrophils, the first cells migrated to an inflammatory
site, develop more receptors for chemoattractants and Fc receptors for the
recognition of immunoglobulin’s. By chemotaxis, promoted by chemokines
and prostaglandins, the neutrophils are guided to the site of inflammation.
The phagocytic activity of macrophages and neutrophils triggers a metabolic
pathway, the respiratory burst , where reactive oxygen species (ROS) and re-
active nitrogen intermediates (RNIs) are produced inside the cells. These
products are partially secreted in the extracellular space, as are peptidases
from neutrophil granules. Besides killing pathogens, the ROS inactivate cer-
tain peptidase inhibitors by oxidation and the peptidases that escape natu-
ral controls degrade the ECM. Collagen for example is degraded by matrix
metallopeptidase-1 (interstitial collagenase) [49], fibronectin, an important
protein in cell-matrix communication [91], is hydrolyzed by cathepsin B [48],
elastin by human elastase-2 (human leukocytes elastase) [95].
1.1.4 Control of Matrix Remodeling and its Failure
In situations like inflammation, it is essential to strictly control the whole
process, for example the action of the peptidases secreted by neutrophils.
Two strategies to control the activity of secreted peptidases are the use
of endogenous inhibitors (Table 1.1, p. 16) and the local restriction of
less specific enzymes, like elastase-2 or cathepsin B, by binding them to
the cellular membrane. Any failure in the control of peptidases results
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in excessive pathological degradation of the ECM as seen for instance in
lung fibrosis [65], osteoarthritis [14], and tumor progression and metastasis
[71, 76, 101, 114].
Typical characteristics of chronic inflammation are the persistent accumu-
lation of active macrophages that secrete peptidases, which in turn degrade
matrix components, and reactive oxygen species that damage the surround-
ing tissue. Furthermore, the activity of macrophages stimulates the prolif-
eration of fibroblast and the production of extracellular matrix components
(stroma reaction). At sites of chronic inflammation, granulomas with a cen-
tral part of macrophages surrounded by lymphocytes are often formed. Dur-
ing the development of chronic inflammation, mediators such as interferon γ
released by T-cells, and tumor necrosis factor secreted by macrophages, play
an important role. These cytokines stimulate the production of cell adhe-
sion molecules, which results in the recruitment of even more inflammatory
cells.
In lung emphysema, the alveolar septum is destroyed by chronic cough,
asthma attacks, oxidants from smoke [111] or air pollution. Following in-
flammation of the lung tissue, flow resistance increases and aggravates expi-
ration resulting in overload and hyperdistension of the lung. Because of the
tissue damaged, neutrophils are attracted and stimulated to secrete prote-
olytic enzymes.
Another severe pulmonary pathology is lung fibrosis, in which fibroblasts
proliferate and large amounts of collagen fibers are stored in the alveolar
septum. As a consequence, the lung loses its elasticity and the ability to
expand reversibly.
Various risk factors such as age, sex, trauma, overuse, genetics determinants
contribute to the onset of osteoarthritis. Following initial weakening in the
collagen network, proteoglycans absorb more water molecules, which results
in a more nutrient-rich and oxygen containing environment. Chondrocytes
within this new environment change their metabolism from anaerobic to aer-
obic and are subjected to phenotypic transition characterized by swelling,
proliferation and the production of collagen types I and III, which are oth-
erwise typical of skin, instead of collagen type II. The stiff collagen types I
and III can not sustain the mechanical requirements of articular cartilage.
A marker of this characteristic osteoarthritic phenotype is cathepsin B, per-
haps the most destructive enzyme in the affected joints [20, 64, 79, 116].
This phase may last several years until physical stress becomes important
for joint stability. The synoviocytes are then induced to produce and secrete
interleukin-1 and tumor necrosis factor, which in turn stimulate chondro-
cytes to express and secrete matrix degrading peptidases such as matrix
metallopeptidases and ADAMTS (a disintegrin and metallopeptidase with
thrombospondin motifs). Moreover, the production of different glycosamino-
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glycans is impaired [14].
In rheumatoid arthritis enzymatic destruction of cartilage is associated with
an autoimmune response, which is responsible for the chronic character of
the pathology.
One of the most intensively investigated fields in the context of pathological
ECM degradation is tumor invasion and metastasis. The pathology of ma-
lignant tumors is characterized by two critical steps: local invasion around
the primary tumor and the following metastatic spread to distant sites in the
organism, where new tumor cell colonies grow up. To accomplish this tasks
tumor cells secrete hydrolytic enzymes, among which several peptidases are
the mediators of ECM degradation.
Endopeptidases favor the detachment of cells from the primary tumor mass
and degrade proteoglycans, collagen, elastic fibers as well as basal membranes
promoting intravasation of tumor cells into blood vessels. Extravasation at
remote sites is sustained enzymatically as well. Cysteine peptidases, notably
the cathepsins B, H, L and S [60, 76], but also serine and metallopeptidases
are the protagonist enzymes in this complex scenery.
1.2 Control of Peptidases in ECM Remodeling and
Degradation
Peptidases are implicated in a multitude of events in an organism, from
its development (fertilization, implantation, embryogenesis, morphogenesis,
differentiation), over healing (inflammation, wound repair) to pathological
events (arthritis, lung emphysema, tumor). A relevant function of pepti-
dases is the processing of precursor proteins to their active forms by limited
proteolysis [21, 59]. A detailed analysis of the life cycle of these enzymes
in the context of ECM degradation is a prerequisite for the development of
efficient strategies against the pathologies in which they are involved.
The peptidases involved in tissue remodeling and degradation, their function
and the problems encountered while planning their control by exogenous in-
hibitors are discussed in this section.
1.2.1 The Peptidases Involved
The pathologically relevant peptidases are exactly the same enzymes needed
by cells for their regular functions. The enzymes are either stored in the
lysosomes or secreted in the extracellular space. The matrix metallopepti-
dases such as MMP-1 (EC 3.4.24.7) also known as interstitial collagenase
1, MMP-2 (EC 3.4.24.24), formerly known as gelatinase A or MMP-3 (EC
3.4.24.17) (stromelysin 1), cleave, as their name implicates, collagen and
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other important proteins in the matrix. The activation of these matrix met-
allopeptidases is achieved by limited proteolysis.
Common to all these enzymes is their need of zinc, cobalt or maganese for
their catalytic activity and some of them require also calcium. Besides matrix
proteins, which among other functions mediate cell attachment to the ECM
(e.g. integrin, perlecan, and syndecan), also cytokines and the tumor necro-
sis factor as well as the endogenous α1-peptidase inhibitor are hydrolyzed by
MMPs.
Often, a teamwork is needed between different enzymes, as for example be-
tween MMP-1 and ADAMTS. Most of the different collagen types are de-
graded by MMP-1 but before this can happen, the aggrecanases ADAMTS4
(EC 3.4.24.82) and ADAMTS5 (3.4.24.-) are required to degrade proteogly-
cans and to demask the collagen fibrils embedded therein. As their practical
name indicates, the substrate of these enzymes is aggrecan, the large pro-
teoglycan typically found in hyaline cartilage [82].
Within the serine peptidase family S1 (trypsin family) three enzymes emerge
for their participation in remodeling and degradation of tissue matrix, namely
elastase-2 (EC 3.4.21.37), cathepsin G (EC 3.4.21.20) and myeloblastin (EC
3.4.21.76), also known as leukocyte proteinase 3. When these enzymes are
secreted into the extracellular space they are extremely destructive enzymes
for the human body.
Elastase-2 and myeloblastin have a similar specificity for substrates and hy-
drolyze among other proteins elastin, collagen, fibronectin as well as plasma
proteins. Cathepsin G is structurally related to elastase-2 and degrades be-
sides matrix components [57], also immunoglobulin G and M [11, 12], a
property shared with elastase-2. The three leukocyte peptidases are also
involved in the digestion of bacteria and are collectively named serprocidins
(serine proteinases with bactericidal activity) to underline this fact [30].
An interesting feature of the three enzymes is their basic isoelectric point and
their highly positive charged surface due to the numerous arginines residues
(Figure 1.2) [85]. These charges are responsible for electrostatic interac-
tions with different glycosaminoglycans, such as chondroitin-4-sulfate and
dermatan sulfate [6, 7]. The strength of the interaction and the resulting
modification of the enzyme activity depends above all on the chain length of
the glycosaminoglycans, the position of the carboxyl groups, the sulfatation
isomerism and sulfatation degree [63], as well as their flexibility [32]. Addi-
tionally, it was shown that, depending on the substrate (peptide or protein
substrate), the interaction of glycosaminoglycans with myeloblastin results
either in an increase or decrease in the enzyme activity [46].
A further group of enzymes strongly involved in tissue remodeling and degra-
dation are some cathepsins of the cysteine peptidases. These enzymes are
not only responsible for intracellular digestion of proteins but also engaged
in extracellular proteolysis [17, 75, 110].
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Figure 1.2: Surface representation of elastase-2 (PDB code 1HNE), ’front’
(left) and ’back’ (right). All 18 (of totally 19) arginines on the surface are
colored in blue. Active site (His57, Asp102, Ser195) is colored in red.
Cathepsins L (EC 3.4.22.15) and B (EC 3.4.22.1) degrade extracellular ma-
trix proteins such as collagen [70], fibronectin [16, 27, 105], link protein of
proteoglycan [29, 78], glucagon [5] and cytosolic proteins [38]. Cathepsin
B regulates the activity of aldolase [24], converts prorenin to renin [2] and
trypsinogen to trypsin [51]. Additionally, cathepsin B is involved in pro-
cessing the prohormone thyroglobulin [26] and in the presentation of antigen
via MHC complexes [74]. Cathepsin K (EC 3.4.22.38) is typically found in
osteoclasts, where it is the major peptidase involved in bone resorption, be-
sides cathepsin B, L and S [54]. Glycosaminoglycans are essential for the
collagenolytic activity of cathepsin K under acidic conditions [68].
Procathepsin L also interacts with different glycosaminoglycans such as dex-
tran sulfate, heparan sulfate and chondroitin sulfate, which promote auto-
catalytic activation of the proenzyme [73]. These interactions do not impair
the ability of cathepsin L to degrade matrix proteins [56].
Cathepsin S (EC 3.4.22.27) is present in all MHC II positive cells, where it
is involved, besides in the degradation of matrix proteins [36], in degrading
the invariant chain of MHC II molecules and subsequent proper antigen pre-
sentation [96].
The aspartic peptidase cathepsin D (EC 3.4.23.5) is found in the lyso-
somes of various cells and degrades several chemokines released by activated
macrophages during inflammation [112].
1.2.2 The Life Cycle and Control of the Peptidases
Knowing the life cycle of an enzyme is essential for identifying potential tar-
gets for therapeutic intervention. The mentioned peptidases show the follow-
ing course until they reach their mature form and degrade ECM structures:
Stimulation → Biosynthesis → Inactive enzyme → Activation → Active en-
zyme → Storage or release as active enzyme → Degradation of the ECM. In
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case of extracellular activation the inactive enzyme is released as a precursor
into the extracellular space.
Theoretically, each of these steps offers a potential target for intervention,
including modulation of stimuli that govern the rate of biosynthesis, inhibi-
tion of intra-/extracellular activators, intra-/extracellular inhibition of the
enzyme, promotion of intracellular storage and protection of the extracellu-
lar matrix. Not all of these interventions may be equally effective and, above
all, feasible.
Considering the life cycle of an enzyme, it is essential to know the properties
of its mature form as well as its relationships with the surroundings in the
extracellular space. These include interactions with matrix molecules, which
may affect enzyme activity. In the specific case of cathepsin B it was shown
that its survival in the extracellular space depends on the local pH [13, 108,
109].
In a healthy organism, it is the duty of specific and effective endogenous
inhibitors to control the action of peptidases [69]. Table 1.1 contains a few
examples of naturally occurring protein inhibitors with their major target
enzymes. A comprehensive treatment of peptidases and their inhibitors can
be found in the MEROPS database [94] (http://merops.sanger.ac.uk).
Proteinaceous inhibitors are often unspecific towards a peptidases [40, 89].
For example, being present in functionally unrelated proteins, thyropins, thy-
roglobulin type-1 domains with inhibitory activity, can interact with mem-
bers of both cysteine and aspartic peptidases [66].
Additionally, many hundreds of synthetic inhibitors are known, such as the
group of the epoxysuccinyl derivatives for the cysteine peptidases [45, 90] or
the pyrrolidine scaffold-based metallopeptidases inhibitors [113].
In pathological situations, extracellularly acting peptidases are insufficiently
controlled by their endogenous inhibitors, and their continuous secretion
leads to excessive local accumulation of unwanted enzyme activities, which
eventually results in pathological ECM turnover.
There are three main reasons why the naturally occurring inhibitors are
unable to efficiently control the system [10, 31]:
- Imbalance between enzymes and their inhibitors. As a result of the
continuous secretion of peptidases into the extracellular space, their
concentration is much higher than the concentration of natural in-
hibitors.
- Formation of a microenvironment between the peptidase-secreting cell
and the ECM, which hinders natural inhibitors to reach their target
enzymes.
- Inactivation of inhibitors by reactive oxygen species produced by phago-
cytic cells during the respiratory burst.
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Table 1.1: Peptidases and their natural inhibitors. MEROPS [94] identifier
in parenthesis. SLPI; secretory leukocyte proteinase inhibitor, timp; tissue
inhibitor of metallopeptidase.
Endogenous inhibitor Main natural peptidases
α-1 peptidase inhibitor (I04.001) elastase-2 (S01.131),
cathepsin G (S01.133)
α-2 macroglobulin (I39.001) elastase-2 (S01.131),
cathepsin B (C01.060),
cathepsin D (A01.009),
cathepsin G (S01.133),
cathepsin H (C01.040)
cystatin A (I25.001) cathepsin S (C01.034),
cathepsin H (C01.040)
cystatin B (I25.003) cathepsin S (C01.034),
cathepsin H (C01.040)
elafin (I17.002) elastase-2 (S01.131),
myeloblastin (S01.134)
SLPI domain 1 (I17.950) elastase-2 (S01.131),
cathepsin G (S01.133)
timp-1 (I35.001) matrix metallopeptidase-1 (M10.001)
timp-2 (I35.002) matrix metallopeptidase-2 (M10.003)
timp-3 (I35.003) matrix metallopeptidase-3 (M10.005)
The following are possible explanations why synthetic inhibitors are ineffi-
cient against their putative target peptidases:
- Peptidases have high affinities to their natural substrates and therefore
they do not dissociate easily. Acting on the ECM these enzymes are
continuously faced with a virtually infinite concentration of substrate
and, assuming the simple Michaelis-Menten mechanism to be valid,
their rate of substrate turnover corresponds to the limiting rate.
Thermodynamically, concentration of any solid (insoluble) molecule is
considered to be 1M by convention, which in the case of ECM compo-
nents means infinite, i.e. enzymes engaged in ECM turnover are always
saturated with respect to substrate. The competition by any inhibitor
needs a particularly strong interaction between enzyme and inhibitor.
- Peptidases secreted into the ECM are surrounded by a multitude of
potential interacting partners, such as the ECM itself, endogenous in-
hibitors or cell membrane receptors. Single or multiple binding to any
of these interaction partners may induces conformational changes in
the enzymes and affect the binding affinity of an exogenous inhibitor.
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- Considering that several peptidases may be engaged in ECM turnover
at the same time and in the same environment, enzyme-enzyme inter-
actions, as well as enzyme-inhibitor interactions are plausible.
A few examples illustrate the complex network of interactions that
may occur: Elastase-2 activates other peptidases such as matrix met-
allopeptidases [81] and procathepsin B [37] and inactivates peptidase
inhibitors (timp-1 [83], cystatin C [29]). Cathepsin B, L and S inac-
tivate the SLPI domain 1 [106], an inhibitor of elastase-2. Elastase-2
preadsorbed on elastin is no longer efficiently inhibited by α1-peptidase
inhibitor [95]. Besides elastase-2, also the cathepsins K, L and S inter-
act with elastin by a two step binding mechanism resulting in a tightly
bound enzyme-elastin complex [86]. Glycosaminoglycans, such as hep-
aran sulfate, bind enzymes (e.g. cathepsin B [1]) but also inhibitors
(e.g. timp-3 [115]), which results in the alteration of enzyme activity.
Polynucleotides, present in the bronchial fluid of patients with lung dis-
eases, bind elastase-2 [18, 19, 67], cathepsin G [42] and myeloblastin
[41] affecting their inhibition by endogenous inhibitors.
1.2.3 New Trends in the Control of Peptidases
A common strategy in industrial and academic research on synthetic in-
hibitors of peptidases, has been, and continues to be, targeting the inhibitors
to the active center of the enzymes. While this is an excellent approach for
inhibiting enzymes acting on soluble substrates, it did not prove to be ef-
fective when the substrates are insoluble [10]. In recent years, the concept
of targeting enzymes with molecules binding outside the active center, has
become increasingly popular [53, 58]. The concept of allosteric control of
enzyme activity, widely exploited in nature (e.g. HIV-1 reverse transcrip-
tase, fructose-1,6-bisphosphatase), is receiving great attention and represents
a challenging alternative to classical inhibitors for pharmacological applica-
tions. Thus, targeting a peptidase that is tightly bound to insoluble compo-
nents of the ECM by allosteric effectors represents a new, stimulating and
still little explored trend.
A promising approach is represented by ’designed ankyrin repeat proteins’
(DARPins) [23], purposely in vitro engineered proteins for specific, high-
affinity target binding [22, 43, 98]. This approach consists in the random
and unspecific search for good binders at the surface of a protein. The prob-
ability of finding good binders is very high but serendipitous, because the
binding portion at the surface of the target protein can not be predicted.
Nevertheless, the hitherto known examples are amazing for their efficiency,
such as the allosteric inhibition of human caspase-2 [98] and of aminoglyco-
side phosphotransferase [61].
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A specific approach on the search of potential allosteric sites in proteins,
is the screening of evolutionarily conserved residues in whole protein fami-
lies. Allosteric communication is an important process during cell signaling
and there is evidence that conserved residues are the structural motifs for
this communication [50, 102]. Proteins such as myoglobin [44] and serine
peptidases related to chymotrypsin, unsuspected to be capable of allosteric
regulation, revealed to be true allosteric proteins. Mutation of the con-
served residues responsible for long-range communication in allosteric en-
zymes could provide valuable information on the possible use of hot spots
for targeting modifying agents.
A widely exploited and fully computational screening method for predicting
the binding mode of small molecules to proteins as well as the affinity of the
interaction is the ’docking’ procedure, a method that is particularly useful
in the development of new drugs. Calculations are performed with a large
amount of virtual molecules to pick out only the most promising binders.
After the establishment of putative binding pockets on the surface of the
target protein, a library of molecules (e.g. the ZINC database [55]) is pre-
pared for the actual docking procedure by conversion of the 2D molecules to
3D compounds and the addition of water molecules (Figure 1.3).
2D molecules
3D & add hydrogens
DAIM
SEED
FFLD
Conformation
optimization
Ranking
Prepared protein
structures
Figure 1.3: Docking procedure. DAIM: Decomposition and Identification of
Molecules, SEED: Solvation Energy for Exhaustive Docking, FFLD: Fragment-
based Flexible Ligand Docking.
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The fragment-based docking procedure can be summarized in three steps:
1) Decomposition of the molecule into small rigid fragments [62]. 2) The
fragments are docked into the putative binding pocket using an accurate
scoring function, which not only considers the internal energies of the two
interacting molecules but also the basic terms of their interactions [72]. 3)
The original structure is re-merged so that the positions with the most fa-
vorable interaction energies can be used as anchors for deciding the definite
position of the ligands [28, 33]. The following two final steps consist of the
conformational optimization and the ranking of the compounds.
The docking method has been used in this thesis for purposely targeting an
inhibitory ligand to the characteristic peptide extension of human cathepsin
B known as the occluding loop. The flexibility of this structure is manifested
after removal of the propeptide [80, 92, 93]. In mature cathepsin B, endo-
and exoproteolytic activity depend on the conformation of the occluding
loop [84]: In the ’closed’ conformation, the primed subsites of the substrate
binding sites are obstructed and therefore only exoproteolytic cleavage takes
place. In the ’open’ conformation, the primed subsites are free and the
enzyme acts as endopeptidase. Theoretically, following fixation of the oc-
cluding loop in its closed position with a ligand, the exopeptidase activity
should be retained and the endopeptidase should be hindered.
1.3 Properties of an Ideal Modifier of Peptidases in
a Pathological Environment
Besides being specific and efficient against their target enzymes, therapeuti-
cally useful modifiers should possess additional properties: an effective over-
all mechanism of action, low toxicity and antigenecity, and good bioavailabil-
ity. Thus, technically precise studies of the modifiers in vitro can suggest
their possible effectiveness in vivo. The successful use of enzyme inhibitors
in vivo depends on the fulfillment of six criteria listed on the right side of
Figure 1.4.
From a theoretical point of view, the best inhibitor of any unwanted enzyme
activity will be the substance possessing a favorable set of all six properties
(Figure 1.4, right side). A critical analysis of the impact of these criteria
in the particular field of inhibition of ECM-degrading peptidases has shown
that some of the six properties of the inhibitors are mutually dependent when
considered in the light of seven properties of the target enzymes and of the
diseases with which they are associated (Figure 1.4, left side).
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Properties of the diseases
and of the enzymes Properties of the inhibitors
More than one enzyme is
active at the pathological sites
Duration of the disease
Pathological enzymes may be
essential at physiological site
The active center of the
enzyme is hardly accessible
High affinity of the enzyme
for the extracellular matrix
Proteolysis may not be the
driving mechanism of the disease
Long latency before the
disease becomes symptomatic
Bioavailability
Toxicity
Antigenicity
Efficient Inhibition
Specificity
Kinetic Mechanism
Figure 1.4: Properties of diseases with involved enzymes (natural factors) and
of inhibitors aimed at attenuating the adverse affects (adapted from [10]). The
objective is to inhibit the enzymes by making the best use of the six properties
of the inhibitors shown on the right side. Dotted arrows join those properties
of the inhibitors that are logically dependent from one another. The central
dashed and full-line arrows denote the problems arising with the practical use
of the inhibitors: full lines represent critical tasks and dashed lines indicate
problems for which individual solutions are theoretically possible. The grey
underscored properties represent three serious drawbacks in the pharmacolog-
ical management of ECM-degrading peptidases.
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1.3.1 Bioavailability, Toxicity and Antigenecity of the In-
hibitor
The pharmacokinetic concept of bioavailability includes all processes respon-
sible for the presence of a drug at the target site and is a complex function
concerned with drug resorption and metabolism. This property describes the
quantity of a substance, which is actually available to the organism. In the
case of ECM-degrading peptidases, drugs must be able to effectively reach
their final target site. A modern approach to this difficult task is the delivery
of peptidase inhibitors incorporated in nanoparticles [34, 35].
Toxicity relates to both the bioavailability and the efficiency of drugs. The
most common warheads used to inactivate peptidases include alkylating or
acylating chemical groups attached to recognition elements specific for the
target enzymes. Unfortunately, while the recognition elements may be spe-
cific for the enzymes, this is not the case of the warheads, which my react
non-specifically with essential metabolites.
The lack of antigenecity (= capacity to induce an immune response), an obvi-
ous requirement for the use of drugs, paradoxically conflicts with the notion
that most physiological inhibitors of endopeptidases are proteins as well.
These inhibitors have the function of defending the organism form excessive
proteolysis due to leakage of the enzymes from dead cells or accidentally
liberated in the extracellular space. The use of heterologous macromolecular
inhibitors is restricted to substances with structural identity or similarity
with the corresponding human inhibitors. In any case, they should not elicit
immunological reactions.
Hence, many macromolecular substances occurring in plants and animals,
e.g. the elastase-2 inhibitor eglin from the leech Hirudo medicinalis [15, 100]
can not be used in humans.
1.3.2 Efficiency, Specificity and Kinetic Mechanism of the
Inhibitors
Avoiding side effects in enzyme inhibition also means conservation of the ac-
tivities of beneficial non-target enzymes while suppressing undesired effects,
and the specificity for the target enzymes is an obvious requirement. Thus,
efficient (potent) inhibition is a welcome property denoted by a large second-
order association constant for enzyme inactivators (irreversible inhibitors),
or low Ki values for reversible inhibitors1.
The progress made in the production of specific and efficient inhibitors of
peptidases is considerable and modern medicinal chemistry excellently han-
dles these two properties. However, the kinetic mechanism of the inhibitors
1Although not universally accepted, the term ’efficiency’ applies to reversible inhibitors,
while ’potency’ is preferred to describe the action of inactivators.
22 | Introduction
plays a decisive role for their practical use. Unfortunately, highly efficient
peptidase inhibitors may present the drawback of low rates of complex for-
mation with the target enzymes resulting in insufficient protection [9, 10].
We can postulate a satisfactory management of the chemical and pharma-
cokinetic requirements of peptidase inhibitors such as to justify their use as
drugs (Figure 1.4, right side). However, the properties of the diseases and
of their associated enzymes (Figure 1.4, left side) represent natural factors,
which are intrinsic to the system and, therefore, not modifiable by external
intervention.
Three aspects are particularly problematic: the double identity of peptidases
in their physiological and pathological function, the frequently inaccessible
active center of the enzymes at their pathological site, and the tight bind-
ing mode of the enzymes to their substrates, insoluble components of the
ECM. Figure 1.4 indicates with connecting double headed arrows the mul-
tiple relationships existing between the properties of the enzymes, of the
diseases and the inhibitors. These render the pharmacological management
of ECM-degrading peptidases remarkably problematic.
The three relationships marked in Figure 1.4 by full-line arrows deserve a
few comments. There is a relationship between the bioavailability and the
toxicity of a drug when reactions occur at non-target sites. To be effec-
tive, inhibitors of ECM-degrading peptidases should be transported to and
interact with the enzymes only at their pathological site, while preserving
their physiological activity. Moreover, enzymes embedded in the ECM are
generally hardly accessible by excellent inhibitors.
The description of a modifier’s mechanism contains not only the interactions
between enzyme and modifier dictated by their chemical structure, but also
the steps and rates with which they react with each other. Knowledge of the
interaction mechanism and its effects on the enzyme activity, which depend
on the inhibitor and substrate concentrations, is very important in the de-
velopment of therapeutically useful compounds. The appendix A.1 and B.1
list the classification of inhibition and activation mechanisms.
It is important to note that the interaction mechanism of a modifier with
an enzyme may depend on the nature of the substrate. In fact, analysis
of the reaction mechanism of inhibitors with peptidases involved in patho-
logical ECM-degradation, reveals quantitative differences in the behavior of
the modifier depending on whether low-molecular-mass substrates or macro-
molecular substrates are considered. In particular, there is experimental ev-
idence that linear competitive inhibitors (classical and tight binding) found
to be effective at given concentrations in presence of low-molecular-mass
substrates, must be used at much higher concentrations to obtain the same
effects with macromolecular substrates [3, 4].
As mentioned above, peptidases acting on insoluble substrates of the ECM
are faced with saturating substrate concentrations and a large concentration
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of inhibitors is needed to gain satisfactory effects. Much more promising are
therefore, linear or hyperbolic mixed-type inhibitors with a high proportion
of uncompetitive character, even if at saturating concentrations hyperbolic
inhibitors will not completely abolish enzyme activity. However, inhibitors
like these are efficient even at saturating substrate concentrations.
1.4 Aim of the Thesis
The control of proteolytic activity in the extracellular space by means of ex-
ogenous enzyme modifiers requires specific strategies, which must cope with
the insoluble nature of the ECM. Three main goals of this thesis were:
- to develop new criteria for peptidase inhibition as an alternative to
classical approaches based on targeting the active sites of the enzymes
- to re-evaluate kinetic diagnostic tools and mathematical models for
analyzing enzyme-modifier interactions
- to explore the interaction mechanisms between enzymes and modifiers
in an experimental system that considers the natural environment.
In this context, the human cysteine peptidase cathepsin B was chosen as
a target for its recognized involvement in key pathophysiological processes.
The particular structure of cathepsin B known as ’occluding loop’ was screened
with a computational approach for selecting binders that would interfere with
this site. The sought ’proof of principle’ was inhibition of enzyme activity
without interference with the catalytic site.
Exogenous modifiers of peptidase activity are likely to interfere with natu-
rally occuring inhibitors and components of the ECM, and these interactions
are expected to generate effects ranging from synergy to antagonism. In this
framework, a reassessment of the theory of multiple enzyme-modifier inter-
actions was compelling. The validation of a general mathematical model for
double interaction between an enzyme and two modifiers, and an exhaustive
screening of plausible interactions, constituted a major task of this thesis.
Furthermore, kinetic mechanism and diagnostic tools for irreversible enzyme
modification were in need of re-evaluation to facilitate mechanism discrimi-
nation by combined graphical and mathematical methods.
The setup of improved methods was aimed at supporting the interpreta-
tion of puzzling effects, such as the interaction between the serine peptidase
elastase-2 with naturally occurring glycosaminoglycans, which results in in-
hibition at low concentrations and reactivation at higher concentrations of
these ECM components.
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These methods should not only allow quantitative predictions of interfer-
ences occurring between endogenous and exogenous inhibitors of peptidases
involved in degradation and remodeling of the ECM, but also in other en-
zyme systems.
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Abstract
Synthetische Inhibitoren der Peptidasen zielen bei der Inhibition der Katal-
yse oftmals auf die aktive Stelle ab, sei dies durch reversible Verdrängung des
Substrats oder durch kovalente Modifikation der katalytischen Gruppen des
entsprechenden Enzyms. Cathepsin B besitzt als einzige Cysteinpeptidase
ein flexibles Segment, den sogenannten ’occluding Loop’, welcher den C-
terminalen Teil der Substratbindungsstelle blockieren kann. Ist dieser Loop
in einer offenen Stellung, agiert das Enzym als Endopeptidase, entsprechend
in der geschlossenen Loopstellung als Exopeptidase.
Wir fokussierten uns unter Anwendung einer Dockingprozedur auf den sich
an der Oberfläche von Cathepsin B und damit ausserhalb des katalytischen
Zentrums befindenden occluding Loops. Ziel war es, Inhibitoren zu identi-
fizieren, welche mit dem occluding Loop interagieren und dadurch die Enzy-
maktivität modulieren, jedoch ohne direkt gegen die katalytischen Gruppen
zu wirken.
Aus einer umfangreichen Bibliothek von Compounds konnte durch die in sil-
ico Annäherung [2-[2-(2,4-dioxo-1,3-thiazolidin-3- yl)ethylamino]-2-oxoethyl]
2-(furan-2-carbonylamino)acetat identifiziert werden, der die Arbeitshypo-
these erfüllte. Das Molekül besitzt zwei individuelle Bindungseinheiten und
verhält sich gegenüber Cathepsin B als reversibler, ’doppelköpfiger’ kompet-
itiver Inhibitor, der synthetische Substrate wie auch Proteinsubstrate vom
aktiven Zentrum ausschliessen kann. Der Inhibitionsmechanismus deutet da-
rauf hin, dass der occluding Loop mit dem Inhibitor vor allem über Wasser-
stoffbrücken interagiert und so in seiner geschlossenen Konformation stabil-
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isiert wird, wobei die Endopeptidaseaktivität des Enzyms eingeschränkt ist.
Ausserdem hindert der Dioxothiazolidinteil des Compounds sterisch die An-
bindung der C-terminalen Einheit des Substrats, was zu einer Inhibition der
Exopeptidaseaktivität von Cathepsin B in einem physiopathologisch relevan-
ten pH Bereich führt.
A double-headed cathepsin B inhibitor devoid
of warhead
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Abstract
Most synthetic inhibitors of peptidases have been targeted to the active site for inhibiting catalysis through
reversible competition with the substrate or by covalent modification of catalytic groups. Cathepsin B is
unique among the cysteine peptidase for the presence of a flexible segment, known as the occluding loop,
which can block the primed subsites of the substrate binding cleft. With the occluding loop in the open
conformation cathepsin B acts as an endopeptidase, and it acts as an exopeptidase when the loop is closed.
We have targeted the occluding loop of human cathepsin B at its surface, outside the catalytic center, using a
high-throughput docking procedure. The aim was to identify inhibitors that would interact with the occluding
loop thereby modulating enzyme activity without the help of chemical warheads against catalytic residues.
From a large library of compounds, the in silico approach identified [2-[2-(2,4-dioxo-1,3-thiazolidin-3-
yl)ethylamino]-2-oxoethyl] 2-(furan-2-carbonylamino) acetate, which fulfills the working hypothesis. This
molecule possesses two distinct binding moieties and behaves as a reversible, double-headed competitive
inhibitor of cathepsin B by excluding synthetic and protein substrates from the active center. The kinetic
mechanism of inhibition suggests that the occluding loop is stabilized in its closed conformation, mainly by
hydrogen bonds with the inhibitor, thus decreasing endoproteolytic activity of the enzyme. Furthermore, the
dioxothiazolidine head of the compound sterically hinders binding of the C-terminal residue of substrates
resulting in inhibition of the exopeptidase activity of cathepsin B in a physiopathologically relevant pH range.
Keywords: cysteine peptidases; inhibition; enzyme kinetics; occluding loop; docking; endopeptidase;
exopeptidase
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Cathepsin B, a cysteine peptidase of the papain family
(EC 3.4.22.1, identifier C01.060 in the Merops database)
(Rawlings et al. 2004), has been classically ranked among
the lysosomal enzymes and implicated in intracellular
protein digestion. Physiologically, cathepsin B is also
involved in antigen processing (Matsunaga et al. 1993), in
the activation of thyroglobulin, the precursor of thyroid
hormones (Friedrichs et al. 2003), and in the maturation
of beta-galactosidase (Okamura-Oho et al. 1997). From a
pathological point of view, cathepsin B activates trypsin-
ogen in hereditary pancreatitis (Kukor et al. 2002) and
participates in apoptosis (Bro¨ker et al. 2005), tumor pro-
gression and malignancy (Yan and Sloane 2003; Mohamed
and Sloane 2006), and rheumatic diseases (Lenarcic et al.
1988; Baici et al. 1995a,b). Particular extralysosomal
functions of cathepsin B are due to altered expression at
the gene level and/or atypical trafficking (Mu¨ntener et al.
2003, 2004; Zwicky et al. 2003; Baici et al. 2006).
ps037341 Schenker et al. ARTICLE RA
Reprint requests to: Antonio Baici, Department of Biochemistry,
University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich,
Switzerland; e-mail: abaici@bioc.uzh.ch; fax: 41-44-6356805.
Abbreviations: Abz, ortho-aminobenzoyl; AMC, 7-amino-4-methyl-
coumarin; DTT, dithiothreitol; Z, benzyloxycarbonyl; Dnp, Ne-2,4-
dinitrophenyl; FRET, Fo¨rster resonance energy transfer; DOFA,
[2-[2-(2,4-dioxo-1,3-thiazolidin-3-yl)ethylamino]-2-oxoethyl] 2-(furan-2-
carbonylamino)acetate; MALDI, matrix-assisted laser desorption/ionization;
MS, mass spectrometry; LC, liquid chromatography; SDS-PAGE, sodium
dodecyl sulfate, polyacrylamide gel electrophoresis.
Article and publication are at http://www.proteinscience.org/cgi/
doi/10.1110/ps.037341.108.
Protein Science (2008), 17:2145–2155. Published by Cold Spring Harbor Laboratory Press. Copyright  2008 The Protein Society 2145
JOBNAME: PROSCI 17#12 2008 PAGE: 1 OUTPUT: Sunday November 2 03:22:56 2008
csh/PROSCI/170217/ps037341
Double-headed Cathepsin B Inhibitor | 29
Cathepsin B is capable of endopeptidase (Mort 2004),
peptidyl-dipeptidase (Aronson Jr. and Barrett 1978; Bond
and Barrett 1980), and carboxypeptidase activities (Takahashi
et al. 1986; Rowan et al. 1993). Among the cysteine pep-
tidases, it owns a unique structural element, called an
occluding loop, which comprises residues Ile105–Pro126
(Fig. 1; Musil et al. 1991). At low pH, two salt bridges,
His110–Asp22 and Arg116–Asp224, hold the loop in a closed
position over the primed subsites of the substrate binding
cleft, thus preventing extended binding of polypeptides and
endoproteolytic activity. The closed conformation, through
the engagement of His111 in a hydrogen bond with the C-
terminal carboxylate of the substrate and the loose specificity
in P29, is responsible for the peptidyl-dipeptidase activity of
cathepsin B (Illy et al. 1997; Quraishi et al. 1999; Krupa et al.
2002). As mutations of the amino acids His110 and Asp22 have
shown, removal of the salt bridges induces endopeptidase
activity, attributed to increased flexibility of the loop (Na¨gler
et al. 1997). This concept agrees with higher endopeptidase
activity and with the competition between the occluding loop
and the propeptide following deprotonation of His110 chang-
ing the pH from 4.0 to 6.0 (Quraishi et al. 1999). The
flexibility of the loop was further demonstrated by the fact
that cystatins A and C were able to displace the loop
(Nycander et al. 1998; Pavlova et al. 2000), and deletion of
residues 108–119 abolished the exopeptidase activity of
cathepsin B (Illy et al. 1997).
A large number of synthetic compounds behave as
inhibitors of cathepsin B. Most of them are either
reversible or irreversible competitive inhibitors acting
‘‘inside the active center’’ (Otto and Schirmeister 1997;
Michaud and Gour 1998; Frlan and Gobec 2006). The
practical use of these inhibitors is in most cases difficult
for reasons analyzed elsewhere (Baici 1998). In the
present study we target cathepsin B ‘‘from the outside,’’
i.e., at the surface of the molecule excluding any direct
interference with catalysis. Our strategy aims at proving
the concept that latching the occluding loop in its closed
conformation may possibly hinder the endo- and/or
exopeptidase activities of the enzyme. The approach
consists of computational analysis by docking a large
number of compounds to the surface of cathepsin B in the
occluding loop region. From 40 compounds matching the
working hypothesis, 29 are commercially available and
one of them inhibits at low micromolar concentration the
endo- and exoproteolytic activities of cathepsin B. We
analyze the kinetic mechanism of inhibition, from which
we propose a model for the interaction between the
compound and the enzyme.
Results
Kinetic mechanism of inhibition with synthetic substrates
Z-RRYAMC and Abz-GIVRYAK(Dnp)-OH were used as
substrates for monitoring the endo- and exoproteolytic
activity of cathepsin B, respectively. Arrows in the
substrate acronyms indicate the scissile bonds. Forty of
47,878 compounds screened in the docking approach
were selected as candidate binders of human cathepsin
B. Twenty-nine of them were commercially available and
were tested as modifiers of enzyme activity, and one of
them, DOFA (Fig. 2), behaved as a true inhibitor. Two
compounds out of 29 were scarcely soluble in DMSO
(Zinc-2005 codes 1271923 and 2990182; Supplemental
Table 1). Five of them were soluble in DMSO but were
prone to aggregation under the assay conditions for
cathepsin B giving rise to modest and inconsistent
inhibition between different assays. We considered these
five compounds (958753, 1837733, 1871954, 3247330,
and 1581881) as promiscuous inhibitors (Shoichet 2006).
None of the compounds tested was a covalent inactivator
of cathepsin B. DOFA did not inhibit human cathepsin L,
and papain was only partially inhibited at millimolar con-
centrations (assays with Z-FRYAMC; data not shown). A
Figure 1. The occluding loop of human cathepsin B. (A) Closed
conformation (red) in the mature enzyme (Musil et al. 1991), where a
hydrogen bond is made between His110 and Asp22. The conformation seen
in procathepsin B with the occluding loop lifted (green) to accommodate
the propeptide, which is not shown for clarity (Turk et al. 1996). Image
generated with PyMOL software (http://www.pymol.org). (B) Scheme of
the occluding loop with hydrogen bonds present in the closed confor-
mation. The symbol Glyc attached to Asn113 indicates the N-linked
oligosaccharide.
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previous report of high-throughput screening classified
DOFA inactive against cathepsin B (http://pubchem.ncbi.
nlm.nih.gov/, CID 2078629, AID 453). Reasons can be
sought in either too strict criteria or in the occasional failure
of high-throughput screening methods in detecting hits
(Buxser and Vroegop 2005). DOFA behaved as a reversible
inhibitor of cathepsin B and manifested neither tight-binding
nor slow-binding inhibition behavior. Reaction traces
were linear from the very beginning of the reaction, i.e.,
from 3–4 ms onward, as measured with a stopped-flow
apparatus. Therefore, initial velocities at variable sub-
strate and modifier concentrations were treated as steady-
state rates. In control experiments we checked the possi-
bility that any inhibitory effect of DOFA was not due to
aggregation of the compound. For this purpose 0.01%
Triton X-100 was added to buffers and the DTT concen-
tration was increased to 5 mM. In comparison with buffer
not containing detergent and with DTT ¼ 2 mM, the basal
activity of cathepsin B was higher by ;40%. However,
inhibition profiles for increasing DOFA concentration,
percentages of inhibition, and inhibition constants were
the same.
The kinetic results in this study refer to those obtained
with the enzyme purified from human liver. Nevertheless,
we confirmed inhibition mechanisms and kinetic param-
eters also with recombinant cathepsin B. The reason was
to ascertain any influence of glycosylation at N113, which
is located at the tip of the occluding loop, on the binding
of potential inhibitors. Both kinetic and modeling results
discussed below suggest that N113 glycosylation possibly
occurring in the wild-type enzyme does not affect
inhibition of cathepsin B by DOFA.
The kinetic mechanism was analyzed by a combination
of graphical and regression methods to discriminate
between models of enzyme–modifier interaction (Fig. 3).
With the Abz-GIVRYAK(Dnp)-OH exoproteolytic sub-
strate at pH 4.5, the best fitting model for cathepsin B
inhibition by DOFA was linear competitive inhibition with
I90/10¼ 81 andKi¼ 6.7mM (Fig. 4A). The specific velocity
plot, typical for this mechanism, is shown in the inset of
Figure 4A. With this substrate, data at pH 6.0 could not be
obtained because of its scarce solubility. DOFA inhibited
the endoproteolytic cathepsin B activity (Z-RRYAMC
as substrate) at pH 4.5 and 6.0. The specific velocity plot
(not shown) established the linear nature of the inhibition
Figure 2. Structure of the inhibitor. The IUPAC name of the compound is
[2-[2-(2,4-dioxo-1,3-thiazolidin-3-yl)ethylamino]-2-oxoethyl] 2-(furan-2-
carbonylamino)acetate (abbreviated DOFA; Zinc-2005 code: 2616818).
Numbering and lettering used as aid for the description in the main text.
Figure 3. Kinetic models for the inhibition of cathepsin B. vi and v0 represent reaction rates in the presence and in the absence of
inhibitor, respectively. s ¼ [S]/Km; I90/10 ¼ ratio of the inhibitor concentrations, which give 90% and 10% inhibition. The double-
headed inhibitor possesses two distinct binding moieties that sequentially bind the enzyme.
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process, i.e., enzyme activity was driven to zero at saturat-
ing inhibitor concentration, and diagnosed competitive-
type inhibition. However, the specific velocity plot would
not be able to discriminate between Models 1–3 in Figure 3.
The activity profiles obtained at a fixed substrate concen-
tration and variable inhibitor concentrations revealed the
I90/10 ratio to be less than 81, which can be estimated by
inspection to be around 60 at pH 4.5 and around 40 at pH 6.0
(Fig. 4B). This suggests that the inhibition mechanism was
not of the classical competitive type, for which I90/10 ¼ 81
(Model 1 in Fig. 3). On the other hand, Models 2 and 3 in the
same figure predict I90/10 values less than 81. For discrim-
inating between models with Z-RRYAMC as substrate, we
set its concentration equal to Km so that s¼ [S]/Km ¼ 1 in
the activity profiles in Figure 4B (thereby it was imperative
to carefully measure the substrate concentration and Km).
In Models 2 and 3, when the factor a ¼ 1, I90/10 depends
only on s, whereas for a 6¼ 1 the I90/10 ratio depends both on
a and s (Fig. 5A,B). Model 2 was ruled out as redundant,
and Model 3 was preferred on the basis of the following
quantitative and logical observations. In Model 2, two
inhibitor molecules should bind to different places at the
surface of the cathepsin B molecule with almost the same
affinity, i.e., with the a value between 1 and 2, as shown in
Figure 5A. The double-headed competitive inhibitor
(Model 3 in Fig. 3) was superior also on the basis of the
following quantitative observations. For Model 3, the
squared symbol with dashed arrows in Figure 5B indicates
the best-fit value for a ¼ 6 at pH 6.0, which corresponds to
I90/10¼ 37 andKi¼ 11.3mM (Fig. 4B). Similarly, at pH 4.5,
Model 3, with a ¼ 34 (the black circle in Fig. 5B), I90/10 ¼
59, and Ki ¼ 4.8 mM, produced a better fit to experimental
data (Fig. 4B) than Model 2.
Inhibition of endo- and exoproteolysis
using protein substrates
While low molecular mass oligopeptides are indispens-
able tools for determining inhibition mechanisms, they do
not represent typical substrates for evaluating true endo-
and exoproteolytic activities. Therefore, inhibition of
cathepsin B endo- and exoproteolysis by DOFAwas further
Figure 4. Inhibition profiles of human cathepsin B by DOFA. Main
conditions and best-fit kinetic parameters are shown. (A) Inhibition profile
using the FRET substrate Abz-GIVRYAK(Dnp)-OH (pH 4.5), [S] ¼ Km ¼
9.7 mM; data were obtained fluorimetrically with lex/lem at 320/420 nm.
The inset shows the specific velocity plot at four substrate and four
inhibitor concentrations. (B) Inhibition profiles with Z-RRYAMC as
substrate; [S] ¼ Km ¼ 0.47 mM at pH 6.0 (black circles) and [S] ¼ Km ¼
1.54 mM at pH 4.5 (black squares). Data at pH 6.0 were collected
photometrically at 360 nm and those at pH 4.5 were obtained fluorimetrically
with lex/lem at 383/455 nm. Fluorescence readings in A and B were
corrected for the inner filter effect.
Figure 5. Ratios of inhibitor concentrations that give 90% and 10%
inhibition. For Models 2 and 3 in Figure 3 the I90/10 ratio depends on a and
s ¼ [S]/Km. Curves were generated with Equations 4 and 6 shown in
Figure 3. (A) Curves for Model 2; (B) curves for Model 3. The black
squares in panels A and B correspond to the best-fit value of the coefficient
a, which coincides with the value obtained by inspection of the inhibition
profiles at pH 6.0 in Figure 4B. The black circle in panel B shows the best-
fit value of the coefficient a (34), close to the value obtained by inspection
of the inhibition profiles at pH 4.5 in Figure 4B.
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investigated with two protein substrates: rabbit muscle
aldolase and the oxidized b-chain of bovine insulin.
Peptide-bond hydrolysis on both proteins at pH 6.0 was
inhibited in a concentration-dependent manner by DOFA
(Fig. 6) and was almost complete at saturating inhibitor
concentration. As commonly observed when switching
from oligopeptide to polypeptide substrates, the modifier
concentrations needed for achieving inhibition were higher.
Cathepsin B has been previously reported to sequentially
remove up to nine dipeptide units from the C terminus of
aldolase with peptidyl-dipeptidase activity (Bond and
Barrett 1980). Aldolase incubated with cathepsin B in the
presence or absence of DOFA was subjected to SDS-PAGE
under reducing conditions. The bands excised after electro-
phoretic separation were N-terminally sequenced and the
masses of the polypeptides determined by mass spectrom-
etry. The SDS gels shown in Figure 7 were purposely over-
loaded to reveal the less prominent bands numbered 2, 3, and 4.
The N-terminal sequence of the polypeptides in bands 1 and 2
was PHSHPAL, which corresponds to positions 2–8 of
aldolase. Mass analysis of the whole broad band 1 revealed
the presence, besides intact aldolase with amino acids 2–364
and a mass of 39,216 Da, C-terminally degraded fragments
corresponding to sequences 2–362, 2–360, and other masses
down to 2–352 that were generated by the sequential removal
of six dipeptide units from the C terminus. The significant
presence of the 2–351 peptide indicates that aldolase degra-
dation also comprises carboxypeptidase activity of cathepsin
B. The tiny band 2 contained the polypeptide 2–347, which
was the smallest fragment obtained under the described
conditions and corresponded to the removal of 17 amino
acids from the C terminus, i.e., 8 dipeptide units (peptidyl–
dipeptidase activity) plus one amino acid (carboxypeptidase
activity). Bands 3 and 4 had the common N terminus
SIGTENT (positions 46–52), suggesting their generation
by a minor (but very useful for the purposes of this test)
endoproteolytic cleavage between Gln45 and Ser46. Band 3
corresponded to the 46–364 sequence and band 4 corre-
sponded to sequence 46–347. Comparison of the relative
intensities of bands 3 and 4 in lanes B and C (Fig. 7) suggests
that DOFA inhibited the exopeptidase activity of cathepsin B
on the macromolecular substrate aldolase, while the inhibitor
was less or not active against the endoproteolytic activity of
cathepsin B, as shown by the persistence of band 3 in lane C.
The bovine insulin b-chain is a helpful substrate for
exploring the specificity of peptide-bond cleavage by
peptidases, including human cathepsin B (McKay et al.
1983). The cleavage at multiple sites of the insulin b-chain
by cathepsin B was almost completely inhibited by a sat-
urating concentration of DOFA at pH 6.0 (Fig. 6). Samples
of insulin b-chain incubated with cathepsin B in the
presence and absence of DOFA were separated by liquid
chromatography, and the eluted peaks were analyzed by
mass spectrometry. We confirmed most of the cathepsin B
cleavages previously described (McKay et al. 1983). Addi-
tional cleavages, which depended on the incubation time
and the relative enzyme to substrate concentrations, were
identified. Each of the chromatographic peaks in Figure 8
contained only one (e.g., peptides 1–13, 1–14, and 6–28) or
more proteolytic fragments (e.g., peptides 20–30 plus 1–
11). Only a few of them will be discussed to demonstrate
the inhibitory activity of DOFA. The generation of peptides
1–11 and 20–30 by endoproteolysis was inhibited by
Figure 6. Inhibition of cleavage of rabbit muscle fructose 1,6-bisphos-
phate aldolase and of the bovine insulin b-chain by cathepsin B.
Concentration-dependent inhibition by DOFA at pH 6.0. Released peptides
were quantified fluorimetrically by the fluorescamine method.
Figure 7. Proteolysis of rabbit muscle fructose 1,6-bisphosphate aldolase
by cathepsin B. Aldolase was incubated 4 h at 25°C with cathepsin B at pH
6.0, and products were separated by SDS-PAGE. (Lane A) Aldolase alone
run in parallel as control; (lane B) aldolase plus cathepsin B; (lane C)
aldolase with cathepsin B and DOFA. The N- and C-terminal parts of the
rabbit aldolase sequence, with numbered amino acid residues, are shown at
the top of the figure. Thin arrows indicate sequential peptidyl-dipeptidase
cleavages by cathepsin B. The two open thick arrows show carboxypepti-
dase cleavages. The black thick arrow indicates a minor endoproteolytic
attack site. Numbers on the left side indicate the molecular masses of
markers in kilodaltons. Numbers 1–4 with long pointing arrows are
assigned to the bands for referencing in the main text, and the peptides
identified within the bands are shown next to the band numbers. Peptides
were identified in the excised bands by N-terminal sequencing and
MALDI analysis.
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DOFA. Fragment 1–13 was a product of carboxypeptidase
activity on peptide 1–14: While DOFA completely
inhibited this exoproteolytic event, endoproteolytic cleav-
age between residues 14 and 15 was unaffected, as shown
by comparing the chromatographic profiles in the absence
(Fig. 8, profile A) and in the presence of DOFA (Fig. 8,
profile B). Fragment 18–29, generated by endoproteolysis
at position 17–18 and exoproteolysis at position 29–30, was
strongly decreased in the presence of DOFA. Comparison
of the areas of fragments 18–29 and 18–30 after inhibition
shows that both the exo- and the endoproteolytic events
concerned with them were affected by the inhibitor. Carboxy-
peptidase activity inhibition is also shown by comparing the
disappearance of fragment 16–29 and the appearance of
fragment 16–30. Finally, the peptidyl–dipeptidase cleavage
shown by fragment 6–28 disappeared in the presence of
DOFA. Since the 6–30 peptide in Figure 8, profile B could
not be unambiguously assigned, inhibition could be as-
cribed to endoproteolytic cleavage at positions 5–6, peptidyl–
dipeptidase inhibition at position 28–29, or both.
Discussion
The docking approach used in this study aimed at
identifying compounds that bind to the occluding loop
of human cathepsin B and thereby modulate its enzymatic
activity. Considering that no other means are available for
selecting small molecules for a rather flexible protein
segment, the most diverse compound library was used.
There is a fundamental difference between our method-
ology and previous approaches to inhibitors that might
interact with parts of the occluding loop of cathepsin B
(Murata et al. 1991; Michaud and Gour 1998; Cathers
et al. 2002). These studies exploited the properties of the
fungal inhibitor E-64 (Hanada et al. 1978) and the crystal
structure of cathepsin B (Musil et al. 1991). New
inhibitors, such as CA-074, were designed by modifica-
tion of the E-64 structure to create interactions with the
primed sites of the substrate binding cleft and thus with
the occluding loop (Murata et al. 1991). In this approach
the epoxy moiety of the modifiers acted as a warhead
against the active site cysteine to produce potent irrever-
sible inhibition (Matsumoto et al. 1999). Conversely, we
did not target the active site, and the molecules selected
by docking were devoid of chemically active warheads.
The finding of only one active compound out of 29
substances is in line with previous studies, which showed
that candidate inhibitors predicted by docking algorithms
are not necessarily active in vitro (Huang et al. 2005).
In agreement with published data (Illy et al. 1997; Na¨gler
et al. 1997; Quraishi et al. 1999; Krupa et al. 2002) our
results support the notion that the occluding loop of cathepsin
B is a highly flexible segment. Short episodes of opening and
closing govern endo- and exoproteolysis, which thus occur
intermittently in the pH range 4.5–6.0. The compound
identified by docking, DOFA, behaves as a reversible
competitive inhibitor of the exo- and endopeptidase activ-
ities of cathepsin B with no involvement of a substrate-like
binding mode in the active center of the enzyme. It can
inhibit endoproteolysis most likely by forcing the loop in the
closed conformation, and exoproteolysis by disturbing the
accommodation of the C terminus of polypeptides in the
primed side of the binding cleft. Docking calculations suggest
that the dioxothiazolidine moiety of DOFA is located in the
binding pocket of the side chain of the substrate C-terminal
residue when the loop is closed. It makes a hydrogen bond with
Nd1 of His110 and sterically hinders substrate binding for
exoproteolytic activity (Fig. 9A,B). In this figure, the struc-
tures of DOFA and the four amino acids VRAK, which are part
of the FRET substrate used for measuring exoproteolytic
activity, were modeled on the known structure of human
cathepsin B merely to show their spatial relationship. In fact,
such a ternary ESI complex does not exist according to the
kinetic mechanism; only the ES and EI complexes exist. This
structural arrangement is consistent with the kinetic mecha-
nism of inhibition: At pH 4.5 the exoproteolytic activity of
cathepsin B is inhibited in a linear competitive manner by
virtue of the dioxothiazolidine ring. Docking suggests that
DOFA binds at the surface of the occluding loop and is
involved in three hydrogen bonds with the enzyme (Fig. 9A).
Of particular interest is that the carbonyl oxygen involved in a
hydrogen bond with the amide of His111 occupies the place of
the oxygen of a conserved water molecule present in the crystal
structures of human cathepsin B. This position is shown as a
red sphere in Figure 9B. Together with the favorable van der
Waals interactions, three hydrogen bonds stabilize the loop in
Figure 8. Proteolysis of the bovine insulin b-chain by cathepsin B.
Incubation at pH 5.5 and 25°C in the absence (A) and in the presence
(B) of DOFA. Peptides released by enzymatic digestion were characterized
by LC/MALDI/MS. The sequence at the top of the figure shows the
sequence of bovine insulin, b-chain with amino acid numbering. Boxed
numbers, e.g., 6–28, indicate peptides released by the endo- and exopro-
teolytic action of cathepsin B.
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the closed conformation (Fig. 9B). These structural properties
are reflected in the kinetic mechanism observed with Z-
RRYAMC. Despite not being a complete model for endopro-
teolysis, the dipeptide is unquestionably cleaved by cathepsin
B in the endo-, not in the exoproteolytic mode. The double-
headed competitive kinetic mechanism diagnosed for DOFA
on Z-RRYAMC, and the changes in the kinetic parameters
observed when going from pH 4.5 to 6.0, insinuate cooperation
between the furan and the dioxothiazolidine moieties. Kinetic
measurements alone would be unable to identify which
element makes the stronger contribution to binding energy.
However, with the support of structural information from
modeling discussed above, we suggest that the dioxothiazoli-
dine moiety takes the leader function. In the double-headed
mechanism at pH 4.5, theKi value of 4.8mM is thus ascribed
to the dioxothiazolidine part of the molecule and Ki  160
mM to the furan part (factor a ¼ 34 in Model 3, Fig. 3). The
increase of pH to 6.0 disfavors theKi of the dioxothiazolidine
portion, which becomes 11.3 mM and favors binding of the
furan moiety, decreasing its Ki to 68 mM.
The measurements with protein substrates, aldolase and
the insulin b-chain, confirm the results just discussed with
synthetic substrates, as well as the previously recorded
ability of cathepsin B to exert peptidyl–dipeptidase and
carboxypeptidase activity in the pH range 5.5–6.0 (Mort
et al. 1998). While efficiently inhibiting these two exopro-
teolytic activities, DOFA was not able to inhibit all endo-
proteolytic events. For instance, the minor endoproteolytic
action at position 45–46 of rabbit muscle aldolase was only
moderately or not affected by DOFA, as was not position
14–15 of the insulin b-chain. Yet, other endoproteolytic
attacks on the insulin b-chain were efficiently inhibited.
The pooled experimental evidence from the above
described properties of DOFA inhibition strengthens the
notion that not only pH dependent, intermittent closing
and opening of the occluding loop, but also substrate
structure determine together the susceptibility of partic-
ular peptide bonds. The binding affinity of DOFA is
possibly not high enough to compete with a substrate, which
optimally binds at both unprimed and primed sites. It appears
that the occluding loop of cathepsin B can be assisted in
assuming its closed or open conformation by particular
polypeptides with an induced fit mechanism that promotes
either exo- or endoproteolysis. This observation forms the
basis of cathepsin B inhibition by its own propeptide
(Quraishi et al. 1999) and its resistance to cystatin A and
C inhibition (Nycander et al. 1998; Pavlova et al. 2000).
The above results draw attention to the physiopatho-
logical role of cathepsin B, which exerts its action in a
relatively broad range of pH values, with exoproteolysis
in the range 5–6 and endoproteolysis in the range 5–7.4.
The pH in early endosomes is ;6.2 and drops to 5.0–5.5
in late endosomes and lysosomes (Gu and Gruenberg 2000).
Extracellularly, the pH can vary from relatively acidic, e.g.,
at the periphery of solid tumors (Rofstad et al. 2006), to 7.4
in blood. Contrary to commonplace textbook information,
proteolysis within phagolysosomes does not quite occur in a
very acidic environment. For instance, 5 min after initiation of
Figure 9. Stereoview of inhibitor and substrate within the structure of
human cathepsin B. (A) The protein surface is shown with the occluding
loop in red, His110 and His111 in orange, and the catalytic Cys29 in yellow.
The substrate (carbon atoms in purple) is shown as residues VRYAK,
which is part of the FRET substrate used in this study to monitor peptidyl–
dipeptidase activity. The Dnp group, which is exposed to the solvent, was
omitted for clarity. The pose of DOFA obtained by docking (carbon atoms
in gray) is visible in the upper part with the furan moiety in the occluding
loop and the dioxothiazolidine ring sterically interfering with the lysine side
chain of the substrate. (B) Details of the presumed interactions between
DOFA and cathepsin B residues (carbon atoms in green). The inhibitor
makes three hydrogen bonds with residues of the occluding loop: carbonyl
group labeled ‘‘a’’ in Figure 2 with amide nitrogen of Cys119, carbonyl
group labeled ‘‘b’’ in Figure 2 with amide nitrogen of His111, and 2-oxo
group of the dioxothiazolidine ring with Nd1 of His110. The hydrogen
bonds of the occluding loop in the closed conformation, His110–Asp22 and
His111 with the C-terminal carbonyl of the substrate, are also shown. The
red sphere indicates the position of a water molecule in the cathepsin B
crystal structure. Images generated with PyMOL software (see Fig. 1).
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phagocytosis in human polymorphonuclear leukocytes, the
relatively acidic milieu of the lysosomes (pH 5) increases in
the phagocytic vacuoles to a value of 7.8. It falls then to 7.4
after 15 min, to 6.4 after 30 min, and 5.7 after 60 min (rounded
values from Cech and Lehrer [1984]). Various hydrolases are
expected to find their optimal conditions of action during this
forth and back excursion of pH (Baici et al. 1996).
It has been suggested that ‘‘targeting of the occluding loop
of cathepsin B may be a poor inhibitor design strategy if the
enzyme environment has a pH greater than 5.5’’ (Cathers
et al. 2002). This statement refers to the above discussed
approach ‘‘from inside.’’ Since endo- and exoproteolysis
by cathepsin B occurs in the physiologically and patholog-
ically relevant pH range of 5–6, our approach of targeting
the occluding loop from the enzyme surface may represent
an alternative starting point for the development of clin-
ically active compounds.
Materials and Methods
Materials and general methods
Recombinant human cathepsin B was prepared from Escherichia
coli inclusion bodies (Kuhelj et al. 1995). Wild-type cathepsin B
from human liver was obtained from Calbiochem. The synthetic
substrates Z-FRYAMC2 and Z-RRYAMC were purchased from
Bachem and the internally quenched fluorogenic substrate Abz-
GIVRYAK(Dnp)OH from Merck. Rabbit muscle fructose-1,6-
bisphosphate aldolase (EC 4.1.2.13) and fluorescamine were from
Sigma-Aldrich Chemie and the oxidized bovine insulin b-chain
from Serva Feinbiochemica. The putative binders/modifiers of
cathepsin B activity determined by docking analysis and their
sources are listed in Supplemental Table 1. The compound studied
in detail, [2-[2-(2,4-dioxo-1,3-thiazolidin-3-yl)ethylamino]-2-
oxoethyl] 2-(furan-2-carbonylamino)acetate (IUPAC name, here
abbreviated DOFA; Fig. 2), Zinc-2005 code 2616818 (Irwin and
Shoichet 2005) was obtained from Enamine. The compounds were
dissolved as concentrated stock solutions in dimethyl sulphoxide,
stored at 4°C, and diluted into the appropriate buffer at the
moment of the assay. Photometric measurements were carried out
with a Cary50 UV-visible spectrophotometer, and fluorescence
was measured with an Aminco SPF-500 fluorimeter operating in
the ratio mode. Reversed phase HPLC was performed in a Hewlett
Packard Series 1100 apparatus with a Nucleosil 120-5 C18
column (4.0 3 250 mm). Matrix-assisted laser desorption/ioniza-
tion mass spectrometry (MALDI-MS) and liquid chromatography
followed by mass analysis, LC-MALDI/MS, was performed at the
Functional Genomics Center in Zurich.
Docking
The A and B chains of the human cathepsin B structure, entry
1HUC in the Brookhaven database, were considered and all
water molecules were removed. Hydrogens were added to side
chains and termini of the protein to simulate conditions at pH 6–
7. Cys29 was in the reduced form, and His110 was protonated at
both imidazole nitrogen atoms. CHARMm atom types and force
field parameters were assigned and used for both protein and
ligands (Momany and Rone 1992), and hydrogens were mini-
mized with the program CHARMM (Brooks et al. 1983). The
search for a putative binding site focused on the occluding loop
of the enzyme, for which no inhibitor has been reported to date.
A benzene molecule was used as a probe with the program
SEED (Solvation Energy for Exhaustive Docking) to identify
possible binding pockets whose main interaction component is
supposed to be hydrophobicity (Majeux et al. 1999). The surface
tested by SEED consists of cathepsin B residues within a 9 A˚
distance from His110, which locks the occluding loop in a closed
position. The benzenes with the most favorable free energy of
binding, excluding those in the catalytic site, were used to
define the binding site for docking, which included all the 42
residues of the protein that had >50% of their atoms within 5 A˚
from the optimal poses of benzenes.
About 3 million compounds in the ZINC 2005 library (Irwin
and Shoichet 2005) were clustered using a 17-field fingerprint
by Decomposition and Identification of Molecules (Kolb and
Caflisch 2006). Molecules with more than nine rotatable bonds
were neglected. The resulting 48,026 cluster representatives
were docked as in previous in silico campaigns (Huang et al.
2005, 2006; Kolb et al. 2008). For each molecule docked by the
program FFLD (Fragment-based Flexible Ligand Docking)
(Budin et al. 2001; Cecchini et al. 2004), the 300 most favorable
poses were clustered with the leader algorithm yielding 764,776
poses (;17 poses per compound, 44,527 compounds). The
cluster representatives were minimized in the rigid protein using
CHARMM.
It is necessary to weed out unlikely poses to prevent a high
number of false positives (Kolb et al. 2008). Suitable filters are
cutoffs in the total van der Waals interaction energy and in the
van der Waals efficiency (defined as the ratio between van der
Waals energy and molecular mass). A cutoff of 30 kcal/mol
for intermolecular van der Waals energy was selected by
plotting a histogram of the van der Waals energies (Supplemen-
tal Fig. 1). Analogously, a cutoff of 0.09 kcal/g was chosen for
the van der Waals efficiency (Supplemental Fig. 2). A total of
106,502 poses of 10,709 compounds survived both filters. Poses
closer than 4 A˚ to Cys29 of the catalytic site and those with no
hydrogen bond to the protein were neglected, yielding 25,178
remaining poses (5678 compounds).
The electrostatic contribution to the binding free energy was
evaluated by the finite difference Poisson approach (module
PBEQ of CHARMM) (Im et al. 1998). Poses were ranked for
visual inspection according to most favorable van der Waals
energy, van der Waals efficiency, electrostatics, and sum of van
der Waals and electrostatic energy. Poses with high ranking in
two lists or more were selected and visually inspected. Forty
poses belonging to 40 different compounds were selected in this
way. According to the predicted binding modes, three regions of
the protein were exploited for binding: one on the occluding
loop and one each on immediately adjacent regions. Twenty-
nine out of the 40 candidate compounds were commercially
available.
Kinetics
The peptide Z-RRYAMC with 7-amino-4-methlycoumarin
(AMC) as leaving group is a handy substrate for measuring
the endopeptidase activity of cathepsin B (Barrett 1980), in
which the two arginine residues correspond to the P1 and P2
positions (Schechter and Berger 1967). We preferred this
substrate over Z-FRYAMC for its slower hydrolysis that allowed
long measuring times with low substrate consumption. The buffer
for measurements at pH 6.00 was 50 mM sodium phosphate
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containing 2 mM EDTA and 2 mM dithiothreitol (DTT), hereafter
referred to as pH 6.0 buffer. For measurements at pH 4.50, 0.1 M
sodium acetate, 0.2 M NaCl, 2 mM EDTA, and 2.5 mM DTT were
used (hereafter referred to as pH 4.5 buffer). In control experi-
ments aimed at ascertaining any aggregation phenomena on the
part of the putative inhibitors, the DTT concentration was
increased to 5 mM and the buffer included 0.01% (v/v) of
hydrogenated Triton X-100, which does not absorb light in the
ultraviolet range and is not fluorescent. The buffers were prepared
and used at the same temperature of the kinetic assays, 25 6 1°C.
The final concentration of dimethyl sulphoxide, used for preparing
stock solutions of the compounds, was 0.2% (v/v) in experiments
with synthetic substrates and 1% (v/v) in those with protein
substrates. Reaction progress with Z-RRYAMC at pH 4.5 and 6.0
was followed by either measuring the change in absorbance at 360
nm, with De ¼ 11,400 M1cm1 as the difference absorption
coefficient between free and bound AMC or fluorimetrically with
excitation and emission wavelengths, lex and lem, set at 383 and
455 nm, respectively. Exopeptidase activity was continuously
monitored fluorimetrically with the Fo¨rster resonance energy
transfer (FRET) labeled substrate Abz-GIVRYAK(Dnp)-OH
(Cotrin et al. 2004). Appropriate corrections for inner filter effects
were taken into account in fluorescence measurements consider-
ing the absorbencies of the substrates and of the tested compounds
at lex and lem (Palmier and Van Doren 2007). With the AMC-
based substrate, lex at 383 nm allowed high substrate concen-
trations to be used with small inner filter corrections. Since with
the FRET substrate inner filter effects were more pronounced, lex
and lem were selected according to the compound being tested.
The combination lex/lem 320/420 nm, often used in assays with
this type of substrate, could not be utilized for the strong
absorbance at 320 nm of one of the compounds (ZINC-2005 code
1797383), which simulated strong enzyme inhibition, whereas the
combination lex/lem 370/430 nm revealed no inhibition. Any
modifier-independent contribution to enzyme activity loss by
denaturation, adherence to the vessel walls, or other causes was
monitored in time-course assays by the Selwyn method (Selwyn
1965). Screening and primary analysis of the kinetic inhibition
mechanism of the compounds was performed on initial velocity
data obtained at various concentrations of substrate and com-
pounds. The specific velocity plot, a sensitive tool for detecting
mixed-type and/or hyperbolic mechanisms was routinely used in
this phase (Baici 1981). The kinetic inhibition models considered
and their related rate equations are shown in Figure 3. In Models 2
and 3, a is a coefficient, which is equal to 1 when the first binding
process does not influence the second one. If the equilibrium
constant of the vacant site is influenced after binding to the first
site, a 6¼ 1. Kinetic analysis was performed by fitting the equations
in Figure 3 to experimental data using GraphPad Prism version
5.00 for Windows. The runs test and analysis of residuals were
performed to monitor deviations from a model, and discrimination
between mechanisms was made by analysis of variance of the
difference between the sum of squares (extra sum-of-squares test)
and calculation of F ratios and p values. According to Occam’s
razor principle, the simplest mechanism describing experimental
data was considered superior to a more complex (redundant)
mechanism. Additionally, a powerful and decisive tool for model
discrimination was the I90/10 ratio, i.e., the ratio of inhibitor
concentration necessary to achieve 90% and 10% inhibition. This
parameter was determined experimentally and compared with
values calculated from Equations 4 and 6 in Figure 3.
Protein substrates
The activity of cathepsin B on rabbit muscle aldolase was quantified
by measuring primary amino groups derived from peptide-bond
hydrolysis with fluorescamine (Schwabe 1975). Aldolase was
dissolved in pH 6.0 buffer without DTT, incubated 3 h at 37°C
with cathepsin B, which was pre-activated with DTT, and DOFA
under vigorous shaking to prevent precipitation. Final concentrations
were: aldolase ¼ 3.5 mg/mL ¼ 21.7 mM, cathepsin B ¼ 2.3 mM,
DOFA ¼ 0.5, 1.0, 1.5, and 2.0 mM. The reaction was stopped with
trichloroacetic acid, 5% (w/v) final concentration, and centrifuged.
We added 0.1 mL of the clear supernatant to 2.0 mL 0.2 M sodium
borate buffer (pH 8.50), and 1.0 mL of fluorescamine solution (15
mg/100 mL acetone). The fluorescence of labeled peptides was
measured with lex/lem ¼ 390/480 nm. Blanks were subtracted and
controls compared with the samples containing the compounds.
Measurements with the oxidized b-chain of bovine insulin as
substrate were performed in pH 6.0 buffer using the same procedure.
Final concentrations were: insulin b-chain ¼ 72 mg/mL ¼ 20.6 mM,
cathepsin B ¼ 2.3 mM, DOFA ¼ 0.5, 1.0, 1.5, and 2.0 mM.
Endo- and exoproteolysis of protein substrates
Reaction products resulting from incubation of aldolase with
cathepsin B and DOFA were also assessed by denaturing gel
electrophoresis. Final concentrations in incubation mixtures at
25°C under continuous shaking for 4 h were: aldolase 3.5 mg/
mL (21.7 mM) in pH 6.0 buffer without DTT, 2.3 mM of
preactivated cathepsin B, and 1.0 mM DOFA. After centrifuga-
tion, the clear supernatant was analyzed by sodium dodecyl
sulphated, polyacrylamide gel electrophoresis (SDS-PAGE)
under reducing conditions with 12.5% polyacrylamide and silver
stained. For N-terminal sequencing by Edman degradation, the
bands were transferred to a polyvinylidene fluoride membrane.
Peptides in the excised bands were also identified by MALDI
analysis.
The oxidized b-chain of bovine insulin was incubated at a
final concentration of 1.0 mg/mL (286 mM) in 0.1 M sodium
acetate buffer containing 0.2 mM NaCl, 2 mM EDTA, and 2.5
mM DTT (pH 5.50) with 1.2 mM cathepsin B (control) or
cathepsin B plus 1.0 mM DOFA. After 20 h at 25°C under
shaking, solutions were centrifuged and the solvent removed in
a Speed Vac concentrator. The residue was resuspended in 60
mL of deionized water containing 0.1% trifluoroacetic acid and
centrifuged before analysis by LC/MALDI/MS.
Electronic supplemental material
Supplemental Table 1 shows the identification codes and the
sources of the cathepsin B inhibitors. Supplemental Figure 1
presents the van der Waals interaction energies distribution used
in the docking procedure and shows the cutoff of 30 kcal/mol
for intermolecular van der Waals energy. Analogously, Supple-
mental Figure 2 shows the van der Waals interaction energy
efficiencies distribution.
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Supplemental Table 1. Identification codes and source of 29 putative inhibitors of human 
cathepsin B. The ZINC-codes are those of the database 2005 [Irwin, J. J., and Shoichet, 
B. K. (2005) J. Chem. Inf. Model. 45, 177-182]. [2-(2,4-dioxothiazolidin-3-yl) 
ethylcarbamoylmethyl 2-(furan-2-carbonylamino) acetate (DOFA) is shown in boldface. 
 
Source ZINC 2005-codes 
ChemDiv (San Diego, USA) 33816, 978038, 2487954, 2560859 
Ambinter (Paris, France) 1271923, 1414169 
ChemBridge (San Diego, USA) 958753, 2904166, 2973678, 2990182 
Pharmerks (Moscow, Russia) 989395, 1755678, 1837733, 1871954 
Life Chemicals (Burlington, Canada) 1797383 
Enamine (Kiev, Ukraine) 
2616818, 2667966, 3247330, 3333255, 3340535, 
3417832, 3439551, 3451184 
IBScreen (Moscow, Russia) 1419203, 2128374, 2131752 
National Cancer Institute, U.S.A. 1581881, 1628238, 1682930 
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Supplemental Figure 1. Van der Waals interaction energies distribution. The 
histogram represents the distribution of van der Waals interaction energies before and 
after the efficiency cutoff. The vertical line marks the cutoff on van der Waals energy. 
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Supplemental Figure 2. Van der Waals interaction energy efficiencies distribution. 
The histogram represents the distribution of van der Waals interaction energy efficiencies 
before and after the energy cutoff. The vertical line represents the cutoff of van der Waals 
efficiency. 
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3-Fluoro-2,4-dioxa-3-phosphadecalins
as inhibitors of acetylcholinesterase.
A reappraisal of kinetic mechanisms
and diagnostic methods
Chemistry and Biodiversity, 2009, 6:261−282
Abstract
Die systematische Untersuchung der Acetylcholin-mimetischen 2,4-dioxa-3-
phosphadecalinen als irreversible Inhibitoren der Acetylcholinesterase er-
öffnete bisher übersehene Eigenschaften was die kinetischen Interaktions-
mechanismen betrifft. Als eine Unterstützung für vergangene wie auch zukün-
ftige Arbeiten in diesem Feld, beschreiben wir die Kinetik von acht Reak-
tionschemata, welche bei irreversiblen Enzymmodifikationen gefunden wer-
den können und in Verbindung damit, zwei Mechanismen des reversiblen
langsam-bindenden Inhibitionstypus. Für alle Mechanismen sind die rele-
vanten kinetischen Gleichungen und die dazugehörigen graphischen Darstel-
lungen gegeben, wie auch konkrete Beispiele, die ihren praktischen Gebrauch
illustrieren. Da die irreversible Inhibition ein zeitabhängiges Phänomen
darstellt, ist die kinetische Analyse durch das Anpassen der entsprechen-
den integrierten Geschwindigkeitsgleichung an eine Kurve des Reaktionsver-
laufs durch nicht-lineare Regression stark vereinfacht. Diese erste Überprü-
fung ergibt kinetische Parameter, welche unabdingbare Werkzeuge für die
Diagnose von kinetischen Mechanismen und die Berechung der Inhibition-
skonstanten darstellen. Numerische Integration eines Sets von Differential-
gleichungen ist zudem ein nützliches Werkzeug in kritischen Situationen, wie
etwa bei unstabilen und/oder temporär irreversiblen Modifiern.
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3-Fluoro-2,4-dioxa-3-phosphadecalins as Inhibitors of Acetylcholinesterase.
A Reappraisal of Kinetic Mechanisms and Diagnostic Methods
by Antonio Baici*a), Patricia Schenkera), Michael Wchterb), and Peter Redi*b)
a) Biochemisches Institut der Universitt Zrich, Winterthurerstrasse 190, CH-8057 Zrich
b) Organisch-chemisches Institut der Universitt Zrich, Winterthurerstrasse 190, CH-8057 Zrich
A systematic survey of the acetylcholine-mimetic 2,4-dioxa-3-phosphadecalins as irreversible
inhibitors of acetylcholinesterase revealed hitherto overlooked properties as far as the kinetic
mechanisms of interaction are concerned. As a support to past and future work in this field, we describe
the kinetics of eight reaction schemes that may be found in irreversible enzyme modification and
compare them with two mechanism of reversible, slow-binding inhibition. The relevant kinetic equations
and their associated graphical representations are given for all mechanisms, and concrete examples
illustrate their practical use. Since irreversible inhibition is a time-dependent phenomenon, kinetic
analysis is greatly facilitated by fitting the appropriate integrated rate equations to reaction-progress
curves by nonlinear regression. This primary scrutiny provides kinetic parameters that are indispensable
tools for diagnosing the kinetic mechanism and for calculating inhibition constants. Numerical
integration of sets of differential equations is an additional useful investigation tool in critical situations,
e.g., when inhibitors are unstable and/or act as irreversible modifiers only temporarily.
1. Introduction. – In an earlier article [1], we have reported on the synthesis and
characterization of the racemic P(3)-axially and P(3)-equatorially substituted cis- and
trans-configured 2,4-dioxa-9-aza-, 2,4-dioxa-8-aza-, and 2,4-dioxa-7-aza-3-phosphabi-
cyclo[4.4.0]decane 3-oxides (I– III, resp.; Fig. 1).
Being configuratively fixed and conformationally constrained P-analogues of
acetylcholine (7-aza and 9-aza isomers) or g-homoacetylcholine (8-aza isomers)
(Scheme 1), these heterocycles represent acetylcholine mimetics, and they are
Fig. 1. The 2,4-dioxa-3-phosphadecalins of types I– IV
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considered to be suitable for the investigation of molecular interactions with
acetylcholinesterase (AChE), such as the recognition conformation of acetylcholine
(ACh) and the stereochemistry of modification reactions1) of serine hydrolases. The
related 3-fluoro- and 3-(2,4-dinitrophenoxy)-2,4-dioxa-3-phosphadecalins (type IV;
Fig. 1 and Scheme 1) have been successfully used as probes for the determination of the
stereochemical course of the inhibition of d-chymotrypsin [2] and the proof for the
covalently phosphorylated enzyme [3] by 31P-NMR spectroscopy. Enzyme-kinetic
studies on the basis of a simplified approach according to Scheme 22) had revealed that
many of the prepared organophosphates of type I– IV (Fig. 1) are inhibitors of AChE
[8–12] (Scheme 2), and preliminary results have been summarized [13]. However,
during the past years, we have encountered significant inconsistencies concerning the
reproducibility of the kinetic data of the phosphadecalins. Meanwhile, we have
synthesized all the optically active (ee>99%) organophosphates of type I– IV (L¼F;
Scheme 1), and the mentioned problems prompted us to start a thorough reinvesti-
gation to find and apply an appropriate enzyme-kinetic system that is generally
applicable to our compounds, providing reliable results.
2. Reappraisal of Kinetic Mechanisms and Diagnostic Methods. – 2.1. General.
Although apparently a simple theme, the reaction of an enzyme with a substrate and/or
an inhibitor to yield products or a modified enzyme species, is a highly complex cycle
with multiple equilibria and accordingly complex rate parameters. As a matter of fact,
there exists no analytical solution for the exact description of the general case [15] [16].
Despite this inherent complexity, the kinetics of irreversible enzyme modification has
been the subject of early studies, in which discontinuous methods were used for
measuring residual enzyme activity after preincubating the enzyme of interest with
modifiers [17–19]. More recently, continuous methods gained popularity because of
the large information contained in progress curves obtained by monitoring the
appearance of product following the hydrolysis of a chromogenic or fluorogenic
substrate [20–23]. However, modifier instability and temporary inhibition constitute
serious drawbacks for the practical use of many compounds, and represent a dilemma
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1) The term modification comprises all types of chemical interactions with enzymes and is not limited
to inhibition reactions. Hence, it is more appropriate in the present re-evaluation that constitutes a
general approach.
2) In most enzyme-kinetic studies on organophosphorus inhibitors of esterases, only the overall
process is considered (Scheme 2). We relied on the basic procedure introduced by Aldridge [4] and
later refined by Main and Dauterman [5], and Hart and OBrien [6]. As our primary goal was the
search for strong inhibitors with respect to their applicability for 31P-NMR studies [2] [3], we used
these simplified, straightforward protocols that were applied at that time by several research groups
(e.g., [7]). For detailed experimental descriptions, representative calculations, and results, see [2] [8–
13]. Racemic 3-phosphadecalins with the following leaving groups have been prepared and tested
(see Scheme 1): L¼F [1] [8] [11–13] (types I– IV), Cl [1] [8–10] (types I, II, and IV), Br, N3 [8] (type
IV), 4-nitrophenoxy [1] [9] [10] (types I and II), 2,4-dinitrophenoxy [1] [8–10] (types I, II, and IV),
OR [8] [9] (types I, II, and IV), NR2 [8] (type IV), and SR [8] (type IV). Remarkably, the N,N-
dimethylammonium compounds (R1¼R2¼Me, L¼Cl, 4-nitrophenoxy, 2,4-dinitrophenoxy) that
constitute the most close mimetics were weak reversible inhibitors [10] (types I and II). For a
compilation of the applied procedures, experimental conditions, cross-comparisons, and a critical
discussion of the respective results, see [14].
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Scheme 1. The Basic Concept of the Organophosphorus Acetylcholine Mimetics
Scheme 2. The Simplified Kinetic Approach
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for the kinetic interpretation of experimental data. In fact, when a continuous progress
curve method for data acquisition is used, temporary inhibition and modifier instability
can be mistaken for true reversibility of the reaction. In this article, we reconsider and
discuss diagnostic criteria for distinguishing mechanisms of enzyme inhibition based on
the analysis of progress curves. We will consider only inhibitors of the competitive type,
i.e., those that bind to free enzyme, not to the enzyme–substrate complex.
2.2. Theoretical Considerations. 2.2.1. Reversible, Slow-Binding Inhibition. For the
purposes of the discussion that will follow on irreversible enzyme modification, it is
useful to examine first the behavior of reversible, slow-acting inhibitors. Scheme 3
shows two common mechanisms, 2A-R and 1A-R, of reversible, slow-binding
inhibition. In mechanism 2A-R, slow production of an enzyme– inhibitor complex
(E · I)3) is preceded by a rapid equilibration between E and I to form an adsorptive
complex (EI). Mechanism 1A-R is a degenerated form of mechanism 2A-R, in which
the concentration of EI is kinetically insignificant. Slow-binding, slow, tight-binding
inhibition, and irreversible enzyme modification are time-dependent phenomena, i.e.,
the final species do not form instantaneously, but in the range of minutes to hours.
Apart from its physiological and pharmacological significance, this behavior offers a
handy tool for measuring the kinetic parameters and for determining the respective
inhibition mechanism. For such slow processes, the integrated rate equation, expressed
as product concentration vs. time, takes the general form (Eqn. 1 in Table 1). The term
us represents the rate after attainment of the steady-state, and uz (for zero time)
corresponds to the rate at t¼0. We purposely use the symbol uz in the case of slow
enzyme-modification reactions as a distinction from u0, which is used to represent the
rate in the absence of modifiers. Depending on the experimental conditions and
mechanism, uz can be greater or less than us, and it can be equal to or less than u0 . The
first-order rate constant l that describes the approach to the steady-state has a
characteristic expression for each mechanism. The parameter d (displacement) is
introduced in Eqn. 1 (Table 1), and other forms of this equation to take into account
product present before the start of the reaction or any spectroscopic signal proportional
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3) For a list of the symbols, see the Appendix.
Scheme 3. Reversible, Slow-Binding Enzyme Inhibition. These are the reversible counterparts (R
indicates reversibility) of mechanisms 2A (Scheme 4) and 1A (Scheme 5), respectively.
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to it, which may be non-zero at the beginning of the reaction. Eqn. 1 was originally
derived for describing the concept of enzyme hysteresis [24], and was later used for
characterizing slow-binding inhibition [25] [26]. It applies to reactions in which
enzymes respond slowly to a rapid change in the concentration of any modifier.
2.2.2. Enzyme Inactivation; Irreversible Inhibition4). In most cases, the kinetics of
irreversible enzyme inhibition can be described by mechanism 2A (Scheme 4).
Mechanism 2A consists in the formation of a fast-equilibrating adsorptive complex
(EI), followed by a slow step in which the enzyme is irreversibly converted to a
covalently modified enzyme (E–I), and thereby inactivated. The concentration of the
reversible adsorptive intermediate may be kinetically insignificant, meaning that the
dissociation constant Ki¼k3/k3 may be high with respect to the concentration of
inhibitor used in the experiments; in this case, mechanism 2A degenerates to
mechanism 1A (Scheme 5). While there is no reason for considering these two
mechanisms as being chemically different (as is also for mechanisms 2A-R and 1A-R ;
Scheme 3), a distinction is made merely for practical purposes and mathematical
convenience.
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Table 1. Equations for Mechanisms 2A-R and 1A-R (cf. Scheme 3). The expressions uz and us apply to
assays in which the reaction is started by adding the enzyme to a solution containing substrate and
inhibitor.
Mechanism 2A-R Mechanism 1A-R
P½  ¼ ust þ
uz  usð Þ 1 eltð Þ
l
þ d (1) P½  as Eqn. 1
l ¼ k7 þ
k7 I½ 
Ki 1þ
S½ 
Km
 
þ I½ 
Ki ¼
k3
k3
(2)
l ¼ k3 þ
k3 I½ 
1þ S½ 
Km
(3)
uz ¼
V S½ 
Km 1þ
I½ 
Ki
 
þ S½ 
(4) uz ¼ u0 ¼
V S½ 
Km þ S½  (5)
us ¼
V S½ 
Km 1þ
I½ 
Ki
k7
k7 þ k7
 
0
BB@
1
CCAþ S½ 
(6)
us ¼
V S½ 
Km 1þ
I½ 
Ki
 
þ S½ 
(7)
4) The term inactivation specifically indicates that a modifier covalently converts the enzyme to a
species devoid of catalytic activity. The expression is preferentially used by the specialists in place of
irreversible inhibition to distinguish reversibility and irreversibility at a glance. Although less
accurate, the classical term irreversible inhibitor, is retained in this article due to practical reasons.
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Often, molecules designed as irreversible modifiers of enzyme activity undergo
spontaneous, nonenzymatic decomposition, usually by hydrolysis to an inert species (I’;
mechanisms 2B (Scheme 4) and 1B (Scheme 5)). Other molecules act as temporary
inhibitors, meaning that free enzyme and an enzymatically cleaved form of the modifier
(I*) are generated (mechanisms 2C (Scheme 4) and 1C (Scheme 5)). In the worst case,
a compound can be unstable and temporary as well (mechanisms 2D (Scheme 4) and
1D (Scheme 5)). In the same way as reversible inhibitors, enzyme inhibitors can be
competitive, uncompetitive, or mixed-type. The latter is a blend of competitive and
uncompetitive character [20]. In the case of genuinely irreversible processes, the
steady-state rate us in Eqn. 1 (Table 1) is set to zero, and the rate is expressed by Eqn. 8
(Table 2).
For reasons of convenience, expressions which are found in the literature (e.g., [16])
are summarized for reversible mechanisms (Table 1), for irreversible mechanisms in
two steps (Table 2), and for irreversible mechanisms in one step (Table 3). To the best
of our knowledge, analytical expressions have not been published for the temporary
Scheme 4. Mechanisms for Two-Step Irreversible Enzyme Modification. In the four variants of this
mechanism (the number 2 denotes a two-step inhibition process), covalent enzyme modification (E–I)
is preceded by the reversible formation of an adsorptive complex EI. Mechanism 2B describes an
unstable modifier, which undergoes spontaneous, nonenzymatic decomposition. Mechanism 2C shows
temporary inhibition, in which the inhibited enzyme decays to free enzyme, which is recycled, and an
inert species I*. Mechanism 2D illustrates the case of a chemically unstable modifier, which, at the same
time, exerts temporary inhibition. I’ and I* do no longer affect enzyme activity and are withdrawn from
the system.
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Scheme 5. Mechanisms for One-Step Irreversible Enzyme Modification. In these mechanisms (the
number 1 denotes one-step inhibition), enzyme and modifier form covalently inhibited E–I in a
bimolecular reaction. The unstable inhibitor (1B), temporary inhibition (1C), and a blend of these two
variants of the mechanism (1D) are analogous to the corresponding panels in Scheme 4.
Table 2. Equations for Mechanisms 2A and 2C (cf. Scheme 4). The expressions uz and u1 apply to assays
in which the reaction is started by adding the enzyme to a solution containing substrate and inhibitor.
Mechanism 2A Mechanism 2C
P½  ¼ uz
l
1 elt þ d (8) P½  ¼ u1t þ uz  u1
l
1 elt þ d (9)
l ¼ k4 I½ 
Ki 1þ
S½ 
Km
 
þ I½ 
Ki ¼
k3
k3
; ki ¼
k4
Ki
(10)
l ¼ k6 þ
k4 I½ 
Ki 1þ
S½ 
Km
 
þ I½ 
Ki ¼
k3
k3
; ki ¼
k4
Ki
(11)
u
z
¼ V S½ 
Km 1þ
I½ 
Ki
 
þ S½  (4) uz as for mechanism 2A
u1 ¼ 0
u1 ¼
V S½ 
Km 1þ
I½ 
Ki
1þ k4
k6
  
þ S½  (12)
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mechanisms 2C (Scheme 4 and Table 2) and 1C (Scheme 5 and Table 3) with explicit
expressions in the style used in this article. The symbol u1 in these Tables is the
counterpart of us in Table 1. The infinity subscript solely indicates that this rate is
calculated at the end of the exponential phase, a condition mathematically obtained by
setting t¼1 in the expression elt.
A complete treatment of mechanisms 2B (Scheme 4) and 1B (Scheme 5) for
unstable inhibitors was published by Topham in a comprehensive theoretical treatment
that also included partial inhibitors as well as activators [23]. This valuable article, in
which an impeccable mathematical language was used, may possibly be difficult for end
users less familiar with this topic. Therefore, this treatment is summarized below for
mechanism 1B to show conceptual differences with integrated rate equations for
systems 2A, 2C, 1A, and 1C, and to explain how to deal in practice with unstable
modifiers. The complex integrated rate equation for mechanism 2B will not be treated
here because its solution is only possible under special circumstances [23]. In the case
of either mechanism 2D or 1D, it is questionable whether the compounds under
investigation should still be called inhibitors. Although integrated rate equations for
these mechanisms can be derived, their concrete application to real cases is
mathematically laborious, and the results are mere of academic interest.
2.2.3. Discrimination of Mechanisms. To provide a convenient reference for
diagnostic purposes, progress curves for the mechanisms shown in this article were
simulated by numerical integration of the appropriate sets of differential equations. All
calculated and experimental curves shown below refer to reactions started by adding
enzyme to a solution containing substrate and inhibitor. The differential diagnosis of
the mechanisms is accomplished by inspection of the shapes of the progress curves, and
by analysis of the dependencies of l and velocities on inhibitor concentration.
Progress curves for mechanisms 2A-R and 1A-R, as well as the dependencies of the
parameters l, uz, and us on [I], are shown in Fig. 2. Distinguishing mechanism 2A-R
Table 3. Equations for Mechanisms 1A and 1C (cf. Scheme 5). The expressions of uz and u1 apply to
assays in which the reaction is started by adding the enzyme to a solution containing substrate and
inhibitor.
Mechanism 1A Mechanism 1C
P½  ¼ uz
l
1 elt þ d (8) P½  ¼ u1t þ uz  u1
l
1 elt þ d (9)
l ¼ k3 I½ 
1þ S½ 
Km
(13) l ¼ k6 þ
k3 I½ 
1þ S½ 
Km
(14)
uz ¼ u0 ¼
V S½ 
Km þ S½  (5) uz as for mechanism 1A
u1 ¼ 0 u1 ¼
V S½ 
Km 1þ
k3
k6
I½ 
 
þ S½ 
(15)
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from its counterpart 1A-R is straightforward, since the dependency of l on [I] is
hyperbolic for mechanism 2A-R and linear for mechanism 1A-R. Furthermore, uz
decreases hyperbolically with [I], or is independent of [I] for mechanisms 2A-R and
1A-R, respectively. Individual kinetic constants can be calculated from the plots of l vs.
[I], as shown in Fig. 2. From the fits of uz and us, Ki , as well as the overall inhibition
constant (Ki k7)/(k7þk7), for mechanism 2A-R can be calculated and used to check
the internal consistency with results from the l vs. [I] plot.
Mechanism 2A for irreversible inhibition can unmistakably be distinguished from
its reversible counterpart 2A-R, if the progress curves can be measured for a
sufficiently long time to allow complete inhibition. The irreversible mechanism is
Fig. 2. Progress curves and diagnostic parameters for mechanisms 2A-R and 1A-R (cf. Scheme 3).
Numbers next to the curves in the top panels indicate inhibitor concentrations (mm). Curves were
generated with the following parameters common to both mechanisms: k2¼20 s1, [E]t ¼ 5 nm, [S]¼
Km¼100 mm ; for mechanism 2A-R : k3¼0.5 mm1 s1, k3¼0.2 s1, k7¼0.01 s1, k7¼0.002 s1; for
mechanism 1A-R : k3¼0.1 mm1 s1, k3¼0.002 s1.
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characterized by an end value of progress curves parallel to the time axis, indicating
that there is no steady-state with a positive slope (Fig. 3). Also, the ordinate intercept
of l vs. [I] is zero in this case, while it is non-zero for mechanism 2A-R. A distinction of
mechanism 2C from 2A-R is impossible, when only progress curves and the
dependencies of parameters on [I] are considered. In fact, the positive slope described
by u1 can be mistaken for the steady-state of a reversible system. Instead, this slope is
determined by free enzyme that is recycled in the reaction following the breakdown of
E–I. However, a reliable discrimination is possible by preincubating enzyme and
inhibitor, and starting the reaction by adding substrate: for a reversible mechanism, the
steady-state slope will be independent of the preincubation time, while, for mechanism
2C, the slope will increase by increasing the preincubation time. This corresponds to the
decreasing inhibitor concentration available to the enzyme.
Fig. 3. Progress curves and diagnostic parameters for mechanisms 2A and 2C (Scheme 4). Numbers next
to the curves in the top panels indicate inhibitor concentrations (mm). Curves were generated with the
following parameters common to both mechanisms: k2¼20 s1, [E]t¼5 nm, [S]¼Km¼100 mm, k3¼
0.5 mm1 s1, k3¼0.2 s1, k4¼0.02 s1; for mechanism 2C : k6¼0.001 s1.
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Progress curves and parameter dependencies for mechanisms 1A and 1C are shown
in Fig. 4. Diagnostic features of system 1A are the reaction profiles ending up with
slope zero and the linear dependency of l on [I] with zero intercept on the ordinate.
The non-zero intersection on the ordinate for mechanism 1C, which corresponds to k6 ,
may not be accessible to unambiguous measurement, and its successful determination
depends on data quality. A statistical test to evaluate a significant non-zero intercept
will be very useful in this case. Also for mechanism 1C, a definite distinction from
mechanism 1A-R is not possible from inspection of the graphics, but the preincubation
method discussed above is reliable again.
2.2.4. Inhibition by an Unstable Compound, Mechanism 1B. An analytical
expression of l does not exist for this model, because the concentration of the
Fig. 4. Progress curves and diagnostic parameters for mechanisms 1A and 1C (Scheme 5). Numbers next
to the curves in the top panels indicate inhibitor concentrations (mm). Curves were generated with the
following parameters common to both mechanisms: k2¼20 s1, [E]t¼5 nm, [S]¼Km¼100 mm, k3¼
0.015 mm1 s1; for mechanism 1C : k6¼0.001 s1.
CHEMISTRY & BIODIVERSITY – Vol. 6 (2009) 271
Inactivators of Acetylcholinesterase | 55
inhibitor varies with time. However, an analytical expression for the integrated rate
equation can be obtained upon Maclaurin series expansion [23]:
P½  ¼ uz
k5
e
 k3Km I½ t
k5 Kmþ S½ ð Þ
n o
k5t þ
X1
i¼1
k3Km I½ t
k5 Km þ S½ ð Þ
 i 1 ek5 tð Þih i
i  i!
8<
:
9=
; ð16Þ
In Eqn. 16, uz¼u0 (the rate in the absence of modifier), Km can be evaluated from
measurements performed with substrate alone, and [I]t is the total inhibitor concen-
tration introduced initially. Therefore, the rate constants k3 and k5 can be obtained by
fitting this equation to progress curves by nonlinear regression. How many terms,
denoted by the index i in Eqn. 16, should be used in the regression analysis depends on
the value of k5: a small value will require more terms than a large one. For instance, with
k5¼0.005 s1, the third term is sufficient to fit a progress curve, while with k5¼0.001 s
1,Maclaurin expansion till the 10th term is necessary. In turn, the last option can be used
routinely.
Simulated progress curves for an unstable inhibitor obeying mechanism 1B are
shown in Fig. 5 (left panel). These do not consist of a single exponential followed by a
straight line parallel to the time axis as shown in the curve labeled k5¼0, which
corresponds to a stable inhibitor. Instead, an increase of k5 means an increase of the
rate of degradation of the inhibitor to the inert species I’, as shown in Fig. 5 (right
panel). Thus, progress curves are similar to those obtained in the presence of a
reversible inhibitor, and, for high values of k5, I is degraded rapidly causing the progress
curve to be linear. The straight line following the exponential phases in Fig. 5 (e.g., in
the curve with k5¼0.01 s1) does not correspond to a steady-state but reflects the
continuous decrease in the concentration of available inhibitor according to Eqn. 16.
Attempting to fit either Eqns. 8 or 9 to data obtained with unstable compounds results
in inconsistent fittings with statistically meaningless results. This is due to the fact that
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Fig. 5. Progress curves for an unstable inhibitor, mechanism 1B (Scheme 5). Left: Progress curves. Right:
concentration of the chemically inert inhibitor, I’. Curves were simulated by numerical integration with
Matlab–Simulink software (www.mathworks.com) using the following parameters: k2¼0.2 s1, k3¼
10 m1 s1, Km¼1 mm, [S]¼1 mm, [E]t¼100 nm, [I]t¼1 mm, k5 from 0 to 0.1 s1 as shown (numbers
next to the curves). For k5¼0, there is no production of I’, and the progress curve corresponds to that of
mechanism 1A (Fig. 4 and Scheme 5).
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the condition of constant [I] during the measurement time, necessary for integrating
the rate equation, is violated. This represents a valuable diagnostic tool for differ-
entiating 1B from other mechanisms. Progress curves for an unstable inhibitor obeying
mechanism 1B are very similar to those of mechanisms 1A-R and 1C. Discrimination is
possible by preincubating the inhibitor in assay buffer for 2–3 periods of time. Then,
substrate is added followed by enzyme: for both mechanisms 1A-R and 1C, the reaction
profiles will be independent on preincubation time, but rate will increase with the
preincubation time in the case of mechanism 1B, reflecting disappearance of inhibitor
through hydrolysis. If all inhibitor undergoes hydrolysis during preincubation the rate
returns to control values (slope of the curve as shown for k50.05 s1 in Fig. 5 (left
panel). For very low values of k5 , the instability of the inhibitor may not be appreciable
in a dynamic assay over a relatively short time (e.g., curve for k5¼0.001 s1).
To summarize, the concept highlights the importance of progress curves as a means
for discriminating among mechanisms and for calculating the second-order inhibition
constants. The progress-curve method offers many practical and statistical advantages
over previous methods [4–7]. After choosing an appropriate substrate that allows
continuous detection of reaction progress, and knowing the kinetic parameters V and
Km for this substrate, data collection consists in continuously recording the appearance
of product at a fixed substrate and enzyme concentration for several concentrations of
the inhibitor. The competitive or other character of the inhibitor can be ascertained by
collecting data at various substrate concentrations. Eqns. 8 or 9 are fitted to each
experimental curve by nonlinear regression to calculate l, uz , and u1 as appropriate,
which are then plotted against the inhibitor concentration for establishing the
mechanism and calculating the relevant kinetic parameters. A hyperbola or a straight
line passing through the origin of the axes is diagnostic for mechanisms 2A and 1A,
respectively. As a caveat, irreversible enzyme inhibition and reversible slow, tight-
binding inhibition can hardly be distinguished from one another by this method.
However, in slow, tight-binding inhibition saturation will occur at total inhibitor
concentrations of the same order of magnitude as the total enzyme concentration
[E]t used in the assays, while in irreversible inhibition this will usually occur at
[I]t [E]t .
3. Representative Examples. – The application of the concept presented above
furnished reproducible and consistent kinetic data of our 2,4-dioxa-3-phosphadecalins
of the types I– IV (Fig. 1 and Scheme 1). In the following, selected representative
results that clearly illustrate the convenient practice of the protocol are presented
(structures in Fig. 6, and kinetic constants in Table 4). The inhibition experiments of
AchE with the organophosphorus compounds were performed by means of the Ellman
assay [27] at pH 7.000.02 in the presence of substrate (acetylthiocholine) and the
chromogenic 5,5’-dithiobis(2-nitrobenzoic acid-3,3’-6). The progress curves were
monitored at 410–414 nm (yellow dianion of 5-thio-2-nitrobenzoic acid, lmax¼
412 nm).
The comparison between DFP and a fully irreversible inhibitor, ()-trans-IVax, is
shown in Fig. 7. There are no diagnostic problems for these two inhibitors, for which the
linear dependence of l upon [I], with the intersection point on the ordinate statistically
indistinguishable from zero, and the independence of uz upon [I] clearly point to
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mechanism 1A for both of them. With a 5.3 times larger second-order inhibition
constant k3, ()-trans-IVax is a significantly better inhibitor than DFP.
In Fig. 8, two examples of irreversible inhibition occurring in two steps are shown.
The progress curves with asymptotes running parallel to the time axis, and the
hyperbolic dependence of uz and l upon [I], with the trace of l passing through the
origin of the axes, leave no doubts about mechanism 2A for (þ)-cis-IVax. Instead, (þ)-
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Fig. 6. The representative 2,4-dioxa-3-fluoro-3-phosphadecalins (DFP as reference)
Table 4. Kinetic Data of the Inhibition of AChE with Selected 3-Fluoro-2,4-dioxa-3-phosphadecalins and
Assigned Mechanisms, DFP ((i-PrO)2POF) as Reference. Numbers indicate best-fit parameters
standard errors from nonlinear regression, with the exception of (þ)-cis-IVeq, for which the parameters
represent values optimized by numerical integration of a set of differential equations corresponding to
mechanism 1D obtained with Matlab–Simulink software (www.mathworks.com).
Compound Kinetic Parameters Mechanism
()-trans-IVax k3¼96843 m1 s1 1A
(þ)-trans-IVeq Ki¼20.81.3 mm 2C
k4¼0.0370.004 s1
ki¼1280150 m1 s1
k6¼0.0140.002 s1
()-trans-IVeq Ki¼46347 mm 2C
k4¼0.0170.004 s1
ki¼379 m1 s1
k6¼0.00130.0007 s1
(þ)-cis-IVax Ki¼853 mm 2A
k4¼0.0260.001 s1
ki¼30616 m1 s1
(þ)-cis-IVeq k3¼2260 m1 s1 1D
k5¼0.026 s1
k6¼0.00004 s1
(þ)-trans-IIIax k3¼393 m1 s1 1C
k6¼0.000840.00024 s1
DFP k3¼18128 m1 s1 1A
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trans-IVeq is characterized by progress curves that would suggest a reversible, slow-
binding mechanism. However, the chemical nature of the inhibitor and independent
evidence from 31P-NMR measurements indicate temporary irreversible inhibition
following formation of E–I in a two-step process. E–I is degraded to free enzyme and
an inert inhibitor derivative with rate constant k6¼0.014 s1, which corresponds to a
half-life of 49.5 s, i.e., the covalent E–I compound is almost completely degraded in ca.
6 min (7 times the half-life).
The examples in Fig. 9 illustrate two critical cases that occur when an irreversible
inhibitor binds slowly to the enzyme (second-order inhibition constants around 40m1 s
1 in these two examples) and is temporary as well. Since E–I formation is quite a slow
process, progress curves can only be measured for a limited time, i.e., until no more
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Fig. 7. Inhibition of AChE byDFP (left panels) and ()-trans-IVax (right panels). In the two top panels,
only every 20th experimental point is shown for clarity, and solid lines are best-fits according to Eqn. 8.
Dashed lines around experimental points in the central and bottom panels indicate 95% confidence
intervals. Both inhibitors are described by mechanism 1A with equations shown in Table 3, reactions
paths in Scheme 5, and theoretical curves in Fig. 4.
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than 10–15% of the substrate employed in the assay is used up. As shown, the curves
obtained are not very useful because they are incomplete. Of course, reactions can be
monitored for longer times, but, in this case, we are faced with two problems. First,
excessive substrate consumption violates the necessary condition that the substrate
concentration does not appreciably change during the measuring time: the resulting
curvature of the progress curves is added to that of irreversible, temporary inhibition.
Second, absorbance readings increase excessively causing deviations from the
Lambert–Beer law. Therefore, a reliable interpretation would be difficult or
impossible. Such inhibitors have, of course, little practical interests, but, nevertheless,
their kinetics can be interpreted at least qualitatively. Thus, the diagnostic plots for (þ)-
CHEMISTRY & BIODIVERSITY – Vol. 6 (2009)276
Fig. 8. Inhibition of AChE by (þ)-trans-IVeq (left panels) and (þ)-cis-IVax (right panels). In the two top
panels, only every 20th experimental point is shown for clarity, and solid lines are best-fits according to
Eqn. 9 (left) orEqn. 8 (right). Dashed lines around experimental points in the central and bottom panels
indicate 95% confidence intervals. (þ)-trans-IVeq is described by mechanism 2C and (þ)-cis-IVax by
mechanism 2A (Eqns. in Table 2, reaction paths in Scheme 4, and theoretical curves in Fig. 3).
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trans-IIIax (right panels in Fig. 9) suggest 1C as the most probable mechanism,
although uz is not perfectly independent of [I]. For ()-trans-IVeq, the left panels in
Fig. 9 show fits with mechanism 2C simply because statistical criteria from nonlinear
regression of the progress curves suggest a better fit with mechanism 2C rather than 1C.
With a little portion of common sense, one must, however, admit that there is not much
difference between the left and right panels in Fig. 9, and that ()-trans-IVeq can also
be described by mechanism 1C. Considering mechanism 1C, the calculated second-
order inhibition constant is k3¼30 m1 s1, and with mechanism 2C, this is ki¼37 m1 s1,
thus a minimal discrepancy considering the technical complexity. This last example
shows the limits of the present analysis in decision making, but, fortunately, this is a
feature confined to molecules of scarce practical interest.
Fig. 9. Inhibition of AChE by ()-trans-IVeq (left panels) and (þ)-trans-IIIax (right panels). In the two
top panels, only every 20th experimental point is shown for clarity, and solid lines are best-fits according
to Eqn. 9. Dashed lines around experimental points in the central and bottom panels indicate 95%
confidence intervals. ()-trans-IVeq is described by mechanism 2C (Eqns. in Table 2, reaction paths in
Scheme 4, and theoretical curves in Fig. 3) and (þ)-trans-IIIax by mechanism 1C (Eqns. in Table 3,
reaction paths in Scheme 5, and theoretical curves in Fig. 4).
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Finally, in Fig. 10, a puzzling case is analyzed for compound (þ)-cis-IVeq. Progress
curves (top left panel) may suggest complete irreversible inhibition according to
mechanism 1A. However, analysis of residuals reveals slight but significantly positive
slopes following the exponential phase, which point to either a reversible (1A-R) or an
irreversible temporary mechanism (1C). Another feature is the inconsistent depend-
ency of l upon inhibitor concentration after primary analysis with Eqns. 1, 8, or 9. This
is now the point where even the best enzyme-kinetic expertise needs help from
chemistry. The right panels in Fig. 10 show the instability of (þ)-cis-IVeq as analyzed by
31P-NMR spectroscopy. The signal corresponding to the original molecule (d¼
13.34 ppm) progressively disappears (lower right panel), because the molecule is
transformed in parallel to the P(3)-epimer (()-cis-IVax, d¼ 12.95 ppm) and to a
hydrolysis product (d¼ 1.98 ppm)5). Thus, this is an example of unstable inhibitor,
and the best-fit curves to experimental data in the top left panel of Fig. 10were obtained
by fitting Eqn. 16 using a Maclaurin expansion to the 10th term under the provisional
assumption of mechanism 1B. However, this equation is valid when the unstable
inhibitor is transformed into inert molecules only, whereas the P(3)-epimer of (þ)-cis-
IVeq also acts as an inhibitor albeit at a much lower rate [14]. Furthermore, we have
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5) For further details, see Exper. Part and [14].
Fig. 10. Inhibition of AChE by (þ)-cis-IVeq. In the top left panel, only every 20th experimental point is
shown for clarity, and solid lines are best-fits according to Eqn. 16. The decay constant k5 is not actually
constant, but depends on inhibitor concentration (see text for interpretation). The lower right panel
shows the instability of the molecule as measured by the disappearance with time of its 31P-NMR signal
(d 13.34 ppm), and the top right panel the appearance of the epimer (d 12.95 ppm), as well as of a
hydrolysis product, also monitored as 31P-NMR signal (d 1.98 ppm). The mechanism for this inhibitor
is 1D (Scheme 5).
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evidence that E–I also slowly decays, liberating free enzyme and generating another
degradation product of the inhibitor. These factors explain why the instability constant
k5 obtained by nonlinear regression is not really constant, but varies with total inhibitor
concentration (Fig. 10, lower left panel) if analysis is performed with Eqn. 16, which
holds for mechanism 1B, while the true mechanism is 1D. Since the contribution of the
epimer to total inhibition during the measuring time was found to be minimal, a
satisfactory solution of this puzzle comes finally from a combination of nonlinear
regression and numerical integration analysis giving the kinetic constants shown in
Table 4.
4. Conclusions. – The compounds are remarkable irreversible inhibitors (inactiva-
tors4)) of AChE, and several of them are significantly stronger than diisopropyl
fluorophosphate (DFP) that is generally used as a very potent standard reference
(Table 4). Moreover, the stereoselectivity of the inhibition reaction is demonstrated for
the enantiomers (þ)- and ()-trans-IVeq. However, since this report places main
emphasis on the methodological aspects, we confine ourselves to just presenting distinct
examples that demonstrate the easy applicability of our approach. Meanwhile, we have
prepared the complete set of the optically active (ee>99%) 2,4-dioxa-3-fluoro-3-
phosphadecalins (type IV) [14], and the N-heterocyclic 9-aza- (type I) [28], 8-aza-
(type II) [29], and 7-aza-congeners (type III) [30]. Full kinetic data with detailed
analyses and interpretations of the inhibition behavior will be presented in following
reports [14] [28–30].
The authors are indebted to the Swiss National Science Foundation and the Albert-Bçni Foundation
(A. B.) for their generous financial support.
Experimental Part
1. General. The preparation and the full characterization of the 3-substituted 3-phosphadecalins of
the types I– IV are described in [1] [14] [28–30]. Acetylcholinesterase (AChE) from Electrophorus
electricus (electric eel), Sigma C-2888, type V-S, lyophilized powder x1000 units/mg protein (lots
39H7402, 103K7651, 129F8080, 228F8040); acetylthiocholine (ATC), Fluka 01480 BioChemika ; 5,5’-
dithiobis(2-nitrobenzoic acid-3,3’-6) (DTNB; Ellmans reagent [27]), Fluka 43760 BioChemika ;
diisopropyl fluorophosphate (DFP), Fluka 38399, pract. ; H2O, Fluka 95304 (HPLC quality); MeCN,
Fluka 00695 puriss. abs. (over molecular sieves); NaCl, Fluka 71378 BioChemikaMicroSelect ; NaH2PO4 ·
H2O, Merck 6346 p.a. ; Na2HPO4 ·2 H2O, Merck 6580 p.a. ; Pluronic F-68, Sigma P-1300 (lot 88H1000);
Tris buffer, Fluka 93349 BioChemika MicroSelect. Volumes X1 ml were measured accurately with
microliter pipettes Socorex Sþ (100–1000 ml) and Socorex Autoclavable Calibra 822 (10–100 ml, 1–
10 ml), and volumes <1 ml by diluting in volumetric flasks. pH Determinations: Knick Portamess 762
Calimatic, electrode: Mettler InLab 423 S7; calibration: Mettler standard buffers pH 4.01 and pH 7.00;
electrolyte: Mettler standard, 3m KCl sat. with AgCl; measurements at 228, accuracy0.02 pH units.
Enzyme kinetic progress curves and photometric titration of the active sites of AChE: Hewlett-Packard
8452A diode array spectrophotometer with HP 89532AUV/VIS Software (Rev. A.00.00). Curve-fitting
and data analyses were performed with OriginPro 7.5G SR3 v.7.5853 (www.originlab.com) andGraphPad
Prism version 5.00 for Windows, GraphPad Software, San Diego California USA (www.graphpad.com).
2.Enzyme Kinetics. 2.1. Phosphate Buffer pH 7.00. Soln.A:Na2HPO4 ·2 H2O (4.45 g), NaCl (1.46 g),
and Pluronic F-68 (25 mg) were dissolved in H2O (250 ml). Soln. B: NaH2PO4 ·H2O (6.90 g), NaCl
(2.92 g), and Pluronic F-68 (25 mg) were dissolved in H2O (500 ml). The solns. were adjusted to
pH 7.000.02 by mixing. Prior to use, the buffer was filtered (TRP syringe filter, max. 0.5 MPa, PES
membrane 0.22 m, gamma sterilized, free of pyrogens).
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2.2. AChE Solns. AChE (1 mg) was dissolved in the phosphate buffer pH 7.00 (1 ml), thoroughly
mixed, and stored at 58 (stock soln.). To the phosphate buffer (5 ml), AChE stock soln. (5 ml) was added
and thoroughly mixed. The soln. (1 ml) was diluted to 10 ml with phosphate buffer. Such a soln. could be
used for the determination of Km and one assay series.
2.3. ATC Soln. ATC (22.6 mg) was dissolved in phosphate buffer (1 ml (! 78 mm)) and thoroughly
mixed. The solns. were freshly prepared prior to use and stored at 08 (ice bath).
2.4.DTNB Soln. DTNB (15 mg) was dissolved in phosphate buffer (2 ml (!19 mm)) and well mixed
prior to use.
2.5. Inhibitor Soln. (representative example). The respective 3-substituted 3-phosphadecalin
(3.5 mg) was dissolved in abs. MeCN (200 ml). From this stock soln., a dilution series was prepared to
yield five different concentrations. The total volume of each assay was 25 ml.
2.6. Determination of Km. Prior to each assay series, the Michaelis constant (Km) was determined
under the assay conditions (instead of an inhibitor, MeCN (25 ml) was added). The linear increase of the
absorption was monitored at 410–414 nm at five different concentrations of the substrate (ATC; [S]¼
[ATC] from 100–500 mm). The Michaelis–Menten equation was fitted to the steady-state rates to
calculate Km by nonlinear regression, which was always in the range of 160 mm.
2.7. Assay. In a polystyrene cell (d¼10 cm), phosphate buffer pH 7.00 (2 ml), DTNB soln. (100 ml),
and ATC soln. (20 ml) were mixed and thermostatted at 258. The inhibitor soln. (25 ml, known [I]) was
added. At t¼0, the AChE soln. (1 ml) was added, and the mixture gently mixed for 20 s. After 20 s, the
monitoring of the absorption automatically started, and 600 data points were collected for 10 min at
various concentrations of the inhibitors. As in the Km determinations, the total volume was 3.15 ml, the
concentration of the substrate [S]¼502 mm. Per inhibitor, at least five measurements with different
inhibitor concentrations were performed, the smallest one being ca. 1/5–1/10 of the largest one.
2.8. Titration of the Active Sites of AChE. The concentrations of the active sites in the AChE samples
were determined photometrically by titration withN,N-dimethyl-O-(2-nitrophenyl)carbamate according
to [31] at 258. In this reaction, the enzyme hydrolyzes an equimolar amount of 2-nitrophenolate that is
monitored at 415 nm. The concentration is determined by means of a calibration line that was established
with 2-nitrophenolate under identical reaction conditions. Phosphate Buffer pH 7.70. Soln.A: NaH2PO4 ·
H2O (39.3 mg), NaCl (58.4 mg), and Pluronic F-68 (1 mg) were dissolved in H2O (10 ml). Soln. B:
Na2HPO4 ·2 H2O (1.25 g), NaCl (584 mg), and Pluronic F-68 (10 mg) were dissolved in H2O (100 ml).
The solns. were adjusted to pH 7.700.02 by mixing. AChE Solutions. AChE (1 mg) was dissolved in the
phosphate buffer pH 7.70 (250 ml). Titration (representative example for AChE lot 129F8080). To
phosphate buffer pH 7.70 (2 ml) in a polystyrene cell (d¼10 cm), a soln. (50 ml) of N,N-dimethyl-O-(2-
nitrophenyl)carbamate (7.57 mg/ml in abs. MeCN) was added, and the absorption was measured at
415 nm for 5 min. Then, the soln. (50 ml) of AChE was added, and the progress curve was monitored for
15 min. The procedure was repeated twice to confirm its reproducibility. Data analysis showed the
concentration of active sites to be 1.75 ·108 mol/mg.
2.9.Data Analysis and Assignment of the Inhibition Mechanisms. Eqns. 8 or 9 were fitted to progress
curves by nonlinear regression using GraphPad Prism version 5.00 for Windows, GraphPad Software,
SanDiego, California USA (www.graphpad.com). The runs test and analysis of residuals were performed
to monitor significant deviations from the model. l, uz, and u1 (where appropriate) obtained as the
parameters of this primary analysis were plotted vs. the inhibitor concentration. The dependence of l on
[I] was analyzed with models 2A, 2C, 1A, and 1C (Eqns. in Tables 2 and 3), andmodel discrimination was
performed by analysis of variance of the difference between the sum of squares (extra sum-of-squares
test), and calculation of F ratios and p values. The dependence of uz and u1 on [I] was analyzed using the
appropriate Eqns. in Tables 2 and 3. When primary fittings to progress curves using Eqns. 8 and 9 were
inconsistent, and there was no clear dependency of l upon [I], mechanism 1B was considered and
Eqn. 16 was fitted to data. 31P-NMRAnalyses confirmed in these cases instability of the inhibitors under
the assay conditions resulting in hydrolysis and/or epimerization of the molecule. Data shown in Table 4
report the mechanism and the best-fit inhibition constants with associated standard error from regression
analysis.
3. 31P-NMR Experiments. Stability of (þ)-cis-IVeq. 3.1. General. The 31P{1H}-NMR spectra were
recorded at 161.98 MHz on a Bruker AV2-400 spectrometer at 300 K (d in ppm, J in Hz).
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3.2. Solvents. Soln. A: Na2HPO4 ·2 H2O (445 mg), NaCl (146 mg), and Pluronic F-68 (2.5 mg) were
dissolved in D2O (25 ml). Soln. B:NaH2PO4 ·H2O (690 mg), NaCl (292 mg), and Pluronic F-68 (2.5 mg)
were dissolved in D2O (50 ml). The solns. were adjusted to pH*6) 7.000.02 by mixing.
3.3.Data. (þ)-cis-IVeq : d 13.34 (d, 1J(P,F)¼986); ()-cis-IVax : d 12.95 (d, 1J(P,F)¼1003). The
hydrolysis product (2,4-dioxa-3-hydroxy-3-phosphabicyclo[4.4.0]decane 3-oxide) appeared at d
1.98 ppm (s), and inorg. phosphate was detected at d 2.11 (s)5).
Appendix. – Symbols and Nomenclature Conventions Used in This Article: d¼Displacement of a
progress curve from the zero value; E¼ free enzyme; EI¼adsorptive enzyme– inhibitor or enzyme–
inactivator4) complex; E · I¼ reversible enzyme– inhibitor complex (competitive with substrate); E–I¼
irreversibly, covalently modified enzyme (competitive with substrate); ES¼enzyme–substrate complex;
I¼ inhibitor (reversible inhibitor or irreversible modifier (inactivator4))); I’¼chemically transformed I
(e.g., by hydrolysis), which does no longer bind to the enzyme; I*¼enzymatically transformed I, which
does no longer bind to the enzyme; k1, k3¼ second-order rate constants; k1, k2, k3 , k4, k5, k6 , k7, k7¼
first-order rate constants; Ki¼k3/k3¼dissociation constant; ki¼k4/Ki¼ second-order inhibition con-
stant; P¼product(s); S¼ substrate; us¼ reaction rate at steady-state; uz¼ reaction rate at time zero (t¼
0); u0¼ reaction rate in the absence of modifiers; l¼ first-order rate constant of the exponential phase for
the formation of E–I or EI; [X]¼concentration of the free species X in mol dm3 ; [X]t¼ total
concentrations of species X; [X]z¼concentrations of species X at t¼0.
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Simultaneous interaction of enzymes
with two modifiers: reappraisal of ki-
netic models and new paradigms
Journal of Theoretical Biology, 2009, 261:318−329
Abstract
Die Aktivität eines Enzyms kann durch die gleichzeitige Einwirkung von zwei
Modifiern, Aktivatoren oder Inhibitoren, moduliert werden. Die kinetischen
Mechanismen für die Interaktion der individuellen Modifier mit dem Enzym
können sich beträchtlich verändern, wenn zwei Modifier gleichzeitig binden.
Wir beschreiben eine generelle Gleichung für diese Art von Interaktionen,
welche das Verhalten von Aktivatoren und Inhibitoren eindeutig beschreiben
kann, bei jegwelcher Kombination von klassischen kinetischen Mechanismen.
Die Flexibilität dieses Modells ist beispielhaft erläutert durch die Kombi-
nation von Aktivatoren und/oder Inhibitoren, die kompetitiv, unkompetitiv
oder vom gemischten Typ sein können und das Enzym in einer vorgeschriebe-
nen oder zufälligen Weise binden und die Enzymaktivität bei Sättigungsbe-
dingungen auf keine oder geringe Aktivität erniedrigen können. Das Modell
zeigt, dass die Effekte von ’Zero-Interaction’ und ’Synergy’ zwischen gleich-
zeitig agierenden Enzymmodifiern häufige Ereignisse sind. Jedoch, im Un-
terschied zu früheren Theorien, ’Antagonism’ zwischen Enzymmodifiern ein
sehr seltener Effekt ist, der nur unter ganz bestimmten Umständen zu er-
warten ist.
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a b s t r a c t
Enzyme activity can be modulated by the concurrent action of two modiﬁers, either activators or
inhibitors. The kinetic mechanisms for the interaction of the individual modiﬁers with the target
enzyme can change considerably when two modiﬁers bind simultaneously. We illustrate a general
equation for this kind of interactions, which can unambiguously describe the behavior of activators and
inhibitors acting by any combination of classical kinetic mechanisms. The ﬂexibility of this model is
exempliﬁed by combinations of activators and/or inhibitors, which can be competitive, uncompetitive
or mixed-type, bind the target enzyme in either compulsory or random order, and are able to drive or
not enzyme activity to zero at saturation. The model shows that the effects of zero-interaction and
synergy between simultaneously acting enzyme modiﬁers are common events. Yet, in disagreement
with previous theories, this model shows that antagonism between enzyme modiﬁers is a rare effect,
which can be predicted only under very particular circumstances.
& 2009 Elsevier Ltd. All rights reserved.
1. Introduction
The velocity of enzyme-catalyzed reactions can be regulated by
modiﬁers, which may be activators or inhibitors. A large number
of classical studies have been dedicated to the development of
methods for gaining information on mechanisms of interaction
and kinetic constants in systems consisting of an enzyme, one or
more substrates, and a modiﬁer. The simultaneous action of two
or more modiﬁers on the same enzyme molecule received
attention after observing that the combination of two modiﬁers
may not result in simple additive effects. This was shown in a
study of the ‘succinic oxidase’ system subjected to simultaneous
inhibition by ﬂuoride and phosphate (Slater and Bonner, 1952).
Other contributions to multiple inhibition of both practical and
theoretical character were published after this seminal paper and
were concerned with speciﬁc mechanism.
Multiple enzyme modiﬁcation by inhibitors and activators is
relevant to biochemistry and pharmacology for several reasons. Two
or more endogenous or exogenous inhibitors may interact with the
same enzyme molecule and generate a multitude of combined effects
that depend on the individual kinetic mechanisms of the inhibitors, as
well as on substrate and inhibitor concentrations. An exogenous
inhibitor may bind a target enzyme and contend or share binding
with an endogenous inhibitor. An inhibitor may bind an enzyme in
concert with an activator, or two activators can act at the same time.
All possible individual inhibition and activation kinetic mechanisms
give rise to a large and multi-faceted spectrum of interactions. Out of
many situations that may occur in vitro, we mention just the example
of an enzyme acting on a racemic substrate, of which only one of the
optical isomers is a true substrate, while the other behaves as a
competitive inhibitor. Hence, in the presence of a true inhibitor, the
enzyme interacts in reality with two inhibitors (Mares-Guia and
Shaw, 1965). Physiopathologically relevant examples can be found in
the ﬁeld of extracellular matrix degrading hydrolases. For instance, in
the extracellular space, the leukocyte peptidases elastase, cathepsin
G and myeloblastin interact unspeciﬁcally with glycosaminoglycans,
components of the extracellular matrix, and this interaction may
result in either inhibition or activation (Baici et al., 1993; Fru¨h et al.,
1996; Kostoulas et al., 1997). In the presence of endogenous or
exogenous inhibitors, these interactions generate a spectrum of
hitherto unpredictable effects spanning from synergy to antagonism.
In the light of these observations, we undertook the study of multiple
enzyme modiﬁcation with the aim of giving a quantitative and
mechanistic interpretation to the difﬁculties encountered with
synthetic inhibitors against enzymes with these unusual properties
(Baici, 1998).
Here we reconsider the simultaneous action of two modiﬁers on
one enzyme molecule by treating the most general situation, from
which particular cases can be derived. For properly understanding
the signiﬁcance of our present treatment, a comparison with
previous literature and a critical assessment of general concepts is
essential. This discussion will be presented in Appendix B. The
literature on multiple inhibition, at least in the early phases of the
development of the underlying theories, suffered from overlooking
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previously published work and caused occasional confusion, redis-
coveries and misinterpretations. This analysis is in no way aimed at
censuring authors but at linking theories with their legitimate
sources to the best of our knowledge and, where appropriate, at
amending mathematical mistakes.
We call attention to linear and hyperbolic mixed-type inhibi-
tion, a blend of competitive and uncompetitive character. The
kinetic mechanism of such inhibitors may be much more
widespread than commonly realized, and may be representative
of a major class of modiﬁers such as allosteric effectors. Results
from our laboratory on a designed ankyrin repeat protein as
inhibitor of caspase-2 are an example (Schweizer et al., 2007). In a
natural environment, e.g. when used as drugs, such artiﬁcially
designed protein modiﬁers and any other synthetic compound
will possibly interact with naturally occurring modiﬁers against
the target enzyme. It is therefore helpful to set up criteria by
which these interactions may be interpreted and predicted on the
basis of mathematical models.
2. Theory of double enzyme modiﬁcation
Double modiﬁer systems have been described in the past with
numerous different terminologies and symbols for kinetic para-
meters and coefﬁcients. In the majority of publications, particular
cases have been considered and the comparison of the associated
theoretical treatments with those in other publications is not
always straightforward, particularly when an extension has to be
made to a general mechanism. In the literature on this subject the
terms non-competitive and mixed-type inhibition have been used
with various ambiguous meanings. In our own theory, in line with
the recommendations of the International Union of Biochemistry,
we will not use the term non-competitive inhibition, which is ‘y
discouraged for all purposes’ (International Union of Biochemistry,
1982). We will use instead the term mixed-type or simply mixed
inhibition, which also includes the non-competitive inhibition as
a special case where the competitive and the uncompetitive
components contribute equally.
2.1. The general modiﬁer mechanism
A generic classical modiﬁer can be adequately described with
the general modiﬁer mechanism (Botts and Morales, 1953) with
the notation shown in Scheme 1. Here, the symbol I denotes an
inhibitor but this can be an activator as well. For inhibitors, the
coefﬁcient a deﬁnes the proportion of competitive and
uncompetitive character and b is a factor that multiplies the
catalytic constant. If bo1 hyperbolic inhibition is observed, b41
describes activation and b ¼ 1, together with 1oaoN, occurs in
the particular case of hyperbolic competitive inhibition.
The use of the symbol S for substrate does not imply that the
scheme is restricted to single-substrate enzymes. In case of
multisubstrate reactions, S represents the varied substrate, while
the other(s) is/are kept at a constant concentration, and the same
is valid for the product(s) P.
The ‘speciﬁc velocity plot’ has been developed as a diagnostic
tool for the analysis of modiﬁcation mechanisms conforming to
Scheme 1 (Baici, 1981). While the method applies equally to
inhibitors and activators, the following speciﬁc velocity equation
is shown here for an inhibitor, I:
v0
vi
¼
½I 1aKi
 1
Ki
 
1þ b ½IaKi
s
1þ sþ
1þ 1
Ki
1þ b ½IaKi
: ð1Þ
v0 and vi are the rates in the absence and in the presence of
inhibitor, respectively, and s ¼ ½S=Km. Eq. (1) was derived under
the assumptions of quasi-equilibrium for the binding of I to E and
ES, and steady-state for the ﬂuxes around ES and ESI. Accordingly,
in Eq. (1) Km substitutes Ks shown in Scheme 1. An expert account
on the validity of these assumptions has been published (Topham
and Brocklehurst, 1992). In Eq. (1) and in all other equations in
this paper, it is assumed that the concentration of modiﬁers is
much larger than the enzyme concentration, i.e. the total and free
modiﬁer concentrations are approximately the same (no deple-
tion of modiﬁer by tight-binding). We will consistently use the
terminology of Scheme 1 throughout this article and will extend it
to the case of two modiﬁers acting on the same enzyme. In
particular, we will retain the b-coefﬁcients as multiplicative
factors for the catalytic step constants.
2.2. The double modiﬁer mechanism
Double interactions by two simultaneously acting modiﬁers, I
and X, can be described with a three-dimensional path of
reactions as shown in Scheme 2a, which is analogous to Scheme
1. In Scheme 2a, the reactant addition paths, such as I+EX-EIX
and similar, have been omitted for simplicity.
The meaning of coefﬁcients and parameters in Scheme 2a is
explained in Table 1 and compared with the corresponding
symbols in three previous theoretical treatments (see
Appendix B). The coefﬁcients aS, aI and aX multiplying KS, KI and
KX, respectively, may appear eccentric at a ﬁrst sight and could
actually be omitted if it were not for some special cases of
modiﬁer binding. In fact, Scheme 2a describes the most general
possibility of interactions but not all paths shown must
necessarily exist and aS, aI and aX can only take the values 1
(the path exists) or N (the path does not exist). The individual
notations for the a- and g-coefﬁcients are useful for the same
reason, and they can take any positive value. This terminology
helps avoid mathematical mistakes in the cases of essential
activation and uncompetitive inhibition because our symbols are
based on the use of multiplication coefﬁcients for equilibrium
constants rather than on the constants themselves, such as for
instance aXSKS, which could be written K’S as well. To illustrate the
usefulness of the terminology in Scheme 2a and b four examples
are discussed in Appendix A, including essential activation.
However, in the general case, all interconversions shown in
Scheme 2a take place and parallel pathways in the
thermodynamic boxes described by the edges of the cube must
be taken into account. In this case it is convenient to proceed with
less cumbersome symbols deﬁned as combined coefﬁcients
a ¼ aIaIS ¼ aSaSI;
b ¼ aXaXS ¼ aSaSX;
c ¼ aXaXI ¼ aIaIX; ð2Þ
and the symbolism in Scheme 2a can be simpliﬁed as shown in
Scheme 2b. Nonetheless, we emphasize that for ordered
mechanisms equalities (2) should be interpreted as follows
Scheme 1. The general modiﬁer mechanism: E ¼ enzyme, S ¼ substrate, and
I ¼ inhibitor or other modiﬁer.
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depending on the existing path:
a ¼ aIaIS or a ¼ aSaSI;
b ¼ aXaXS or b ¼ aSaSX;
c ¼ aXaXI or c ¼ aIaIX: ð3Þ
For the three paths leading to ESIX in Scheme 2b, the interaction
coefﬁcients gS, gI and gX are left as they are in Scheme 2a. Without
the explicit aS, aI and aX coefﬁcients in Scheme 2a, the symbols in
Scheme 2b, although correct, may lead to ambiguities in the case
of essential activation, uncompetitive inhibition and compulsory
order of reactant binding as illustrated by examples in Appendix
A. The general equation for double enzyme modiﬁcation contains
a further combined interaction constant, e, from equalities (4).
This constant derives from microreversibility and does not
explicitly appear in the reaction scheme of the system:
e ¼ agX ¼ bgI ¼ cgS: ð4Þ
Again, in special cases the value of e in (4) will correspond to
either one of the terms. With these notions, considering quasi-
equilibrium conditions for all steps but the catalytic paths and
steady-state conditions for the four ﬂuxes around the catalytic
steps, the rate equation for the mechanism in Scheme 2a and its
variant in Scheme 2b is given by
vIX ¼ v0ð1þ sÞ
1
aS
þ bI
½I
aKI
þ bX
½X
bKX
þ bIX
½I½X
eKIKX
1þ ½IaIKI
þ ½XaXKX
þ ½I½X
cKIKX
þ s 1aS
þ ½I
aKI
þ ½X
bKX
þ ½I½X
eKIKX
  :
ð5Þ
The terms in the right hand side of Eq. (5) are grouped to explicitly
show four terms in the numerator, which correspond to the four
catalytic steps, and eight terms in the denominator, which
correspond to the enzyme-containing species, i.e. the corners of
the cube, with the number 1 representing free enzyme. Particular
cases can be derived from this general equation by deleting terms
as needed as illustrated in the examples in Appendix A. The
coefﬁcient e characterizes the paths leading to the quaternary
complex ESIX, in the respect of the underlying thermodynamic
boxes, according to relationship (4).
The coefﬁcient c in Scheme 2b and Eq. (5) is a measure of four
types of interaction that may occur between the modiﬁers I and X
on the free enzyme (Keleti and Fajszi, 1971):
facilitation 0oco1;
Scheme 2. (a) Extension of the general modiﬁer mechanism to the simultaneous action of two modiﬁers, I and X and (b) the same mechanismwritten with the deﬁnitions
in equalities (2).
Table 1
Deﬁnition of elementary reaction steps, equilibrium and interaction constants in Scheme 2a, and comparison with previously published terminology.
# Elementary reactions This work Keleti and Fajszi (1971) Segel (1975) Webb (1963)
1 Eþ S"ES aSKS ¼
½E½S
½ES
K0 Ks Ks
2 Eþ I"EI aIKI ¼
½E½I
½EI
K1 Ki Ki1
3 Eþ X"EX aXKX ¼
½E½X
½EX
K2 Kx Ki2
4 ESþ I"ESI aSIKI ¼
½ES½I
½ESI
K01 aKi bKi1
5 ESþ X"ESX aSXKX ¼
½ES½X
½ESX
K02 bKx gKi2
6 EIþ S"ESI aISKS ¼
½EI½S
½ESI
K10 aKs bKs
7 EXþ S"EXS aXSKS ¼
½EX½S
½ESX
K20 bKs gKs
8 EIþ X"EIX aIXKX ¼
½EI½X
½EIX
K12 gKx aKi2
9 EXþ I"EIX aXIKI ¼
½EX½I
½EIX
K21 gKi aKi1
10 ESIþ X"ESIX gXKX ¼
½ESI½X
½ESIX
K012 bgKx agKi2
11 ESXþ I"ESIX gIKI ¼
½ESX½I
½ESIX
K021 agKi abKi1
12 EIXþ S"ESIX gSKS ¼
½EIX½S
½ESIX
K120 abKs bgKs
aS, aI and aX can only take the values 1 (the path exists) or N (the path does not exist).
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independence c ¼ 1;
hindrance 1oco1;
exclusion c ¼ 1: ð6Þ
These interactions, which are deﬁned on the assumption of a
model such as Eq. (5), should not be mistaken for and used as
synonyms of phenomenological effects that may be observed in
double modiﬁer systems and deﬁned as synergy, antagonism or
zero-interaction (discussed in Section 3). In particular, the
coefﬁcient c alone cannot be used as a criterion for predicting
such effects. Criteria (6) can, however, be used to analyze
experimental data and to discriminate between synergy and
zero-interaction provided the mathematical model truthfully
describes the system. The most important issue in this matter is
whether or not the individual behavior of the modiﬁers I and X
changes upon concomitantly binding to the enzyme, a property
taken into account by the coefﬁcients c and e in Scheme 2b and
Eq. (5), respectively.
We consider now the possible combinations of two inhibitors I
and X, which can individually be competitive, uncompetitive or
mixed and additionally linear or hyperbolic. When acting together
on the same enzyme molecule, the possibilities can be calculated
considering an r-combination of a multiset M of size r, chosen
from a set of n elements, M(n+r1, r). This is also called
r-combination with repetition allowed. In this case, r ¼ 2 (the two
inhibitors I and X) and the set has six elements (n ¼ 6), i.e. a
hyperbolic inhibitor can be competitive, uncompetitive or mixed
and the same holds for a linear inhibitor. The number of
r-combinations is therefore given by
n
r
 
¼ nþ r  1
r
 
¼ ðnþ r  1Þ!
r!ðn 1Þ!
 
; ð7Þ
which gives a total of 21:
Mð6þ 2 1;2Þ ¼ 7!
2!5!
 
¼ 21: ð8Þ
The interaction coefﬁcients c and e and the possibility that ESIX is
catalytically active (bIXa0) give rise to six situations (Table 2).
Thus, excluding occurrences of ordered binding, a total of
216 ¼ 126 cases can be predicted for double inhibitions. In
practice, however, many of these 126 cases will hardly occur
because they are either non-sensical or very rare.
A non-sensical combination is for instance that of two linear
competitive inhibitors with coN, eoN and bIXa0. Uncompeti-
tive inhibition is a well-known feature of multisubstrate systems,
in which inhibition by one of the products is genuinely
uncompetitive (Segel, 1975, Chapter 9). Uncompetitive inhibition
in multisubstrate systems is also possible for molecules structu-
rally unrelated to the substrates of the reaction (King et al., 2009).
Nevertheless, in single substrate enzyme-catalyzed reactions
uncompetitive inhibition is more a theoretical than a real
situation, which is yet necessary, together with competitive
inhibition, to describe all gradations of mixed inhibition
(Scheme 1). Uncompetitive inhibition is a very rare mechanism
in nature because of its detrimental effects. Indeed, metabolites
acting as uncompetitive inhibitors have conceivably been evolu-
tionarily excluded by selection but this does not preclude the
utilization of synthetic uncompetitive inhibitors as toxic agents,
e.g. for pest control (Cornish-Bowden, 1986). Linear non-compe-
titive inhibition, in its classical deﬁnition, is described by a ¼ 1
and b ¼ 0 in Scheme 1. As commented by Cornish-Bowden, this
type of inhibition is limited to protons, metal ions and small
anions like chloride, and it is unlikely that molecules larger than
these simple ions obey this mechanism. Furthermore, non-
competitive inhibition has in many cases been mistaken for
partial irreversible inactivation (Cornish-Bowden, 2004, p. 117).
Thus, double inhibition systems containing linear non-competi-
tive modiﬁers will have little chance to be observed in nature.
Nevertheless, double inhibitions with the participation of an
uncompetitive inhibitor are observed in multisubstrate systems,
e.g. (Brandt et al., 1990; King et al., 2009).
3. Synergy, antagonism and zero interaction
In pharmacology, synergy and antagonism between drugs is
customarily described with isobolograms, a graphical procedure
for characterizing their equieffective combinations. In the case of
two substances A and B, isobolograms are obtained by represent-
ing the ‘doses’ or concentrations in an orthogonal coordinate
system. Lines in this diagram, the isoboles, connect different dose
combinations which produce the same effect. A ﬁrst empirical
description of this concept (Fraser, 1870–1871), was expanded by
Loewe and Muischnek (1926), who also coined the term isobole.
Berenbaum (1977, 1989) reviewed the rich literature on this
subject, discussed nomenclature conﬂicts and provided a math-
ematical proof for the equation used to describe interactions
between drugs. For two compounds A and B, a resulting effect E is
characterized by the relationship
da
Da
þ db
Db
¼ E; ð9Þ
where da and db are the doses (or concentrations as appropriate)
of A and B used in combination, while Da and Db are the doses of A
and B, which individually produce the same effect as the
combination. The effect is deﬁned as synergy if Eo1, antagonism
if E41 and zero-interaction if E ¼ 1, and we will consistently use
these terms. The third effect, zero interaction, is also called
addition, additivism or summation, synonyms which have,
however, been used with several different meanings (Berenbaum,
1989). Examples of isoboles are illustrated in Fig. 1: zero-
interaction in Fig. 1a, synergy in Fig. 1b and c, and antagonism
in Fig. 1d (convex curve following straight zero-interaction lines).
Webb (1963, Chapter 10) suggested that the effects observed in
multiple enzyme inhibitions may be represented by isobolograms
in a way similar to that used in pharmacology and that
interactions taking place between two inhibitors simultaneously
acting on an enzyme may also be classiﬁed as synergism,
antagonism and summation. In the treatment of double inhibi-
tions by Keleti and Fajszi (1971), the rate equations were derived
correctly for the general case (Scheme 7c in Appendix B) as well as
for all special cases discussed therein. However, in making
predictions about synergy and antagonism, the authors used the
following relationships for all purposes, i.e. for any combination of
mechanisms and interaction coefﬁcients, in particular whether
the two inhibitors were or were not mutually exclusive:
zero-interaction v1;2 ¼
v1v2
v0
; ð10Þ
Table 2
Interactions between two inhibitors in the double modiﬁer mechanism (Scheme
2b) considering the linear or the hyperbolic character of double inhibition.
Interaction c e
1 I and X exclude each other on E and on ES and bIX ¼ 0 N N
2 I and X exclude each other only on ES and bIX ¼ 0 (0,N) N
3 I and X exclude each other only on E and bIX ¼ 0 N (0,N)
4 EIX does not exist but ESIX does exist and 0obIXr1 N (0,N)
5 EIX and ESIX exist but bIX ¼ 0 (0,N) (0,N)
6 EIX and ESIX exist, and 0obIXr1 (0,N) (0,N)
P. Schenker, A. Baici / Journal of Theoretical Biology 261 (2009) 318–329 321
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antagonism v1;24
v1v2
v0
; ð11Þ
synergy v1;2o
v1v2
v0
: ð12Þ
In Eqs. (10)–(12), v1, v2 and v1,2 correspond to the rates in the
presence of modiﬁer 1 alone, modiﬁer 2 alone, and in the presence
of both modiﬁers, respectively.
Indeed, Eq. (10) is valid only if a ¼ b ¼ c ¼ e ¼ 1 and
bI ¼ bX ¼ bIX ¼ 0. If satisﬁed, this equation predicts zero-interac-
tion. The prediction of antagonism with (11) and synergy with
(12) is a minimal statement that says nothing but that there is a
deviation from the behavior predicted by Eq. (10). We will show
below that, while synergy is a genuine and common feature,
antagonism is a rare property in double inhibition systems and
that it occurs only with peculiar combinations of the interaction
coefﬁcients in Scheme 2b.
Chou and Talalay (1977) extended the relationship (10) to n
mutually non-exclusive inhibitors, of which at least one must be
non-competitive:
v1;2;3;...;n
v0
¼ v1
v0
 v2
v0
 v3
v0
   vn
v0
: ð13Þ
v1–vn represent the rates in the presence of the individual
modiﬁers and v1,2,y,n the rate in the presence of all modiﬁers.
With n ¼ 2 Eq. (13) is the same as Eq. (10). Fajszi and Keleti (1974)
used expressions (10)–(12) in a rearranged form in making
predictions of effects arising from combinations of mechanisms
and listed several special cases. Unfortunately, their estimates are
true only in a few particular cases because expressions (10)–(12)
cannot be indiscriminately used for any combination of inhibition
mechanisms. For instance, the authors predicted antagonism
between two mutually exclusive competitive inhibitors, whereas
in this case only zero-interaction can result. Also, when two
competitive inhibitors are mutually non-exclusive with hindrance
(1ocoN) Fajszi and Keleti predicted antagonism or zero-
interaction depending on the substrate concentration. However,
in this case only synergy will be observed independently of
substrate concentration.
The theory named by Fajszi and Keleti (1974) ‘the triple-faced
enzyme–inhibitor relation’ must be rejected in its original form
because it is based on a wrong general assumption which leads to
false predictions. In some instances (Leoncini et al., 1989; Lien
et al., 1979a, 1979b), the term ‘antagonism’ has been misapplied as
a synonym of mutual exclusion or hindrance, but this is likely to
be a linguistic lapse. In fact, mutual exclusion (c ¼ e ¼N, bIX ¼ 0)
results by deﬁnition in zero-interaction.
The following Eq. (14) was originally proposed to describe the
combined effects of a linear competitive and of a linear non-
competitive inhibitor, which do not interact with each other
(Lienhard, 1971):
1
v1;2
¼ 1
v1
þ 1
v2
 1
v0
: ð14Þ
Fig. 1. Plots of the reaction rate as a function of the concentration of two modiﬁers. Concentrations and inhibition constants are in mM units, coefﬁcients as deﬁned in
Scheme 2. (a) I and X are linear, mutually exclusive mixed-type inhibitors, aI ¼ aX ¼ aS ¼ 1, a ¼ 2, b ¼ 4, c ¼N (exclusion), e ¼N, s ¼ 1, bI ¼ bX ¼ bIX ¼ 0, KI ¼ 2, KX ¼ 5.
(b) I is a linear competitive inhibitor and X is a linear mixed-type inhibitor, aI ¼ aX ¼ aS ¼ 1, a ¼N, b ¼ 4, c ¼ 1 (independence), e ¼N, s ¼ 1, bI ¼ bX ¼ bIX ¼ 0, KI ¼ 2,
KX ¼ 5. (c) I is a linear uncompetitive inhibitor and X a linear mixed-type inhibitor, aI ¼N, aX ¼ aS ¼ 1, a ¼ 1, b ¼ 4, c ¼ 5 (hindrance), e ¼ 8, s ¼ 1, bI ¼ bX ¼ bIX ¼ 0,
KI ¼ 1, KX ¼ 6. (d) I is a hyperbolic competitive inhibitor and X is a hyperbolic mixed-type inhibitor, aI ¼ aX ¼ aS ¼ 1, a ¼ 5, b ¼ 4, c ¼ 5, e ¼ 8, s ¼ 1, bI ¼ 1, bX ¼ 0.3,
bIX ¼ 0.8, KI ¼ 2, KX ¼ 5. The straight, convex and concave lines in these plots represent the isoboles, i.e. the equieffective concentrations of the modiﬁers, I and X, obtained
by projection of the three-dimensional graphs onto the [I]–[X] plane.
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In a more general context, Fajszi (1974) used Eq. (14) as ‘an
immediate method’ to ascertain whether both the EIX and ESIX
complexes are absent in the general case (Scheme 2). This means,
if the relationship (14) between the velocities does not apply, then
the two inhibitors interact in some way or are of the hyperbolic
type. Overlooking the previous publications by Keleti and Fajszi,
Chou and Talalay (1977) provided an extension of (14) to n
modiﬁers as
1
v1;2;3;...;n
¼
Xn
i¼1
1
vi
 n 1
v0
; ð15Þ
but acknowledged without comment the contributions of Keleti
and Fajszi in a subsequent paper (Chou and Talalay, 1981). It
should be pointed out that neither Eq. (15) nor Eq. (13) fulﬁll the
statement of being a ‘simple generalized equation for the analysis
of multiple inhibitions’ (Chou and Talalay, 1977). In fact, these
equations are valid only in particular cases and predict zero-
interaction between linear, mutually exclusive inhibitors
(c ¼ e ¼N, bIX ¼ 0 in Scheme 2) independently of their indivi-
dual mechanisms [Eq. (15)]. Synergy is observed in the case of
non-exclusive linear inhibitors [Eq. (13)] when a ¼ b ¼ c ¼ e ¼ 1.
If the result of (15) is not satisﬁed the only reliable prediction that
can be made is that the EIX and ESIX do exist or at least one
inhibitor is of the hyperbolic type. The prediction of antagonism
when 1=v1;2o1=v1 þ 1=v2  1=v0 (Chou and Talalay, 1977) is valid
only if at least one of the inhibitors is hyperbolic and only for
particular values of the interaction coefﬁcients (Section 3.1). The
same comments apply to the ‘general coefﬁcient’ as a measure of
synergy for all purposes (Mazat et al., 1981) because the highly
unpredictable behavior of hyperbolic mixed inhibitors is not taken
into account also in this case.
From the issues discussed above it becomes clear that a general
expression relating the initial rate in presence of two modiﬁers,
vIX, to the individual rates of the modiﬁers, vI and vX, and to the
rate in absence of modiﬁers, v0, with the purpose of predicting
synergistic and antagonistic effects, can theoretically be derived
but results in a too complex expression for practical purposes.
Additionally, it is mandatory to take into account mixed type
inhibitors and the possible hyperbolic nature of one or both of the
modiﬁers. As mentioned in the Introduction, we believe that
hyperbolic mixed-type modiﬁers represent a class of inhibitors
with crucial physiological roles that have been poorly character-
ized in the past. However, positive examples are antitumoral
agents as inhibitors of cathepsin B (Bincoletto et al., 2005);
antistatin as inhibitor of the coagulation factor Xa (Dunwiddie
et al., 1989); antileukoprotease as inhibitor of the stratum
corneum chymotryptic enzyme involved in physiological detach-
ment of corneocytes (Franzke et al., 1996); a cleavage product of
von Willebrand factor as inhibitor of ADAMTS13, a metallopepti-
dase that mediates platelet adhesion (Gao et al., 2006); sulfated
glycosaminoglycans as inhibitors of human leukocyte elastase,
which participate in compartmentalization and inhibition of this
and similar enzymes in lysosomes (Kostoulas et al., 1997); a
designed ankyrin repeat protein, inhibitor of caspase-2 as a
potential agent to control apoptosis (Schweizer et al., 2007).
Taking advantage of modern information technology, forecast-
ing synergy, antagonism or zero-interaction is a simple task with
the aid of the general equation (5) and its graphical representation
in three dimensions with two axes representing the effectors I and
X and the third axis representing vIX, i.e. the effect. At the same
time, equieffective concentrations of the two modiﬁers, the
isoboles, can be obtained as projection of the effects on the I–X
plane. All three-dimensional graphics in this article were
produced with Matlabs software.
Generalized predictions on synergy and antagonism are
difﬁcult because dozens of possible combinations should be
listed. However, based on our exhaustive analysis of all possible
combinations of modiﬁers, the following statements can be made
(Scheme 2b and Eq. (5)). Any combination of mutually exclusive
inhibitors (c ¼ e ¼N, bIX ¼ 0) invariably results in zero-interac-
tions. The isoboles consist of parallel straight lines if both
inhibitors are linear and of straight lines intersecting at a common
point if at least one of the two modiﬁers is a hyperbolic inhibitor.
An example is shown in Fig. 1a. With 0oco1 (facilitation) or c ¼ 1
(independence), any combination of inhibitors (competitive,
uncompetitive or mixed) results in synergy with the exception
of particular cases of two mixed inhibitors, where at least one of
the two modiﬁers is hyperbolic and the ESIX complex is
catalytically active (see Section 3.1). An example with c ¼ 1 is
shown in Fig. 1b. With 1ocoN (hindrance) combinations of
inhibitors result in synergy with the exception resulting from two
linear mixed or one linear and one hyperbolic mixed inhibitors
with predominantly uncompetitive character, and for combina-
tions of two hyperbolic inhibitors. In such cases an indeﬁnite
number of effects can be observed, which depend on the
coefﬁcients a, b, c, e, bI, bX and bIX, as well as on the substrate
and inhibitor concentrations. We show here two examples in
Fig. 1c (only synergy in the whole inhibitor concentration range)
and in Fig. 1d (zero-interaction at low concentration changes into
antagonism by increasing the concentration of the inhibitors, see
also Section 3.1).
3.1. Reactivation following inhibition and the inhibition paradox
An apparently odd effect can be observed when all paths
shown in Scheme 2b exist, including the four catalytic steps,
which consists of enzyme inhibition in a low concentration range
of the two modiﬁers, and reactivation by further increasing their
concentrations. This effect was predicted by Fajszi and Keleti and
what follows is our interpretation of the phenomenon. Although
Fajszi and Keleti’s treatment is only partially valid because it is
affected by mathematical mistakes (reasons discussed above), we
wish to credit these authors with the fatherhood of the concept
described in this section. The concentration of modiﬁer for which
the inhibitory phase changes into reactivation has been called
characteristic inhibitor concentration (Fajszi and Keleti, 1974).
In our analysis there are three possibilities for this behavior,
and their distinction depends on the nature and availability of the
modiﬁers I and X. If the two compounds are individually available,
experiments can ﬁrst be performed at various substrate concen-
trations and various I and X concentrations separately, and then
using combinations of their concentrations. However, two or more
modiﬁers may be the constituents of a complex mixture, from
which they cannot be separated. In this case measurements can
only be performed by increasing the concentration of the
modiﬁers at a constant ratio.
Case 1 (I and X are separately available): the ESIX complex is
catalytically more efﬁcient than ESI and ESX; case 2 (I and X are
separately available): either I or X is a liberator (Appendix B); and
case 3 (I and X are components of an inseparable mixture): the
individual contributions of the various components to enzyme
modiﬁcation cannot be evaluated, and only a two-dimensional
representation of the effect can be produced. In case 1, besides
observing a recovery of activity by increasing the concentration of
the modiﬁers in combination over a certain threshold, it may
happen that the rate in the presence of both modiﬁers exceeds the
rate measured in the absence of modiﬁers, i.e. vIX4v0 despite the
values of bI, bX and bIX being r1. This property has been called
inhibition paradox (Fajszi and Keleti, 1974). An example of activity
recovery by increasing the concentrations of inhibitors is shown
in Fig. 2a, and the inhibition paradox is illustrated in Fig. 2b. In
P. Schenker, A. Baici / Journal of Theoretical Biology 261 (2009) 318–329 323
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case 2 the liberator I has no effect whatsoever on enzyme activity
(a ¼ 1 and bI ¼ 1 in Scheme 2b) unless a genuine inhibitor X is
also present (Fig. 2c). Experimentally, a distinction of case 2
towards case 1 is straightforward because the liberator I does not
inﬂuence enzyme activity in the absence of the other modiﬁer. A
further difference with respect to case 1 is that a liberator can
reverse inhibition maximally to the rate in the absence of
modiﬁer, v0, but cannot enhance the rate to values exceeding
those in the absence of modiﬁers. To illustrate the great variety of
effects that can arise from combinations of modiﬁers, we show in
Fig. 2d the case of a non-essential activator with a hyperbolic
mixed inhibitor.
Besides the three mentioned cases, a special effect is observed
when an initial activation in presence of two modiﬁers is followed
by inhibition after increasing their concentration. To explain this
effect we examine the properties of one of the modiﬁers, say I,
whose behavior as inhibitor or activator depends on the
coefﬁcients in Scheme 1. If ao1, br1 and b4a, I behaves as a
hyperbolic mixed modiﬁer with predominantly uncompetitive
character and has a higher afﬁnity for ES than for E (Frieden, 1964,
non-limiting case 3). When [S]/Km ¼ (ba)/(1b) the modiﬁer
has no effect on the enzyme. This critical substrate concentration
is obtained by differentiating the equation for the mechanism in
Scheme 1 (the reciprocal of Eq. (1)) with respect to modiﬁer
concentration, setting the derivative equal to zero and solving for
[S]. Below this value the modiﬁer behaves as activator and above
it as inhibitor. Increasing the substrate concentration favors the
formation of ESI rather than EI and results in activation or
inhibition depending on substrate concentration (Fig. 3). When
such a modiﬁer I is used concomitantly with an inhibitor X at
various substrate concentrations, the resulting effects are as those
shown in the example of Fig. 4. The three-dimensional plots,
which show the change of character of modiﬁer I from inhibitor to
Fig. 2. Plots of the reaction rate as a function of the concentration of two modiﬁers in special cases. Concentrations and inhibition constants are in mM units, coefﬁcients as
deﬁned in Scheme 2b. In all examples shown here aI ¼ aX ¼ aS ¼ 1. (a) I is and X are hyperbolic, non-exclusive mixed inhibitors, a ¼ 2, b ¼ 4, c ¼ 3.5 (hindrance), e ¼ 1.5,
s ¼ 1, bI ¼ 0.4, bX ¼ 0.6, bIX ¼ 0.8, KI ¼ 2, KX ¼ 3. (b) The same parameters as in (a) but e ¼ 0.8 and bIX ¼ 0.9 (a case of inhibition paradox). (c) I is a liberator and X a linear
competitive inhibitor, a ¼ 1, b ¼N, c ¼ 5 (hindrance), e ¼N, s ¼ 1, bI ¼ 1, bX ¼ bIX ¼ 0, KI ¼ 2, KX ¼ 4. (d) I is a non-essential activator and X is a hyperbolic mixed
inhibitor, a ¼ 2, b ¼ 2, c ¼ 4 (hindrance), e ¼ 5, s ¼ 1, bI ¼ 4, bX ¼ 0.6, bIX ¼ 1.4, KI ¼ 2, KX ¼ 4.
Fig. 3. A modiﬁer activates at low substrate concentration and inhibits at high
substrate concentration. Drawn according to Scheme 1 with the rate in arbitrary
units and a ¼ 0.1, b ¼ 0.6. At the characteristic ratio [S]/Km ¼ (ba)/(1b), which
is 1.25 in this speciﬁc example, the modiﬁer has no effect on the enzyme.
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activator, differ only in the [S]/Km ratio (0.1 or 2.0), whereas all
other parameters are the same. Depending on how much the
[I]:[X] ratio is shifted in favor of [I], the activation effect of this
modiﬁer becomes more evident as the substrate concentration
decreases.
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Appendix A
A.1. Essential activator and linear competitive inhibitor
Let X be an essential activator of the enzyme E, S a substrate
and I a linear competitive inhibitor, which does not share the
same binding site with the activator and is therefore non-
exclusive with X. In the absence of X, S would not productively
bind the enzyme. This is one of two possible mechanisms of
essential activation as described by Frieden (1964), namely his
limiting case 1b. With the notation in Scheme 2b, this situation
implies KS ¼N and this may sound mathematically strange
because at the same time bKS must have a ﬁnite value. Using the
unambiguous nomenclature in Scheme 2a for the mechanism
under consideration, this can be sketched as shown in Scheme 3a,
where the ES complex is missing because aS ¼N and therefore
also aSaSX ¼N. The relationship aI KI aIX KX ¼ aX KX aXI KI
holds (thermodynamic box), and from the deﬁnitions in (2) and
(3) the mechanism can be simpliﬁed as shown in Scheme 3b, with
aI ¼ aX ¼ 1, aS ¼N, a ¼N, b ¼ aXS, c ¼ aXI ¼ aIX (coN), e ¼N,
bI ¼ bIX ¼ 0, and bxa0.
The rate equation can be deduced from (5) by introducing
these coefﬁcients:
vIX ¼ v0ð1þ sÞ
bX
½X
bKX
1þ ½I
KI
þ ½X
KX
þ ½I½X
cKIKX
þ s ½X
bKX
: ð16Þ
The ‘Km’ for the path Sþ EX"ESX-EXþ P corresponds for this
mechanism to ‘bKm’. A graphic representation of this system is
shown in Fig. 5a.
A.2. Two hyperbolic mixed inhibitors mutually exclusive on ES
Let I and X be two hyperbolic mixed inhibitors which exclude
each other in presence of the substrate but not on the free
enzyme. Scheme 2a corresponds in this case to Scheme 4a. The
thermodynamic boxes imply that aS ¼ aI ¼ aX ¼ 1, a ¼ aIS ¼ aSI,
b ¼ aXS ¼ aSX, c ¼ aXI ¼ aIX. Since the simultaneous presence of I
and X is not possible when S is bound, all three g-interaction
constants are inﬁnite. This reduces symbols as shown in Scheme
4b and the rate equation is given by (17). A graphic representation
of this system is shown in Fig. 5b.
vIX ¼ v0ð1þ sÞ
1þ bI
½I
aKI
þ bX
½X
bKX
1þ ½I
KI
þ ½X
KX
þ ½I½X
cKIKX
þ s 1þ ½I
aKI
þ ½X
bKX
  : ð17Þ
A.3. Linear competitive and hyperbolic, mixed inhibitor, mutually
exclusive on ES
The species I is considered to be the competitive inhibitor and
the hyperbolic mixed inhibitor is X: I and X are non-exclusive on E
(coN) but exclusive on ES (gS ¼ gI ¼ gX ¼N). Using the same
reasoning of the two preceding examples, the reaction schemes
using the detailed and the simpliﬁed nomenclature are shown in
Scheme 5 and the rate equation is expression (18). A plot is shown
in Fig. 5c.
vIX ¼ v0ð1þ sÞ
1þ bX
½X
bKX
1þ ½I
KI
þ ½X
KX
þ ½I½X
cKIKX
þ s 1þ ½X
bKX
  : ð18Þ
Fig. 4. Hyperbolic mixed-type modiﬁer (I) together with a linear competitive inhibitor (X). The modiﬁer I has the same properties shown in Fig. 3. I and X are non-exclusive
on E. Concentrations and inhibition constants are in mM units, coefﬁcients as deﬁned in Scheme 2b with values (for both panels a and b): a ¼ 0.2, b ¼N, c ¼ 0.5, e ¼N,
bI ¼ 0.6, bX ¼ bIX ¼ 0, KI ¼ 2, KX ¼ 5. The plots differ only in the value of s, which is 0.1 in a and 2.0 in b.
Scheme 3. X is an essential activator and I a linear competitive inhibitor. (a)
Explicit symbols as in Scheme 2a and (b) simpliﬁed symbols with deﬁnitions (2)
and (3) as in Scheme 2b.
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A.4. Two non-exclusive, hyperbolic mixed inhibitors
The reactions are those shown in Scheme 2b and the rate
equation is
vIX ¼ v0ð1þ sÞ
1þ bI
½I
aKI
þ bX
½X
bKX
þ bIX
½I½X
eKIKX
1þ ½I
KI
þ ½X
KX
þ ½I½X
cKIKX
þ s 1þ ½I
aKI
þ ½X
bKX
þ ½I½X
eKIKX
  :
ð19Þ
Depending on the interaction coefﬁcients a, b, c, and e, on the
residual activities characterized by the three b-values in the
numerator of (19), as well as on substrate concentration, this
model gives rise to manifold effects that include bizarre results,
such as inhibition in a given range of inhibitor concentrations and
re-activation from the inhibited state in another (plot in Fig. 5d).
An extreme case is the inhibition paradox discussed in Section 3.1.
Appendix B
In the early literature on double inhibition systems, reaction
schemes were not always explicitly shown, making readability
and interpretation difﬁcult. Therefore, in discussing previous
Fig. 5. Plots of the reaction rate as a function of the concentration of two modiﬁers. Concentrations and inhibition constants are in mM units. (a) An essential activator (X)
and a linear competitive inhibitor (I) as shown in Scheme 3, aI ¼ aX ¼ 1, aS ¼N, a ¼N, b ¼ 1, c ¼ 3 (hindrance), e ¼N, s ¼ 1, bI ¼ 0, bX ¼ 1, bIX ¼ 0, KI ¼ 2, KX ¼ 5.
(b) Two hyperbolic mixed inhibitors exclusive on ES (Scheme 4), aI ¼ aX ¼ aS ¼ 1, a ¼ 2, b ¼ 4, c ¼ 1 (independence), e ¼N, s ¼ 1, bI ¼ 0.5, bX ¼ 0.3, bIX ¼ 0, KI ¼ 2, KX ¼ 5.
(c) A linear competitive inhibitor (I) and a hyperbolic mixed inhibitor (X) mutually exclusive on ES (Scheme 5), aI ¼ aX ¼ aS ¼ 1, a ¼N, b ¼ 4, c ¼ 0.5 (facilitation), e ¼N,
s ¼ 1, bI ¼ 0, bX ¼ 0.3, bIX ¼ 0, KI ¼ 2, KX ¼ 5. (d) Two non-exclusive hyperbolic mixed inhibitors, both have a predominantly uncompetitive character (Scheme 2),
aI ¼ aX ¼ aS ¼ 1, a ¼ 0.2, b ¼ 0.5, c ¼ 0.5 (facilitation), e ¼ 0.8, s ¼ 1, bI ¼ 0.3, bX ¼ 0.1, bIX ¼ 0.9, KI ¼ 2, KX ¼ 5.
Scheme 4. Two hyperbolic mixed inhibitors. I and X exclude each other when
substrate is bound but can coexist in complex with the enzyme alone. Terminology
of Scheme 2a (a) and of Scheme 2b (b).
Scheme 5. Reaction paths for a double modiﬁer system consisting of a
linear competitive inhibitor (I) and a hyperbolic, mixed inhibitor (X), which can
coexist in complex with the enzyme alone. Terminology of Scheme 2a (a) and of
Scheme 2b (b).
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contributions to this topic in comparison with the present
treatment we will show the reaction schemes by sketching them
with reactants placed at the eight corners of a cube in the same
positions as shown in Scheme 2 even if this was not explicitly
done in the original publications. Non-existing paths will be
substituted by dashed lines and kinetic parameters will be those
of the original publications. For clarity, however, the original rate
equations will be written using our present terminology.
B.1. Two competitive inhibitors
Slater and Bonner studied the simultaneous action of ﬂuoride
and phosphate on the ‘succinic oxidase’ system (Slater and
Bonner, 1952). This paper dealt with two non-exclusive, linear
competitive inhibitors as shown in Scheme 6b. The rate equation
(10) by Slater and Bonner in the presence of the two inhibitors,
rewritten using our terminology, is the following:
vIX ¼
v0ð1þ sÞ
1þ ½I
KI
þ ½X
KX
þ ½I½X
cKIKX
þ s
: ð20Þ
The four parameters for ﬂuoride and phosphate, KF, KFP, KP and KPF,
corresponding to our KX, cKI, KI and cKX, respectively (Scheme 6a)
were calculated graphically using double reciprocal plots. The
interaction constant between phosphate and ﬂuoride, c in our
terminology, can thus be calculated from the data of Slater and
Bonner as KPF/KF ¼ KFP/KP ¼ 3.3103 (facilitation).
While investigating the inhibition of D-amino acid oxidase, Yagi
and Ozawa (1960a) proposed a graphical method for establishing
if any interaction occurred between two simultaneously bound
inhibitors with the mechanism shown in Scheme 6c. Eq. (6) in
Yagi–Ozawa’s paper can be rewritten using our general equation
(5) and rearranging it with v0/vIX as the independent variable.
This gives
v0
vIX
¼
1þ ½I
KI
þ ½X
KX
þ ½I½X
cKIKX
þ s
1þ s ð21Þ
and Eq. (5) in Yagi and Ozawa (1960a) is obtained by setting
c ¼N in (21):
v0
vIX
¼
1þ ½I
KI
þ ½X
KX
þ s
1þ s : ð22Þ
Eq. (21) is identical with Eq. (20) published eight years before
(Slater and Bonner, 1952), which Yagi and Ozawa overlooked. The
plot proposed by these authors, v0/vIX versus a mixture of two
inhibitors I and X gives a straight line if the EIX complex is not
formed, Eq. (22), or a second-order curve if both inhibitors coexist
in a complex with the enzyme, Eq. (21). This method was
successful for determining the mechanism of action of antibiotics
on D-amino acid oxidase (Yagi and Ozawa, 1960a, 1960b) and was
later used by several investigators.
The theoretical issues of the two studies mentioned above
were extended to describe double inhibition of liver alcohol
dehydrogenase by coenzyme–competitive inhibitor pairs with the
reaction scheme shown in Scheme 6d (Yonetani and Theorell,
1964). The interaction coefﬁcient between the two inhibitors, a, is
equivalent to the coefﬁcient c in our present symbolism and the
equation derived by the authors (their Eq. (13)) is identical to
Eq. (10) of (Slater and Bonner, 1952), i.e. Eq. (20) in our
terminology. As an elegant variant, Yonetani and Theorell devised
a graphical method in which the v0/vi ratio is plotted versus the
concentration of I1 while I2 is kept constant, and versus I2 at
constant I1. This plot results in a family of parallel straight lines if
c ¼N (the two inhibitors exclude each other) and in a set of
straight lines converging to a common point in the second
quadrant if 0ocoN (the two inhibitors are non-exclusive). The
Yagi–Ozawa plot can be represented within the Yonetani–Theorell
plot by connecting ordinate values for successively increasing I1
and I2 concentrations. Among numerous other practical applica-
tions, the Yonetani–Theorell plot was used to demonstrate
allosteric regulation of a-oxoglutarate dehydrogenase by NADred
(Hall and Weitzman, 1977), and synergism in the inhibition of the
HIV type 1 protease by couples of inhibitors (Asante-Appiah and
Chan, 1996b). Nevertheless, the Yonetani–Theorell plot cannot be
generalized because it is valid only for two linear competitive
inhibitors.
In a study of acetylcholinesterase, Allen and Abeles (1989) did
not consider any of the previous contributions on double
inhibition and re-published the equation for the simultaneous
action of two competitive inhibitors discussed above, which was
originally derived by Slater and Bonner. The plot used by the
authors was based on the reciprocal of Eq. (21) and their
coefﬁcient M is equivalent to our 1/c. While nothing is wrong in
this paper, the use of the terms positive cooperativity and negative
cooperativity to describe the concepts of synergism and antagon-
ism, respectively, cannot be recommended (see Section 3).
B.2. More complex systems
We discuss here double inhibition in a more general context,
which includes mixed-type and hyperbolic inhibitors. The basic
theories are mainly due to Webb (1963, Chapter 10), Keleti and
Fajszi (1971), Fajszi (1974), and Segel (1975, Chapter 8). To
facilitate comparison of different treatments, Table 1 lists the
elementary steps at the edges of the cube in Scheme 2a, and
shows the symbolism used by us and by the authors mentioned in
this section. Also, Table 3 lists the interactions that may occur
between inhibitors, the free enzyme and the ES complex, their
meaning and the symbolism used by different authors.
Chronologically, Webb (1963, Chapter 10) was the ﬁrst to
consider combinations of inhibitions other than competitive.
Besides discussing the combination of two competitive inhibitors,
Scheme 6. Abridged reaction schemes for double inhibition by two linear
competitive inhibitors described in the literature. Paths from the original
publications are compared with the symbolism in this paper. (a) Symbolism in
this paper (Scheme 2b); (b) Slater and Bonner (1952); (c) Yagi and Ozawa (1960a);
and (d) Yonetani and Theorell (1964).
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he derived kinetic equations based on the mechanism shown in
Scheme 7b also for the combination of two non-competitive
inhibitors or one competitive and one non-competitive inhibitor.
On the basis of the coefﬁcient a, the interactions between the two
inhibitors were classiﬁed as negative (1oaoN) or positive
(ao1). The latter case was exempliﬁed by Webb using results
discussed above on succinic oxidase (Slater and Bonner, 1952).
Keleti and Fajszi (1971) published a comprehensive treatment
of double inhibitions by taking into account all preceding
literature and extending the theory to include hyperbolic inhibi-
tion. Their reaction scheme is shown in Scheme 7c, which is again
written in a way to match the orientation of reactants in our
symbolism (Scheme 7a). Keleti and Fajszi used individual symbols
for each of the twelve edges of the cube. Apart K0, K1 and K2, which
correspond to our KS, KI and KX, respectively, the other symbols
include the coefﬁcients of interaction, which can be calculated as
the ratio of the constants of two reaction steps on opposite edges
on the same face of the cube. For instance, K12/K2 ¼ a is equivalent
to our coefﬁcient c. Using the interaction coefﬁcients, Keleti and
Fajszi deﬁned the types of interaction that may occur in double
inhibition systems as independence, facilitation, hindrance and
exclusion, as speciﬁed in the main text (6). A subsequent
publication (Fajszi, 1974) was a review of the 1971-paper and
included a critical survey of graphical methods for the analysis of
double inhibition data.
In the context of double modiﬁer interactions, Keleti (1967)
deﬁned liberator ‘a substance which may liberate the enzyme from
the action of an inhibitor without affecting the enzyme activity
alone’, which is characterized by a ¼ b ¼ 1 in Scheme 1. This
deﬁnition was extended also to include the neutralizing action
towards activators. In this paper, the author created the
mathematical basis and derived equations for describing the
kinetics of compounds that were known to act as liberators from a
few examples, e.g. the reversible competitive liberation by urea of
N-acetylglutamate 5-phosphotransferase from inhibition by argi-
nine (Farago´ and Denes, 1967). Keleti pointed out that a liberator
may be competitive, non-competitive or uncompetitive with an
inhibitor, and worked out criteria for the differentiation of these
mechanisms by considering nine combinations of liberator and
inhibitor. There are no mistakes in this interesting treatment, but
an attempt at unifying the particular cases in a general scheme is
impossible, since Keleti used the same notation of kinetic
constants for different paths in nine individually analyzed
particular cases. For instance, the symbol Ks’ was used for
different, unrelated equilibria such as EL+S"ELS and EI+S"ESI.
However, Keleti’s treatment for the liberator action can be
implemented by using our general Scheme 2a and its simpliﬁed
variant in Scheme 2b as applicable, as well as the general equation
for two modiﬁers (5), from which the particular cases can be
derived in unambiguously. For instance it is sufﬁcient to consider
our modiﬁer X to be the liberator, L, described by Keleti.
Segel (1975, Chapter 8) published another thorough scrutiny of
double inhibition systems on the basis of the general mechanism
shown in Scheme 7d. His theory exactly reproduces the results
discussed above (Keleti and Fajszi, 1971; Webb, 1963, Chapter 10),
although explicit reference to these previous contributions was
not made. All particular cases discussed by Segel can be derived
from the general mechanism in Scheme 2 and the corresponding
equations can be deduced as particular cases of Eq. (5).
Other contributions to the analysis of combined effects dealt
with linear inhibitors (Martinez-Irujo et al., 1998; Reynolds et al.,
1970; Semenza and von Balthazar, 1974; Thoma and Crook, 1982).
Useful graphical methods for the analysis of the effects produced
by two linear inhibitors have been developed (Asante-Appiah and
Chan, 1996a; Palatini, 1983a) or for a linear inhibitor combined
with a hyperbolic inhibitor (Palatini, 1983b).
The studies mentioned in this section created the frame for a
modern interpretation of double inhibition systems. The only
difﬁculty that readers less experienced in enzyme kinetics may
encounter with the equations published in these papers is the
labor necessary to decipher symbols and to put equations to work
in practical cases. The explicit labeling of interaction coefﬁcients
with reactant-related indices, as shown in Scheme 2a, avoids the
need of continuous referencing to their deﬁnitions and makes
them understandable at ﬁrst sight. When one or more of the paths
in the general mechanism (Scheme 2a) do not exist, or if ordered
binding is present, our nomenclature provides an unambiguous
description of the system. The interpretation of the interaction
coefﬁcients is more straightforward in our treatment than in
those of Segel and Webb. At ﬁrst sight, the notation in our
nomenclature (Scheme 2b), does not clearly show the property of
the thermodynamic boxes. For instance cKIgSKS is seemingly not
the same as bKSgIKI in our nomenclature but this apparent
discrepancy is removed after considering the relationships (4) in
the main text. Segel and Webb notation is on the contrary
immediate and clearly reveals the consistency of the thermo-
dynamic boxes. However, as shown in Table 3, the interactions of I
and X on E, and of I and X on ES, appear to be the same using the
Table 3
Interaction coefﬁcients for the double modiﬁer mechanism when all paths exist
(Scheme 2b).
Interaction This work Keleti and Fajszi (1971) Segel (1975) Webb (1963)
I and X on E c a ¼ K12
K2
¼ K21
K1
g a
I and X on ES gX
b
¼ gI
a b ¼
K012
K02
¼ K021
K01
g a
S and X on EI gS
a
¼ gX
c g ¼
K012
K12
¼ K120
K10
b g
S and I on EX gI
c
¼ gS
b d ¼
K021
K21
¼ K120
K20
a b
S on EIX gS Built-in in K120 ab bg
I on ESX gI Built-in in K021 ag ab
X on ESI gX Built-in in K012 bg ag
Comparison of symbols and coefﬁcients used by different authors.
Scheme 7. Abridged reaction schemes for generalized double inhibitions de-
scribed in the literature. Paths from the original publications are compared with
the symbolism in this paper. (a) Symbolism in this paper (Scheme 2a); (b) Webb
(1963, Chapter 10); (c) Keleti and Fajszi (1971); and (d) Segel (1975, Chapter 8).
Arrows indicate the catalytic steps without symbols.
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terminologies of Segel or Webb. This arises from the use of the
same symbol (g by Segel and a by Webb) in two different
thermodynamic boxes, which implies that the relationship of the
ternary complexes ESI, ESX and EIX with the quaternary complex
ESIX can be deduced from the preceding steps.
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Abstract
Die Serinendopeptidase Elastase-2 der menschlichen polymorphonuklearen
Leukozyten wird in Verbindung gebracht mit der physiologischen Umgestal-
tung und dem pathologischen Abbau der extrazellulären Matrix. Die während
dem proteolytischen Abbau der ’Core’-Proteine freigesetzten Glykosamino-
glykane sind potentielle Liganden der Elastase-2. In vitro resultiert diese
Interaktion bei tiefer Konzentration der Glykosaminoglykane in einer Hem-
mung der Enzymaktivität. Diese Hemmung wird jedoch bei höheren Konzen-
trationen der Liganden teilweise oder gar vollständig aufgehoben. Ein solches
Verhalten, ausgelöst durch einen Mechanismus welcher mindestens zwei Glyko-
saminoglykan-Moleküle involviert, kann den Effekt natürlich vorkommender
Inhibitoren beeinflussen, insbesondere jener des α1-Peptidaseinhibitors. Vor
allem bei tiefen Konzentrationen wirken die Glykosaminoglykane der Forma-
tion eines Enzym-Inhibitor Komplexes entgegen und stimulieren zudem die
proteolytische Aktivität. Diese Beeinträchtigung der Hemmung der Elastase-
2 im extrazellulären Raum wird in Verbindung gebracht mit einem fein abges-
timmten Kontrollmechanismus in der Mikroumgebung eines Enzyms beim
Um- und Abbau der extrazellulären Matrix.
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Abstract
The serine endopeptidase elastase-2 from human polymorphonuclear leukocytes is
associated with physiological remodeling and pathological degradation of the extra-
cellular matrix. Glycosaminoglycans released after proteolytic processing of the core
proteins of proteoglycans are potential ligands of elastase-2. In vitro, this interaction
results in enzyme inhibition in a low concentration range of the glycosaminoglycans.
However, inhibition is reversed and even abolished at high concentrations of the lig-
ands. This behavior, which can be interpreted with a mechanism involving at least
two molecules of glycosaminoglycan binding the enzyme at different sites, may cause
interferences with the natural protein inhibitors of elastase-2, particularly the α-1-
peptidase inhibitor. Especially at low concentrations, glycosaminoglycans contrast
the formation of the enzyme-inhibitor complex and stimulate proteolytic activity as
well. This negative interference on elastase-2 inhibition in the extracellular space is
put in relation with a finely-tuned control mechanism in the microenvironment of the
enzyme during remodeling and degradation of the extracellular matrix.
Keywords: Inhibition, Activation, Multiple interactions, Serine peptidases, Electro-
static interactions, Glycosaminoglycans
List of abbreviations: MeOSuc, N-Methoxysuccinyl; pNA, p-nitroanilide; α1-PI, α-
1-peptidase inhibitor; Ch4S, chondroitin-4-sulfate; Ch6S, chondroitin-6-sulfate; DS,
dermatan sulfate; PPS, pentosan polysulfate. DU, disaccharide units; MU, monomer
units.
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1 Introduction
The serine endopeptidase elastase-2
(human leukocyte elastase) is a basic
protein with an isoelectric point of 10.5.
Eighteen of the 19 arginine residues
constituting the primary structure of
the protein are located at the surface of
the molecule [1] and may be engaged in
electrostatic interactions with anionic
partners [2]. Elastase-2, together with
cathepsin G and myeloblastin, released
extracellularly from neutrophilic poly-
morphonuclear leukocytes during in-
flammation and in a variety of patho-
logical conditions, can be very destruc-
tive by degrading several components
of the extracellular matrix [3]. Sul-
fated glycosaminoglycans, constituents
of the proteoglycans, have been shown
to interact with the three leukocytic en-
zymes and to modulate their enzymatic
activity [2,4-9]. In particular, elastase-
2 undergoes inhibition by chondroitin
sulfate isomers, dermatan sulfate (DS)
and related sulfated polysaccharides
with a high-affinity, electrostatically-
driven, hyperbolic mixed-type inhibi-
tion mechanism with a predominantly
competitive character [2]. The evalu-
ation of these interactions was based
on measuring enzymatic activity for in-
creasing concentrations of the modi-
fiers at several fixed concentrations of
a suitable substrate until a plateau was
reached. We and others [10] observed a
puzzling reversal of inhibition, and oc-
casionally complete abolishment of the
original inhibition, by increasing the
concentration of modifiers by orders of
magnitude beyond the level that pro-
duced inhibition but did not discuss
this phenomenon for the lack of a plau-
sible molecular explanation.
After excluding experimental arti-
facts and in the light of a recent theoret-
ical assessment of multiple interactions
between enzymes and modifiers [11], we
describe here the varying behavior of
sulfated polysaccharides as modulators
of elastase-2 activity. These interac-
tions become important at the inter-
face between insoluble extracellular ma-
trix components and physiological flu-
ids, where the enzyme is engaged in
multiple interactions with glycosamino-
glycans bound to the matrix, or re-
leased from it, and naturally-occurring
inhibitors.
2 Materials and Methods
2.1 Materials
Elastase-2 (EC 3.4.21.37, Merops
database S01.131) was obtained from
Elastin Product Company (Owensville,
USA). The lyophilized enzyme was dis-
solved at a concentration of 2.5 mg/mL
in 0.1 M sodium acetate buffer, pH =
4.50 and stored in aliquots at -20◦C.
The concentration of enzyme active
sites was determined by titration with
MeOSuc-AAPV-CH2Cl and measur-
ing the residual activity with MeOSuc-
AAPV-pNA. Inactivator and substrate
were purchased from Bachem (Buben-
dorf, Switzerland).
Chondroitin-4-sulfate (Ch4S)
sodium salt from bovine trachea
2
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and chondroitin sulfate (mixed iso-
mers) from whale cartilage, as well
as chondroitin-6-sulfate (Ch6S) sodium
salt from shark cartilage were obtained
by Sigma - Aldrich Chemie (Buchs,
Switzerland). DS from porcine in-
testinal mucosa was purchased from
Calbiochem (Nottingham, UK). Al-
though labeled ’chondroitin-4-sulfate’
and ’chondroitin-6-sulfate’, these com-
pounds are in reality co-polymers of
the 4- and 6-isomers along the same
chain and contain also sulfate-free se-
quences. Ch4S from bovine trachea
contained 69% of 4-sulfate and 25%
of 6-sulfate; Ch6S contained 45% of
4-sulfate and 54% of 6-sulfate; DS con-
tained 98% of 4-sulfate. Balance to
100% was non-sulfated material. Anal-
yses were performed by HPLC of the
unsaturated disaccharides after diges-
tion with chondroitinase ABC as de-
scribed previously [12]. Pentosan poly-
sulfate (PPS, structure shown in Fig.
3F) was a generous gift from Bene
PharmaChem (Geretsried, Germany).
All sulfated polysaccharides were dried
for 4 hours at 95◦C to remove water,
weighted and immediately dissolved in
distilled water to produce stock solu-
tions of known concentrations. The
molecular masses were determined at
the Istituto di Ricerche Chimiche e
Biochimiche G. Ronzoni (Milano, Italy)
by the courtesy of Dr. Antonella Bisio.
The procedure is based on high per-
formance liquid chromatography com-
bined with a triple detector array com-
posed of right-angle laser light scatter-
ing, refractometer and viscometer [13].
Table 1: Molecular mass of the modifiers. Molecular masses are shown as Mn (number-
average), Mw (weight-average) and Mp (molecular mass at the top of the chromatographic
peak) measured as described by Bertini et al. [13]. The polydispersity index Mw/Mn is a
measure of the molecular mass distribution within a sample. Mp would coincide with Mn
and Mw for Mn/Mw = 1. DU, disaccharide units; MU, monomeric units. Ch4S was from
bovine trachea.
Modifier Mn Mw Mp Mw/Mn Average number
of units/chain
DS 22,022 26,488 25,297 1.203 ∼ 52 DU
Ch4S 18,843 23,229 20,912 1.233 ∼ 46 DU
Ch6S 58,810 65,668 63,023 1.117 ∼ 130 DU
PPS 3,687 5,202 3,888 1.411 ∼ 15 MU
3
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The isomeric composition and
molecular mass of chondroitin sulfate
from whale cartilage were not deter-
mined (this compound was used for
qualitative comparisons), while the
characteristics of the other polysaccha-
rides are summarized in Table 1. Their
concentration will be expressed as the
concentration of the basic unit, which is
a monosulfated disaccharide for chon-
droitin sulfates and DS (Mr = 503.36)
and a disulfated monosaccharide for
PPS (Mr = 336.27).
Eglin c from the leech Hirudo
medicinalis (Merops database identi-
fier I13.001) was purified and char-
acterized as described [14,15] and its
protein concentration was confirmed
by amino acid analysis. A tetrapep-
tide inhibitor based on the amino acid
sequence 60-63 of eglin c, H-TNVV-
OMe [16], was obtained from Bachem
(Bubendorf, Switzerland). Human α-
1-peptidase inhibitor (α1-PI, Merops
database identifier I04.001) was from
Behring.
2.2 Kinetic methods
Kinetic measurements were performed
using disposable acrylic cuvettes at 25
± 1◦C in 50 mM Tris/HCl buffer with
NaCl added to an ionic strength of 100
mM; the pH was 7.40 and 0.01% Tri-
ton X-100 was added to prevent enzyme
adsorption to vessels. The buffer was
prepared and used at 25◦C. The sub-
strate MeOSuc-AAPV-pNA was dis-
solved in dimethyl sulfoxide before dilu-
tion into the assay buffer, and the final
assay concentration of dimethyl sulfox-
ide was less than 0.1% (v/v). Km was
determined by fitting the Michaelis-
Menten equation by non-linear regres-
sion to data with substrate concen-
trations ranging from 0.2 Km to 5
Km. Reaction progress was moni-
tored at 405 nm with a Cary 50 spec-
trophotometer and the concentration
of released p-nitroaniline was calcu-
lated using an absorption coefficient of
9920 M−1cm−1. Regression analysis
was performed with GraphPad Prism
version 5.02 for Windows (GraphPad
Software, San Diego California USA,
www.graphpad.com). Inhibition of
elastase-2 by sulfated polysaccharides
was analyzed with the four parame-
ter logistic equation adapted to kinetic
measurements [2]:
v i = v0 − (v0 − v∞) [I]
h
Kh0.5 + [I]h
(1)
In equation (1) v i is the inhibited ve-
locity, v0 is the velocity in the absence
of modifiers, v∞ is the velocity after
reaching the plateau (saturating in-
hibitor I), K0.5 is the inhibitor con-
centration for which the velocity equals
(v0-v∞)/2, and h is the Hill coeffi-
cient, usually not an integer. All mea-
surements were performed at a known,
fixed substrate concentration.
Double enzyme-modifier inter-
actions were treated according to
Schenker and Baici [11] with the mech-
anism shown in Scheme 1 and equation
4
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(2).
vIX = v0(1 + σ)
(
1 + βI
[I]
aKI
+βX
[X]
bKX
+ βIX
[I][X]
eKIKX
)
/(
1 +
[I]
KI
+
[X]
KX
+
[I][X]
cKIKX
)
σ
(
1 +
[I]
aKI
+
[X]
bKX
+
[I][X]
eKIKX
)
(2)
vIX represents the rate in presence of
the two modifiers I and X, v0 the rate
in the absence of modifiers, and σ =
[S]/Km. The coefficients a, b and c are
those in Scheme 1, and e = aγX = bγI
= cγS.
3 Results and Discussion
3.1 Inhibition of elastase-2 by
sulfated polysaccharides
We previously demonstrated that the
interaction between elastase-2 and
sulfated polysaccharides resulted in
concentration-dependent inhibition of
the enzyme activity. We used semisyn-
thetic glycosaminoglycan derivatives of
precisely defined isomeric composition
and molecular mass for interpreting
the effects arising from specific struc-
tural elements of the polysaccharides
[2]. These effects were based on elec-
trostatic interactions between the pos-
itively charged arginine residues at the
surface of the enzyme molecule and
the negatively charged polysaccharides.
The general inhibition mechanism was
hyperbolic mixed-type with predomi-
nantly competitive character but could
not be adequately analyzed with the
specific velocity equation [17] because
of cooperative effects and multiple
binding of the modifiers at different
sites. Therefore, the affinity between
binders and the enzyme was evaluated
with the four parameter logistic equa-
tion (1). Without assuming a particular
mechanism, this empirical model gives
a good estimate of the affinity (K0.5),
an equivalent of the inhibition constant,
and of any cooperativity in the binding
process described by the Hill coefficient
h. This is a useful approach for com-
paring the properties of structurally re-
lated modifiers.
In nature, sulfated glycosamino-
glycans are highly polydisperse and
the chondroitin sulfates exist as co-
polymers of the 4- and 6-sulfate isomers
with composition and average molecu-
lar masses depending on animal species
and tissue. Fig. 1 shows the inhibi-
tion of elastase-2 by naturally occurring
chondroitin and dermatan sulfates and
by a semisynthetic sulfated polysaccha-
ride of plant origin (PPS) used as a ref-
erence. Solid curves represent fits to
data using equation (1) and the best
fit parameters K0.5 and h are shown
in the panels of Fig. 1. Ch4S had
the weakest interaction with elastase-2
among the tested polysaccharides and
Ch6S the strongest. Two factors con-
tribute to the higher affinity of the
6-isomer: the larger average molecu-
lar mass, with about 130 disaccharide
units per chain, compared with only 46
for the 4-isomer (Table 1), and more
favorable electrostatic interaction with
5
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elastase-2 [2]. DS is sulfated at posi-
tion 4 of the galactosamine ring and
shows higher affinity to elastase-2 com-
pared with chondroitin4-sulfate with a
similar average molecular mass. The
tighter binding is due to higher confor-
mational flexibility that allows adapt-
ing the molecule to strong interactions
with several biomolecules [18]. PPS
was considered in this study as a ref-
erence molecule with a high degree of
uniform sulfation and moderate poly-
dispersity. The affinity of this sulfated
polysaccharide was high, with K0.5 =
49 nM and a Hill coefficient of 2.3, indi-
cating cooperative binding to elastase-
2 evidenced by the sigmoid appearance
of the saturation curve (Fig. 1D). As
discussed previously [2], partial inhibi-
tion of elastase-2 by negatively charged
polymers can be ascribed to electro-
static interactions between the 18 pos-
itively charged arginine residues at the
surface of the enzyme (Fig. 2) and the
negatively charged polysaccharides. In
particular, when Arg217A interacts elec-
trostatically with polyanions, interfer-
ence with substrate binding causes par-
tial inhibition.
3.2 Reactivation of elastase-2
following inhibition
In order to simulate a plausible nat-
ural situation, in which glycosamino-
glycans are present at high concentra-
tion in the microenvironment in which
elastase-2 is active, we performed mea-
surements as shown in Fig. 3 with mod-
ifier concentrations increased as much
as experimentally possible. Partial or
full, concentration-dependent reactiva-
tion following the original inhibition oc-
curred in all cases and is best repre-
sented on a logarithmic scale. In Fig.
3, Ch4S from whale cartilage is shown
in addition to the four polysaccharides
in Fig. 1 to show that isomer com-
position and chain length give rise to
different effects (compare panels C and
D in Fig. 3). The paradoxical effects
shown in Fig. 3 can be interpreted
by considering at least two molecules
of the polyanion concomitantly bind-
ing elastase-2 as shown in the double-
modifier mechanism in Scheme 1 and
equation (2). According to this mecha-
nism, two hyperbolic inhibitors, or two
molecules of the same hyperbolic in-
hibitor, which bind an enzyme at the
same time at two different sites, can in-
duce inhibition in the low concentration
range of the modifiers and reverse in-
hibition at higher concentrations [11].
The analysis of such a system with two
modifiers that are individually available
is straightforward: measurements are
first performed with the modifiers sepa-
rately and then in various combinations
of concentrations. In the case of the
sulfated polysaccharides, the effector
molecules are constituents of the same
sample and their effects on enzyme ac-
tivity can only be measured by increas-
ing their concentration at a constant ra-
tio. The mole fraction of the individ-
ual molecules binding the enzyme at ei-
ther site is unknown and any attempt at
calculating the individual kinetic con-
stants by regression analysis would be
6
88 | Publications
arbitrary. Nevertheless, the simulated
inhibition-reactivation profiles shown in
Fig. 4, which produce the same effects
observed in this study, suggest that a
double-modifier mechanism is a plausi-
ble model to explain the observed ef-
fects. The parameters used for simulat-
ing the effects in Fig. 4 were chosen ar-
bitrarily to match experimental results
such as those shown in Fig. 3.
The heterogeneous composition of
the glycosaminoglycans does not allow
speculating which molecular species are
responsible for inhibition and its rever-
sal. Given the three arginine residue
belts at the surface of the enzyme
molecule (Fig. 2), even three binding
modes can be envisaged. For this rea-
son, PPS, which has a uniform struc-
ture (Fig. 3F), was taken as a refer-
ence. As shown in Fig. 3E, reversal of
inhibition was complete much like the
chondroitin sulfates pointing to the sug-
gestion that the same molecule is ca-
pable of binding the enzyme at differ-
ent sites with different effects. Thus,
assuming only two binding sites, one
binding mode is responsible for partial
inhibition and the other acts as either
a liberator (Fig. 4A) or produce an an-
tagonistic effect (Fig. 4B). In the ab-
sence of inhibitors or activators, a lib-
erator does not interfere with enzyme
activity [11,19].
3.3 Interference of polysaccha-
rides with inhibitors of
elastase-2
The interaction between sulfated
polysaccharides and elastase-2 may fa-
vor or disfavor the action of naturally
occurring protein inhibitors at sites
of action of the enzyme. This event
is likely to occur at the interface be-
tween extracellular matrix and enzyme
engaged in the turnover of proteogly-
cans. We measured the effects of sul-
fated polysaccharides on inhibition of
elastase-2 by eglin c and α1-PI, whose
kinetic mechanisms of inhibition are
known [14,20]. Furthermore, we consid-
ered the low molecular mass tetrapep-
tide inhibitor H-TNVV-OMe derived
from the active site sequence, amino
acids 60-63, of eglin c [16]. The goal
of these measurements was to evaluate
any disturbance to inhibition by added
polysaccharides at two fixed concen-
trations representing their inhibitory
and reactivation concentration ranges.
Since eglin c and α1-PI are slow act-
ing modifiers of elastase-2, progress
curves were collected at five concen-
trations of the two inhibitors without
added polysaccharides and in the pres-
ence of Ch4S from whale cartilage as
well as PPS. The reaction profiles are
shown in Supplementary Material as
Suppl. Fig. 1. The information sought
with these experiments was to deter-
mine the apparent first-order rate con-
stant of the exponential phase (λ) and
the steady-state rate (vs). Therefore,
we fitted an equation for exponential
7
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rise followed by steady-state without
ascribing results to a particular mech-
anism (Suppl. Fig. 1). Problems aris-
ing from tight-binding did not affect
interpretation because the purpose of
the experiment was to compare kinetic
parameters obtained in the absence
or presence of effectors, not to deter-
mine absolute values from their depen-
dency on the concentration of eglin c
and α1-PI. The effects brought about
on inhibition by α1-PI and eglin c by
Ch4S, calculated by regression analysis
of progress curves, are shown in Fig.
5. For increasing α1-PI and eglin c
concentrations the steady-state rate for
substrate hydrolysis leveled off to zero
as expected but in presence of the gly-
cosaminoglycan the rate was 10 times
higher at the highest α1-PI concentra-
tion and 4 times higher at the high-
est eglin c concentration (Fig. 5A,C
and insets). The first-order rate con-
stant (λ) for the exponential approach
to steady-state (Fig. 5B,D) was sig-
nificantly smaller in presence of Ch4S,
and the effect was more appreciable
at a low concentration of Ch4S. This
retardation effect on the functionality
of α1-PI towards elastase-2 is similar to
that caused by heparin, DNA and other
polynucleotides on the inhibition of the
same enzyme by the secretory leukocyte
peptidase inhibitor and α1-PI [21-24].
Lowering the rate for enzyme-inhibitor
complex formation, which can arise for
a variety of reasons, is a serious draw-
back for the control of extracellularly
acting peptidases [25]. An almost iden-
tical behavior with the same trends
shown in Fig. 5 was present in PPS
added to both α1-PI and eglin c. These
data are not shown here but the trend
can easily be deduced from the original
progress curves shown in Supplemen-
tary material.
The effect of PPS on elastase-2 in-
hibition by H-TNVV-OMe, a classical,
fast acting linear competitive inhibitor
of elastase-2 corresponding to amino
acids 60-63 of eglin c, is shown in Fig.
6. The polysaccharide weakened the
effectiveness of the inhibitor at a low
concentration and potentiated it at a
higher concentration. Such effects are
not predictable by considering the ac-
tion of the polysaccharide alone at the
same concentration. In fact, 0.28 µM
MU of PPS reduced enzyme activity
by about 80% (Fig. 1D) and 5.6 mM
MU of this polysaccharide reduced the
activity by 40% (Fig. 3E), while in the
presence of the tetrapeptide inhibitor,
PPS showed an opposite trend. The
same experiments were performed also
with Ch6S and DS and the equation for
linear competitive inhibition was fitted
to data to calculate the changes in Ki.
Curves are not shown for Ch6S and DS
but all numerical results are shown in
Table 2.
Due to multiple binding interactions
resulting from the binding of eglin c and
the modifiers, Ki must be interpreted
as an apparent Ki. A common trend
of the sulfated polysaccharides was to
increase the apparent Ki (thus decreas-
ing the affinity of eglin c for elastase-
2) when used at a low concentration,
i.e. that producing the maximal in-
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hibitory activity when acting on the
enzyme alone. At a higher concentra-
tion of the polysaccharides, correspond-
ing to the reactivating phase when used
alone (Fig. 3), the effects ranged from
lowering Ki by PPS, moderately in-
creasing Ki by DS and no effect on
Ki by Ch6S (Table 2). The different
effects produced by sulfated polysac-
charides on inhibition of elastase-2 by
eglin c and by the tetrapeptide derived
from his sequence, suggest a particu-
lar binding mode of the polysaccha-
rides to elastase-2. In the nomenclature
of Schechter and Berger [26], the four
amino acids of H-TNVV-OMe bind at
positions S4-S3-S2-S1 in the same order
as written, namely T binds to S4 and so
on, while eglin c is expected to occupy
also the primed positions. The fact
that polysaccharides exert concentra-
tion dependent effects on the efficiency
of H-TNVV-OMe for the enzyme (Ta-
ble 2) but always weaken eglin c bind-
ing (Fig. 5) suggests an interaction of
polysaccharides with the primed sites
of elastase-2, where protein substrates
and macromolecular protein inhibitors
bind.
Table 2: Inhibition of elastase-2 by the eglin c derived tetrapeptide H-TNVV-OMe. Mea-
surement conditions specified in Fig. 6. The equation for classical competitive inhibition
was fitted to data and the Ki values, calculated to take into account a [S]/Km ratio of 1, are
expressed as µM of DU (Ch4S and DS) or in µM of MU (PPS). Ki represents the inhibition
dissociation constant of the enzyme-inhibitor complex. In the presence of polysaccharides
this must be considered a Ki,app value.
Modifier Ki (µM) fold increase
or decrease
None 87.7 ± 2.2
PPS, 0.28 µM MU 142.5 ± 9.2 1.62
PPS, 5.6 mM MU 37.7 ± 1.2 0.43
None 79.3 ± 4.5
DS, 0.1 mM DU 229.9 ± 14.5 2.90
DS, 10 mM DU 112.0 ± 12.4 1.41
None 104.4 ± 12.8
Ch6S, 0.2 µM DU 147.8 ± 9.7 1.41
Ch6S, 200 µM DU 94.6 ± 23.2 0.91
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In conclusion, the pooled results
from this study suggest that gly-
cosaminoglycans released from connec-
tive tissues by the action of hydrolases
during inflammation or tissue remod-
eling, may contribute to regulation of
elastase-2 by themselves and in associa-
tion with protein inhibitors. As long as
tissue degradation is required, such as
in wound healing, the efficiency of α1-
PI, the major physiological inhibitor of
elastase-2, may be finely tuned by the
local concentration of glycosaminogly-
cans resulting in slowing down its ac-
tivity. After completion of remodeling,
glycosaminoglycans are expected to dis-
appear rapidly allowing efficient inhibi-
tion of the no longer needed peptidases.
If this is true, the same mechanism is
likely to be responsible for the ineffi-
cient inhibition of elastase-2 in patho-
logical situations.
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Scheme 1: Simultaneous interaction of two modifiers I and X on the enzyme E [11]. S
= substrate, P = product. The coefficients a, b describe the proportion of competitive
and uncompetitive inhibition in mixed inhibition. The coefficient c defines four types of
interaction between the modifiers I and X on the free enzyme: facilitation (0 < c < 1),
independence (c = 1), hindrance (1 < c < ∞) and exclusion (c = ∞). The coefficients γS,
γI and γX characterize the interactions between reactants in the formation of the quaternary
complex ESIX.
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Figure 1: Inhibition of elastase-2 by sulfated polysaccharides. Equation (1) was fitted to
data and the solid lines represent the best fit. Parameters from regression analysis are shown
together with their standard errors in panels A-D. The substrate was MeOSuc-AAPV-pNA
at a fixed concentration [S] = Km = 0.070 mM. 50mM Tris-HCl buffer, pH = 7.40, with
NaCl added to an ionic strength of 100 mM and 0.01% (v/v) Triton-X100; temperature 25
± 1◦C. The elastase-2 concentration in all assays was 8.6 nM
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Figure 2: Three-dimensional structure of elastase-2 (protein data bank code 1HNE). Posi-
tively charged arginine residues are shown in blue and the active site (His57, Asp102, Ser195)
in red. The negative charges form three belts around the enzyme molecule, which is shown
here in the front (A) and backside position (B). Arg217A is positioned along the extended
hydrophobic substrate binding pocket in such a way to interfere with substrate binding when
masked by interaction with polyanions.
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Figure 3: Inhibition and reactivation of elastase-2 by sulfated polysaccharides. Concen-
tration axes are drawn as log10 scale of the constitutive basic units: disaccharide units for
chondroitin sulfates and DS (A-D), and monomer units for PPS (E). Experimental conditions
as in Fig. 1.
16
98 | Publications
Figure 4: Simulated enzyme inhibition and reactivation by the concomitant action of two
modifiers I and X. Plots of the reaction rate as a function of the concentration of two
modifiers, which are expressed in mM units. The kinetic parameters and coefficients are
defined in Scheme 1 and simulations were performed with Matlabr software using equation
(2) as detailed previously [11]. In panel A, I is considered to be a liberator and X a hyperbolic
inhibitor with the following parameters: a = 1, b = 7.6, c = ∞ (exclusion), e = 0.77, σ =
1, βI = 1, βX = 0.244, βIX = 1, KI = 63 mM, KX = 0.67 mM. In panel B, I and X are
non-exclusive hyperbolic inhibitors, a = b = 0.32, c = ∞ (exclusion), e = 1.42, σ = 1, βI
= βX = 0.048, βIX = 1.0, KI = KX = 4.77 mM. The curves in the [I]−[X] plane represent
isoboles, i.e. equieffective concentrations of the modifiers, obtained by projection of the
three-dimensional graphs.
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Figure 5: Effect of Ch4S from whale cartilage on the inhibition of elastase-2 by α1-PI. Bars
represent the best fits of parameters ± S.E. obtained by non-linear regression to the progress
curves shown in Supplementary Material. The insets in panels A and B show the enlarged
bars at the highest inhibitor concentrations. The steady-state rates in presence of Ch4S were
significantly different from those in their absence (one-way analysis of variance and Tukey
multiple comparison test). One-way analysis of variance also showed that all values of λ
with the exception of α1-PI at the lowest concentration, were significantly different from one
another in all pair combinations (p < 0.05). Column legends for all data are shown in panel
D.
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Figure 6: Inhibition of elastase-2 by H-TNVV-OMe (amino acids 60-63 of eglin c) with and
without PPS. The elastase-2 concentration in all assays was 6.9 nM of titrated active sites
and other experimental conditions were as in Fig. 1.
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Suppl. Fig. 1: Inhibition of elastase-2 by α1-PI and interference by sulfated polysaccharides.
The curves were corrected for baseline. Progress curves in experiments A-C and D-F were
performed on different days. A and D, only α1-PI, B and C, chondroitin-4-sulfate (Ch4S)
from whale cartilage added at two concentrations; E and F, pentosan polysulfate (PPS)
added at two concentrations as indicated. Numbers adjacent to the curves represent nM
concentrations of α1-PI and the color codes, shown only on the top panels, also apply to
the other curves. The substrate was MeOSuc-AAPV-pNA at a fixed concentration [S] =
0.14 mM (Km = 0.070 mM). 50mM Tris-HCl buffer, pH = 7.40, with NaCl added to an
ionic strength of 100 mM and 0.01% (v/v) Triton-X100; temperature 25 ± 1◦C. The final
elastase-2 concentration in all assays was 2.3 nM of titrated active sites. The following equa-
tion for exponential rise followed by a linear steady-state was fitted to all curves to calculate
the apparent first-order constant of the exponential phase (λ) and the steady-state slope (vs).
y = A
(
1− e−λt)+vst+ d
A is the amplitude of the exponential and d is a displacement factor for any non-zero value
of the absorbance at the beginning of the reaction.
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Suppl. Fig. 2: Inhibition of elastase-2 by eglin c and interference by sulfated polysaccha-
rides. Progress curves in experiments A-C and D-F were performed on different days. A and
D, only eglin c, B and C, chondroitin-4-sulfate (Ch4S) from whale cartilage added at two
concentrations; E and F, PPS added at two concentrations as indicated. Numbers adjacent
to the curves represent nM concentrations of eglin c and the color codes, shown only on the
top panels, also apply to the other curves. Experimental conditions and kinetic analysis as
in Suppl. Fig. 1.
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Conclusion

Conclusion
ECM-degrading peptidases are tightly bound to their insoluble substrates in
the extracellular space and their active site is barely accessible by exogenous
modifiers. We successfully demonstrated that targeting the occluding loop
of cathepsin B, a flexible structure outside the active center that governs
the exo- and endoproteolytic activity of this enzyme, is a promising strat-
egy deserving further development. One compound, identified by computa-
tional docking methods, behaved as a reversible, double-headed competitive
inhibitor of cathepsin B that acted by steric hindrance of substrate accessi-
bility to the active site. Effective modification of the cathepsin B activity
can thus be achieved through modifiers binding outside the active center.
This approach represents an alternative strategy for the development of new
inhibitors with potential pharmacological interest.
While developing new, therapeutically useful modifiers, proper kinetic char-
acterization of their interaction mechanism with the target enzymes is vital
for any future use. Besides reversible inhibitors, inactivators are synthesized
worldwide with a large spectrum of applications. Therefore, we re-evaluated
in a systematic way the mechanisms by which inactivators block enzyme ac-
tivity exploiting model compounds of acetylcholinesterase, here considered as
a model target enzyme. The frequently occurring phenomenon of temporary
inactivation and the chemical instability of the modifiers were highlighted
to allow mechanistic discrimination towards reversible inhibitors. Supported
by a large number of measurements with molecules that inactivated acetyl-
cholinesterase by several different mechanisms, we assembled a collection of
diagnostic tools, which will serve as a reference for the classification and
analysis irreversible enzyme modification reactions.
In vitro studies typically deal with interactions involving a single modifier
and one enzyme molecule. Nevertheless, the numerous potential binding
partners for peptidases in the ECM raise the question of multiple interac-
tions. In particular, in vitro designed modifiers targeted outside the active
site are likely to be involved in such interactions. Hence, we re-evaluated
the double inhibition concept and proposed a new kinetic model that allows
a rigorous mathematical description of the behavior of inhibitors and acti-
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vators in multiple interaction systems. This treatment settled discrepancies
in the literature on the prediction of synergistic and antagonistic effects of
pharmacological importance. Unusual kinetic phenomena, such as reactiva-
tion following inhibition and the inhibition paradox, in which two modifiers
that produce inhibition when used separately but activation when used si-
multaneously, can be described quantitatively with the new approach.
Human elastase-2, a key enzyme of neutrophilic leukocytes, is better known
for its adverse effects than for a few recognized physiological functions. This
enzyme, involved in ECM degradation, is often found at extracellular sites
rich in glycosaminoglycans, with which it interacts. At low glycosaminogly-
can concentrations elastase-2 is inhibited but is partially or fully reactivated
as the glycosaminoglycan concentration increases. Glycosaminoglycans can
seriously impair the action of naturally occurring inhibitors of elastase-2 in
a glycosaminoglycan-concentration depending manner. The phenomenon,
which involves a network of complex interactions, can to some extent be
explained with the general model of two modifiers interacting at the same
time with one enzyme molecule.
The results of this thesis highlight the importance of methodological pro-
cedures in characterizing modifier mechanisms with kinetic techniqes. New
paradigms emerged revealing hitherto unpredictable effects. The discovery
and correct interpretation of new mechanisms is subordinated to meticulous
data collection and analysis as a support in the development of pharmaco-
logically active substances.
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Appendix

Enzyme Inhibition
Mechanisms
A.1 Classification
Enzyme inhibitors are classified, whether the enzyme inhibitor complex can
freely dissociate or not, into reversible inhibitors and inactivators (Table
A.1). Further classification of the different reversible inhibition mechanisms
is based on the ratio of [E]t, [I]t and Ki as well as on the reaction velocity
of the formation of the EI complex.
Table A.1: Classification of Enzyme Inhibitors.
type characteristics reaction velocity
of EI formation
Reversible
classical [I]t  [E]t fast
slow-binding [I]t  [E]t slow
tight binding [I]t ≈ [E]t and Ki fast
slow-tight binding [I]t ≈ [E]t and Ki slow
type examples
Irreversible
unspecific group-specific reactions
specific active site binding,
mechanism based inactivation
(e.g. kcat-inactivators, suicide inhibitors)
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A.2 Reversible Kinetic Inhibition Mechanisms
A.2.1 Classical Inhibition
Scheme A.1, the General Modifier Mechanism, is the basic mechanism for the
description of all classical reversible inhibition mechanisms [25]. Depending
on the value of β, a linear (β = 0) or a hyperbolic (0 < β 6 1) inhibitor is
described, meaning that at saturating inhibitor concentrations the residual
enzyme activity is either fully or partially decreased, respectively. Competi-
tive, uncompetitive or mixed type inhibition is distinguished by the value of
α and Ki adopting any positive values (Table A.2).
I I
+ +
S + E
Ks /

ESo
αKi

k2 // E + P
S + EI
αKs /
Ki
O
ESIo
O
βk2 // EI + P
Scheme A.1: The General Modifier Mechanism [25]. E: enzyme, S: substrate,
I: inhibitor, Ks: substrate dissociation constant, Ki: inhibitor dissociation
constant, kcat: catalytic activity, α and β: dimensionless constants that define
the characteristics of the inhibition mechanism.
Table A.2: Classical Reversible Inhibition Types.
relative values of α and β inhibition type
α =∞ β = 0 linear competitive
1 < α <∞ β = 1 hyperbolic competitive
α→ 0, Ki →∞ β = 0 linear uncompetitive
0 < α < 1 0 < β < 1 and α = β hyperbolic uncompetitive
1 6 α <∞ β = 0 linear mixed-type
1 6 α <∞ 0 < β < 1 hyperbolic mixed-type
The rate equation A.1 is valid for the General Modifier Mechanism (scheme
A.1) under the assumption of quasi-equilibrium for the binding of I to E and
ES, and steady-state for the fluxes around ES and ESI. v0 and v i are the
initial rates in absence and presence of the inhibitor and σ = [S]/Km.
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v i =
v0(1 + σ)
(
1 + β
[I]
αKi
)
1 +
[I]
Ki
+ σ
(
1 +
[I]
αKi
) (A.1)
A.2.2 Slow-Binding Inhibition
The formation of an intermediate during catalysis with structural analogy
to the transition state, or the fact that the actual inhibition needs a confor-
mational change in the enzyme that is slow on the steady-state time scale,
can result in a slow formation of the enzyme-inhibitor complex.
I
+
S + E
Ks /
k3

ESo
k2 // E + P
EI
k4 /
k−3
O
E · I
k−4
o
(a) two step mechanism
I
+
S + E
Ks /
k3

ESo
k2 // E + P
E · I
k−3
O
(b) one step mechanism
Scheme A.2: Reversible slow-binding inhibition mechanism in two steps (a)
and in one step (b). E: enzyme, S: substrate, I: inhibitor, EI: adsorptive
complex, E·I: noncovalent complex. In both cases the formation of E·I is slow.
Two common reaction mechanisms of slow-binding competitive inhibition
are shown in Scheme A.2, with EI indicating an adsorptive complex and
E·I a stable noncovalent complex. In case of the slow-binding mechanism in
two steps (Scheme A.2a) the fast formation of the adsorptive EI complex is
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followed by a slow generation of a stable but reversible E·I complex. In the
case of Scheme A.2b, a degeneration of Scheme A.2a, already the first step
is slow.
The progress curves of both mechanisms are described by the integrated rate
equation A.2.
P = vst +
(vz − vs)
λ
(1− e−λt) (A.2)
vs is the velocity of the reaction at steady state, vz the velocity at the be-
ginning of the reaction (zero time), λ a first order constant, which describes
the exponential phase and t indicates time.
To distinguish whether a one or a two step slow-binding inhibition mecha-
nism is present, progress curves with different inhibitor concentrations are
analyzed. The behavior of the parameters λ, vz and vs in dependence of
the inhibitor concentration indicate the proper mechanism. For example, for
mechanism A.2a vz depends on the inhibitor concentration, for mechanism
A.2b it does not.
A.2.3 Tight Binding Inhibition
In case of a tight binding inhibitor, [I]t ≈ [E]t and Ki (Table A.1), the affin-
ity of the inhibitor for the enzyme is very high and the inhibition process
fast. In this case, it can not be assumed any longer that the free inhibitor
concentration [I] is identical with the total inhibitor concentration [I]t, but
its decrease has to be taken into account.
Equation A.3 describes classical reversible tight binding inhibition based on
the General Modifier Mechanism (Scheme A.1) [8, 104]. Again, the param-
eters α, β and Ki determine the characteristics of the inhibitor.
v i =
v0
2
[
α+ σ − β(1 + σ)
α+ σ
][√[(
1 + σ
α+ σ
αKi
[E]t
+
[I]t
[E]t
− 1
)2
+ 4
1 + σ
α+ σ
αKi
[E]t
]
+
α+ σ + β(1 + σ)
α+ σ − β(1 + σ) −
1 + σ
α+ σ
αKi
[E]t
− [I]t
[E]t
]
(A.3)
It is advantageous that the values for v0, σ and [E]t are known, what eases
the fitting of the experimental data by nonlinear regression analysis.
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A.2.4 Slow, Tight-Binding Inhibition
A tight binding inhibitor can additionally show slow-binding characteristics
[77, 99, 103]. Similarly to slow-binding inhibition, the mathematical treat-
ment of such an inhibition is fitting of Eq. A.4 to progress curves. The
meaning of the parameters vz, vs and λ is the same as in slow-binding
mechanisms (Section A.2.2), but Eq. A.4 describes the one step mechanism
only.
P = vst +
(vz − vs)(1− γ)
γλ
ln
(1− γe−λt)
1− γ (A.4)
γ =
Ki(1 + σ) + [E]t + [I]t −Q
Ki(1 + σ) + [E]t + [I]t +Q
(A.5)
with Q =
√
(Ki(1 + σ) + [E]t + [I]t)
2 − 4[E]t[I]t (A.6)
A.3 Mechanisms of Inactivation
Inactivators have a more drastic effect on the enzyme activity than reversible
inhibitors. Similarly to the slow-binding mechanisms, a primary distinction
is made between a one and a two step inactivation mechanism (Scheme A.3).
In case of a two step mechanism, a reversible step with the formation of an
adsorptive EI complex precedes the inactivation step resulting in the covalent
binding of the inhibitor to the enzyme (E-I).
Similarly to slow-binding inhibition mechanisms, progress curves in presence
of different inactivator concentrations are fitted to Eq. A.7.
P =
vz
λ
(
1− e−λt
)
(A.7)
The values of λ obtained for different inactivator concentrations are fitted
either to Eq. A.8 or A.9, depending on whether the inactivation occurs in
two or in one step, respectively.
λ =
k4
1 +
K3
[I]
(1 + σ)
(A.8)
λ =
k3
1 + σ
[I] (A.9)
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I
+
S + E
Ks /
k3

ESo
k2 // E + P
EI
k4 //
k−3
O
E− I
(a) two step mechanism
I
+
S + E
Ks /
k3

ESo
k2 // E + P
E− I
(b) one step mechanism
Scheme A.3: Inactivator mechanisms in two steps (a) and in one step (b).
E: enzyme, S: substrate, I: inhibitor, EI: adsorptive complex, E-I: covalent
complex.
The meaning of vz and λ are the same as in slow-binding mechanisms. vs is
not present because after a certain time all enzyme will be covalently bound
to the inhibitor and therefore no substrate is transformed and the reaction
velocity at steady state is necessarily zero.
Enzyme Activation
Mechanisms
B.1 Classification and Mechanisms
Classical activators are as well described by Scheme A.1. Similarly to the
inhibition mechanisms, the definition of activation mechanisms is based on
the characteristics of the parameters α, β and Ki.
There are two mechanisms worth mentioning in the context of an overview
of activation mechanisms, namely the essential (Scheme B.1a) and the mixed
activation (Scheme B.1b).
In case of an essential activator, its presence is necessary for substrate binding
to the enzyme. The activator is needed only for catalysis of the substrate
in case of a mixed activator, but its presence is not necessary for substrate
binding to the enzyme.
The rate equations for essential (Eq. B.10) and mixed activation (Eq. B.11),
indicate their analogy to linear competitive and mixed type inhibition.
va =
v0(1 + σ)
1 +
Kx
[X]
+ σ
(B.10)
va =
v0(1 + σ)
α
(
1 +
Kx
[X]
)
+ σ
(
1 +
αKx
[X]
) (B.11)
Nevertheless, there are some differences between these mechanisms: Firstly,
a competitive inhibitor does most likely not bind simultaneously with sub-
strate, whereas an essential activator does so. Secondly, essential activation
are much less frequently observed than competitive inhibition.
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X
+
E

S + EX
Ks /
Kx
O
ESXo
k2 // EX+ P
(a) essential activation
X X
+ +
S + E
Ks /

ESo
αKx

S + EX
αKs /
Kx
O
ESXo
O
βk2 // EX+ P
(b) mixed activation
Scheme B.1: Mechanisms of activation.
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